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Venous thromboembolism (VTE) is the formation of a blood clot in, most commonly, the 
deep veins of the lower extremities and the pulmonary circulation. VTE is a prevalent disease 
associated with severe short- and long-term complications. Negatively charged procoagulant 
phospholipids (PPL), and phosphatidylserine (PS) in particular, are vital to efficient 
coagulation activation, and found expressed on the surface of extracellular vesicles (EVs) and 
activated platelets.  
The overall aim of the present thesis was to develop an easily available and 
reproducible FXa-dependent clotting assay to measure PPL activity in plasma, and further use 
the assay to investigate the association between plasma PPL activity and the risk of VTE.  
In paper I, we investigate the impact of several pre-analytical conditions on EV 
concentration and size measured by Nanoparticle Tracking Analysis (NTA) and scanning 
electron microscopy (SEM). In paper II, we developed a modified FXa-dependent clotting 
assay by substituting the chemically phospholipid depleted plasma with PPL-depleted plasma 
obtained by ultracentrifugation. In paper III, we used our modified PPL assay to investigate 
the association between PPL clotting time (PPLCT) and the risk of incident VTE in a nested 
case-control study derived from a population based cohort (the Tromsø study). Previous 
studies have suggest that statin treatment reduced the risk of recurrent VTE. In paper IV, we 
investigated the impact of statin treatment (rosuvastatin) on PPL activity, using the modified 
PPL assay and plasma samples from the STAtins Reduce Thrombophilia trial. 
The impact of pre-analytical conditions (i.e. anticoagulants, centrifugation protocols, 
and fasting status) on EV measurements was demonstrated, and the obstacle of post-prandial 
lipoproteins interfering with NTA analysis was particularly highlighted. We found that the 
modified PPL assay displayed similar sensitivity and reproducibility compared to commercial 
assays based on chemically phospholipid-depleted plasma. We observed an inverse 
association between plasma PPLCT, assessed by the modified assay, and the risk of future 
VTE in a population-based nested case-control study. Additionally, rosuvastatin treatment 
aused a substantial decrease in plasma PPL activity in subjects with a history of VTE. The 
development of the modified PPL assay enabled us to perform high-quality measurements in 
large-scale studies. The inverse association between PPLCT and VTE risk supports an 
important role of plasma PPL in the pathogenesis of VTE and may partly explain the reduced 





Venøs tromboembolisme (VTE) er en fellesbetegnelse for blodpropp som dannes i de dype 
venene i underekstremitetene eller i lungekretsløpet. VTE er en vanlig sykdom med alvorlige 
kort- og langtidskomplikasjoner. Negativt ladede prokoagulante fosfolipider (PPL), og da 
spesielt fosfatidylserin, er avgjørende for en effektiv aktiveringen av koagulasjonskaskaden, 
og finnes uttrykt på overflaten av ekstracellulære vesikler (EVs) og aktiverte blodplater.  
 Det overordnede målet med denne avhandlingen var å utvikle et lett tilgjengelig og 
reproduserbart FXa-avhengig koagulasjonsassay for å kunne måle PPL-aktiviteten i 
plasmaprøver. Vi brukte så assayet til å undersøke sammenhengen mellom PPL-aktivitet i 
plasma og risikoen for VTE.  
 I artikkel I undersøkte vi effekten av ulike pre-analytiske faktorer på konsentrasjonen 
og størrelsen av EVs, målt ved hjelp av Nanoparticle Tracking Analysis (NTA) og skanning 
elektronmikroskopi (SEM). I artikkel II utviklet vi et modifisert FXa-avhengig 
koagulasjonsassay ved å erstatte plasma hvor PPL var kjemisk fjernet med plasma hvor vi 
brukte ultrasentrifugering for å oppnå samme effekt. I artikkel III brukte vi det modifiserte 
PPL assayet for å undersøke sammenhengen mellom PPL-koagulasjonstid (PPLCT) og 
risikoen for førstegangs VTE i en nøstet kasus-kontroll studie avledet fra en populasjonsbasert 
kohortestudie (Tromsøundersøkelsen). Tidligere studier har vist at statinbehandling reduserte 
risikoen for residiv av VTE. I artikkel IV undersøkte vi effekten av statinbehandling 
(rosuvastatin) på PPL-aktiviteten, målt ved hjelp av det modifiserte PPL assayet i 
plasmaprøver fra studien STAtins Reduce Thrombophilia. 
Effekten av pre-analytiske faktorer (dvs. antikoagulanter, sentrifugeringsprotokoller og 
fastestatus) på EV-målinger ble demonstrert, og utfordringen med at postprandiale 
lipoproteiner forstyrret NTA-analysene ble fremhevet spesifikt. Vi fant at det modifiserte PPL 
assayet viste lik sensitivitet og reproduserbarhet som kommersielle assay hvor fosfolipider fra 
plasma er fjernet kjemisk. Vi observerte en invers sammenheng mellom PPLCT, målt i det 
modifiserte PPL assayet, og risikoen for fremtidig VTE. I tillegg viste vi at 
rosuvastatinbehandlingen gav en betydelig reduksjon i PPL-aktiviteten i plasma hos personer 
med tidligere VTE. Utviklingen av det modifiserte PPL assayet gjorde det mulig for oss å 
utføre målinger av høy kvalitet i stor skala. Den inverse sammenhengen mellom PPLCT og 
VTE-risiko underbygger en viktig rolle for plasma PPL i sykdomsutviklingen av VTE og kan 
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1. Introduction  
Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is the formation of a blood clot in, most commonly, the deep veins of the 
lower extremities. The clot prevents the return of blood from the legs to the heart and cause 
pain, swelling and redness in the affected limb. Traditionally, a PE has been seen as a 
complication of a DVT, where a part of the thrombus breaks off and travels with the blood-
stream through the heart to the lungs 1. In later years, research has found that a PE might also 
arise de novo in the lungs 2 or originate from a right intracardiac thrombi in patients with atrial 
fibrillation 3,4. VTE is effectively treated with anticoagulation, but at the cost of increased risk 
of potentially lethal major bleeding events 5. VTE is considered a multicausal disease, where 
the sum of an individual’s risk factors at a particular point in time might exceed the 
thrombosis threshold and cause and event 6. A number of acquired and inherited risk factors 
for VTE have been identified. However, only a few of the currently known risk factors are 
modifiable and related to lifestyle. A VTE event is classified as provoked if it occurs in the 
presence of known risk factors (transient or persistent), while an unprovoked event occurs in 
the absence of known triggers. The classification of an event influences both the prognostics 
as well as the treatment strategy 7,8. 
 
Extracellular vesicles (EVs), including exosomes, microvesicles and apoptotic bodies, are bi-
layered vesicles, which are either released from or bud off a parental cell membrane 9. EVs 
have been extensively studied in recent years and found to be associated with several disease 
states 10-18. The proposed role of EVs in VTE has mainly been thought to be caused by the 
surface expression of tissue factor (TF), a well-known trigger of the coagulations system. In 
contrast to TFs vital role in activating coagulation, elevated levels of TF+EVs are only found 
in certain disease states such as severe cancers or disseminated intravascular coagulation 
(DIC) 19-22. Negatively charged procoagulant phospholipids (PPL), and particularly 
phosphatidylserine (PS), are exposed on the EV surface as a consequence of the budding 
process 9,23. They are vital to coagulation activation, and the mere presence of negatively 
charged phospholipids increases the activity of the extrinsic tenase complex (TF-FVII) by 
several orders of magnitude 24. Given the importance of PPL to coagulation, we sought out to 
modify a clot-based FXa dependent assay, creating a sensitive and reproducible method for 
measuring PPL clotting time (PPLCT). We addressed several pre-analytical challenges when 




status. Further, we investigated the association between procoagulant phospholipids, and the 
risk of incident and recurrent VTE.  
 
1.1 Epidemiology of VTE 
VTE is considered the third most common cardiovascular disease, following myocardial 
infarction and ischemic stroke 25. The annual incidence rate of VTE for people of European 
ancestry is estimated to 1-2 per 1000 person years 7,26,27. The annual incidence has remained 
unchanged or even increased over time 28,29, in contrast to the decreasing incidences of 
myocardial infarction 30 and ischemic stroke 31.  
 
VTE is primarily a disease of older age and the incidence increases exponentially with age for 
both sexes. The reported incidences of VTE for men and women separately range from 
studies reporting an overall higher risk in women 28, to a higher risk in men 29,32,33 to no 
difference between the sexes 34. However, when considering sex and age groups together, it 
appears that in the younger population (< 50 years) women have a higher risk of VTE than 
men, most probably due to female reproductive risk factors 35. Though, in the middle aged (50 
to 70 years) the risk was reported higher for men than women 32,36. Still, the life-time risk of 
VTE for men and women individually is not known. The incidence rate of VTE differs with 
regards to patient ethnicity. The African-American population has the highest incidence rate 
of a first time VTE, followed by the Caucasian, Hispanic and Asian/Pacific Islander 
populations, respectively 37,38.  
 
VTE most commonly presents as DVT, which accounts for approximately two-thirds of all 
events, while one-third of patients experience a PE 39. However, recent studies have 
challenged this ratio where an increase in PE events were observed, while the number of DVT 
events remained unchanged or even decreased over the same period of time 28,36, most 
probably explained by improved diagnostic tools as well as growing awareness of the disease 
28. Approximately 30% of patients will experience a recurrent event within 10 years. The risk 
of recurrence is highest the first 6 to 12 months after the initial VTE event 40. DVT patients 
are at higher risk of a recurrent event than PE patients, with a 1.4-fold higher hazard ratio 41. 
Recurrent events are more likely to occur at the same site as the initial event, hence patients 




Similarly, a first unprovoked event more likely recurs as an unprovoked event, while a 
provoked first event is as likely to recur as an unprovoked as a provoked event 41.  
 
In addition to the risk of recurrence, VTE can lead to severe short- and long-term 
complications such as the post-thrombotic syndrome (PTS), the post PE- syndrome including 
its most extreme manifestation chronic thromboembolic pulmonary hypertension (CTEPH), 
and death. PTS is a chronic complication of DVT where the venous valves are damaged by 
insufficient thrombus resolution, leading to venous hypertension, structural changes in the 
vessel wall, and impaired venous return 43. The clinical signs of PTS include chronic pain, 
swelling, edema, skin changes, and heaviness of the affected leg. PTS develops in 20 to 50% 
of DVT patients, with 5% developing severe ulcers within a 10-year period 44. Risk factors for 
developing PTS include obesity, female sex, proximal DVT and varicose veins 45. The health 
burden of PTS is substantial, both in terms of cost to the healthcare system as well as the 
reduced quality of life of the patients 43,44.   
 
Long-term follow-up studies have consistently reported that 50% of patients, after an acute 
PE event, suffer from functional limitations and/or decreased quality of life. The concept of 
“post-PE syndrome” was suggested as a collective term encompassing all complications of 
PE, where CTEPH is the most extreme manifestation of the syndrome 46. CTEPH affects 0.4 
to 4% of PE patients and is a serious complication 47,48 which may ultimately result in right 
ventricular failure 49. CTEPH leads to occlusive vascular remodeling and obstruction of 
pulmonary arteries, as well as increased resistance in the pulmonary circulation due to 
incomplete thromboembolic resolution after a PE event 43,50. CTEPH patients typically suffer 
from exertional dyspnea, and with disease progression leading to further limitations of cardiac 
output, exertion-related presyncope, frank syncope, and exertional chest pain may develop 49. 
As the clinical presentation of CTEPH is often nonspecific and subtle, and survival without 
intervention is poor, correct and early diagnosis is of high importance 49.  
 
The 30-day case-fatality rate for all VTE was reported to be from 6 to 11 %, while the 1-year 
case-fatality rate ranged from 21 to 24% 27,41,51,52. PE is the most fatal manifestation of VTE, 




event is regarded as an independent predictor of reduced survival for up to three months post 
event. It has been reported that 25% of PE cases present with sudden death 53. Still, the 
highest fatality rates are found in cancer-related VTE with a 1-year case fatality rate reported 
to range from 63% to 88% 27,54.  
 
1.2 Pathophysiology of VTE 
In 1856 the German scientist Rudolph Virchow proposed three components, later named 
Virchow’s triad, which he found essential in thrombus formation. The triad is comprised of 
changes in blood flow (stasis), changes in the composition of blood (hypercoagulability) and 
vessel wall injury (Figure 1) 55. The triad is still used today to explain the pathophysiology of 
VTE, and most known risk factors for the disease can be classified under one or more of the 
three components of the triad.  
 
Figure 1. Illustration of Virchow’s triad with risk factors for VTE categorized by the triad 





Autopsy and phlebography studies have suggested that non-trauma related venous thrombi 
typically originate in the deep recess of the valvular sinuses in the presence of an intact 
endothelium 1,56,57. The observation of intact endothelium advocates for a TF driven fibrin 
generation and deposition as the initiating event 1. As blood crosses the leaflets of the venous 
valves, some blood begins a vortical flow (Figure 2). As a consequence, blood cells and blood 
components are trapped in the deepest recesses of the valvular sinuses, where a severely 
hypoxic environment develops. Local hypoxia leads to a proinflammatory state where 
leukocytes and platelets are activated and release procoagulant EVs 1,56,58. It has been shown 
that the number of venous valves positively correlates with the risk of VTE, and that a limb 
with more valves has a higher risk of DVT 59. As we age, veins lose their compliance and the 
venous valves stiffen from fibrosis, which further results in disrupted blood flow. Such 
physical changes in the veins likely contribute to the increased incidence of VTE with 
increasing age 1.  
 
Figure 2. The pathophysiology of venous thrombosis. Blood is trapped in the valve pockets 
by a counter rotating vortex at the base of the sinus, creating a hypoxic and proinflammatory 
milieu. Blood cells, as well as the endothelium, are activated and produce procoagulant 
extracellular vesicles. EVs= Extracellular vesicles, Plt= Platelet, Mc =Monocyte 
 
The evidence for a relationship between stasis and thrombosis is substantial. Contrast media 




the procedure, supporting the presence of stasis in the venous valves 60. Observations of VTE 
after long-haul flights, increased incidence of DVT in a paralyzed leg compared to the normal 
leg, increasing risk of DVT with the length of immobilization of a patient, as well as a 
decrease in risk of DVT in hospitalized patients when they begin to walk again or use 
pneumatic leg compression, all strengthen the role of stasis in the development of VTE 1,61.  
 
Hypercoagulability is the abnormal tendency for blood to clot and can either be due to 
inherited genetic factors or caused by external factors. An inherited hypercoagulable state can 
be caused by single nucleotide polymorphisms, such as Factor V Leiden and prothrombin 
mutation G20210A, and deficiencies in natural anticoagulants such as protein S, protein C or 
antithrombin (AT) 62. External factors that cause a hypercoagulable state include oral 
contraceptive use, hormone replacement therapy, pregnancy and obesity 8,63.   
 
An undamaged endothelium expresses a range of anticoagulants like tissue factor pathway 
inhibitor (TFPI), heparin-like proteoglycans, thrombomodulin, and endothelial protein C 
receptor 64. Upon activation, the endothelium will downregulate the expression of its 
anticoagulant properties, while the procoagulant properties are upregulated. In response to 
vessel wall injury, TF as well as adhesive molecules like P-selectin, E-selectin and vWF are 
exposed initiating the extrinsic coagulation pathway and recruit platelets and leukocytes to the 
site of injury 64. Hypoxia and inflammatory mediators have been suggested as causes of 
endothelial dysfunction in relation to VTE 8. However, the role of the third component of the 
triad, vessel injury, in venous thrombosis is debated, and most often associated with surgery 
or trauma related thrombosis 56. In a study from 1974, Sevitt investigated 50 small thrombi 
from femoral valve pockets without finding any significant evidence of preceding intimal 
damage in the vessel wall 57. This indicates that “endothelial dysfunction” would possibly be a 
more fitting term.    
 
1.3 Risk factors for VTE 
A risk factor is defined as any attribute, characteristic or exposure of an individual that 
increases the chance of developing a disease. As VTE is a multicausal disease, a combination 
of risk factors is required for disease development. The risk factors for VTE can further be 




relationship between an individual’s risk factors is illustrated by the thrombosis potential 
model (Figure 3) 6. The model describes how the combination of two or more risk factors at a 
particular point in time exceeds a threshold and results in a VTE event. Figure 3 exemplifies 
the effect of different types of risk factors on the thrombosis threshold. An inherited risk 
factor, like FVL, is constant over time. While age, an acquired risk factor, will increase an 
individual’s risk over time. The combination of risk factors is the individual’s baseline 
potential. If a provoking factor, like immobilization, cancer or pregnancy, occurs it could 
potentially lead to a combined effect that exceeds the thrombosis threshold and cause an 
event. The baseline risk of an individual is higher after a first event, and about 30% of patients 
will experience a recurrent event within 10 years. The risk of recurrence is highest the first 6 
to 12 months after the initial VTE event 40. The presence of a residual thrombus after a first 
DVT event is considered an independent risk factor for recurrence 65. Potential mechanisms 
leading to the higher baseline risk after a first event are alterations in the vessel wall, impaired 
venous outflow, or the presence of additional risk factors.   
 
Figure 3. The thrombosis potential model. Factor V Leiden (FVL) (blue) exemplifies a 
hereditary risk factor, while age (green) represents an acquired risk factor that increases with 
time. The orange line illustrates an individual’s baseline potential, with provoking factors (red 
bars) at different time points in life. The thrombosis threshold is illustrated by the dotted line 




exceeds the thrombosis threshold, a VTE event occurs, and potentially reoccurs. (Adapted 
from Rosendaal, Lancet 1999 6)   
 
1.3.1 Hereditary risk factors  
VTE has a strong genetic component with an overall heritability of 50-60% as estimated by 
twin and family studies 66,67. The functional and clinical importance of the genetic risk factors 
has been unraveled over time through case reports, observations and knock-out mouse studies 
on abnormal levels of coagulation factors, regulators and anticoagulants 68,69. The 
methodological advances in science, such as high-throughput micro-array based genotyping 
and genome-wide association studies (GWAS), have contributed greatly in both confirming 
previous gene findings as well as discovering novel genes and loci associated with the risk of 
VTE 70. Although several gene variants have been proposed, only 16 of the genes have been 
robustly associated with VTE risk 71. More recent GWAS studies and meta-analysis have 
discovered additional gene variants and loci associated with VTE, however the strength of the 
associations and effect sizes found might suggest that the most important common variants 
have already been discovered 72-74.  
 
The thrombotic tendency caused by inherited thrombophilias can either be by mutations 
leading to the loss of anticoagulant function or by gained procoagulant function. Inherited 
loss-of-function thrombophilias include antithrombin, protein S and protein C deficiencies. 
They are all natural inhibitors of the coagulation cascade, and the loss of function is often 
quite severe. AT deficiency is associated with a 10-50 fold increased risk of VTE but rarely 
occurs in the general population (0.02%) although it can be caused by more than 200 different 
mutations 68,71. Protein C and protein S deficiencies are also rare in the population (<1%). 
These deficiencies are associated with an 8-10 fold higher risk of VTE and several mutations 
have been reported 71,75.  
 
Inherited gain-of-function thrombophilias are more prevalent in the general population but 
often less severe in effect. The non-O blood group, with a prevalence of approximately 60%, 
is the most common gain-of-function mutation affecting VTE risk 76-78. The risk of VTE is 
1.5-2 fold higher for individuals with blood groups A1 and B compared to blood group O 
76,79. 




general population makes this an important inherited risk factor for VTE. The factor V 
Leiden mutation (FVL) is caused by a single point mutation (G to A substitution) in the factor 
V gene causing APC resistance 80. The FVL variant varies among ethnicities, with the highest 
prevalence of approximately 5% found in the Caucasian population 71,81. The risk of VTE for 
heterozygous carriers of FVL is 2-5 fold increased, while homozygous carriers have a 10-80 
fold increased risk, compared with non-carriers 82,83. The prothrombin G20210A mutation is 
similarly more prevalent in the Caucasian population with a prevalence of 1-3% 83,84, and 
carriers have a 3-4 fold increased risk of VTE compared to non-carriers 71,85. The prothrombin 
mutation leads to a hypercoagulable state through increased levels of prothrombin, and 
consequently enhanced thrombin generation 85.  
 
1.3.2 Acquired risk factors   
A number of acquired risk factors for VTE have been identified through epidemiological 
studies. High and advancing age is one of the strongest risk factors for VTE, and about 70-
90% of VTE events in the population can be ascribed to aging 86,87. The risk increases 
exponentially after the age of 50, while at  85 years of age the risk of VTE is 80 fold higher, 
compared to individuals aged 20-30 years 27,29,88. The proposed mechanisms behind the 
observed association are increased levels of procoagulant factors in blood, degenerative and 
functional changes to the vessels and valves, and general frailty and immobility due to illness, 
infection and comorbidities. The loss of muscle mass following inactivity also contributes to 
reduced venous return and stasis in the lower extremities 1,56,86.  
 
Obesity, defined as body mass index (BMI) above 30 kg/m2, is associated with a 2-3 fold 
higher risk of VTE, compared with normal weight individuals 89. Furthermore, there is a dose-
dependent relationship between increasing BMI and increasing VTE risk 89. Weight gain 
increases the risk for VTE, particularly for already obese individuals where a 4-fold increase 
in risk is seen, compared to obese individuals maintaining a stable weight 90. Although BMI is 
the most commonly used anthropometric measure of obesity, waist circumference has been 
shown to be a more precise measure for detecting and predicting the risk of VTE in obese 
individuals 91. The proposed mechanisms behind the association are venous stasis due to intra-
abdominal pressure, changes in blood components leading to a procoagulant state 




Mendelian randomization studies imply a causal relationship between obesity and VTE 92-94. 
As the prevalence of obesity increases worldwide 95, it is an important risk factor to consider 
when evaluating VTE risk as it is one of the few modifiable lifestyle risk factors currently 
known. Additionally, studies on the synergistic effects of obesity in combination with risk 
factors like prothrombotic genotypes (FVL, prothrombin mutation G20210A, non-O blood 
group), and oral contraceptive use on VTE risk have been reported 96-99. The joint effect of 
obesity and FVL and prothrombin mutation G20210A increased the risk of VTE 6-8 fold, 
compared to normal weight individuals without the genetic predispositions 96. Similarly, the 
joint effect of obesity and oral contraceptive use imposed a 24-fold higher risk of VTE 
compared to normal weight women who did not use oral contraceptives 96.  
 
Body Height is a risk factor for VTE observed particularly in men 33,100. A prospective cohort 
study reported a 34% increased risk of VTE per 10 cm increase in body height in men, and a 
13% increase in risk in women 100. The link between tall stature and VTE could be explained 
by the fact that an increase in height will subsequently also increase the vessel area at risk, the 
hydrostatic pressure, as well as the number of venous valves in the legs 101,102. Height has 
been found to be more strongly associated with DVT than PE, supporting the proposed 
mechanisms behind the observed association 102. A synergistic effect of body height and 
obesity on VTE risk has been reported 103. Men who were tall (182 cm) and obese had a 5-
fold higher risk of VTE than short (≤172 cm) and normal weight men 103. For women, the 
combination of tall stature and obesity increased the risk of VTE 3-fold, compared to short, 
normal weight women 103.  
 
Cancer imposes a major risk for VTE, and about 20-30% of all incident VTE events are 
associated with cancer 27,104,105. Overall cancer increases the risk of VTE 4-7 fold compared to 
the general population, but the risk varies considerably according to both cancer type and 
treatment regime 106,107. The cancer types associated with the highest risk of VTE include 
pancreatic, ovarian, brain, hematological and lung cancers 104,108. The risk of VTE in cancer 
patients is found to be the highest 6 months before cancer diagnosis and up to 12 months after 
diagnosis 104,109. The potential explanations for the association between VTE and cancer can 
be grouped into treatment-, patient- and cancer-related factors. The treatment related factors 




erythropoiesis-stimulating agents. Patient-related factors include increasing age, a previous 
history of VTE, comorbidities, obesity and immobilization. Cancer type, cancer stage and 
time since cancer diagnosis are cancer-related factors 104,110. The impact of the tumor itself 
may play a greater role on the risk of VTE than the treatment related risk factors, as it has 
been shown that the risk of VTE was similar six months prior to and after a cancer diagnosis, 
when taking competing risk by death into account 109. Tumor growth can lead to a physical 
obstruction in the vessels and result in stasis. Additionally, tumor cells are known to enhance 
the procoagulant potential by activating coagulation through TF positive extracellular vesicles 
(TF+EVs), interacting directly with platelets and endothelial cells, influencing the release of 
proinflammatory cytokines and dysregulating the fibrinolytic system 106. For instance, in 
pancreatic cancer a hypercoagulable state is caused by the release of TF+ tumor-derived EVs 
into the circulation, which in turn triggers a VTE event 22,111. Lung cancer has been found 
associated with leukocytosis, which may enhance the risk of VTE through neutrophils and the 
generation of neutrophil extracellular traps (NETs) 111.  
 
Hospitalization, current or recent, is estimated to account for more than 50% of all VTE 
events, due to factors like immobilization, infection, surgery and fractures 105,112. 
Hospitalization-related VTE events were found to be the leading cause of disability-adjusted 
life-years lost in low and middle income countries, and second in high income countries 
worldwide emphasizing the global burden of VTE 113. Major surgery, that is surgery under 
general anesthesia exceeding 30 minutes, is one of the most important hospital-related risk 
factors for VTE, accounting for about 20% of the VTE events in the general population 87.  
Major surgery in general is associated with a 4-22 fold increased risk of VTE 114, but the risk 
estimates vary according to the type of surgery. Orthopedic surgery, and particularly total hip 
arthroplasty, as well as major vascular surgery and neurosurgery are procedures with 
particularly high risk for VTE 115. Patients suffering major trauma are at a 12-fold increased 
risk of VTE 107, and it has been estimated that as many as 58% of trauma patients may suffer 
from DVT in the absence of thromboprophylaxis 116. Similarly, acute medical conditions, 
like myocardial infarction, ischemic stroke, heart failure, infections and respiratory diseases 
are all associated with increased risk of VTE 117. Immobilization is a risk factor often 
accompanying hospitalization in the form of confinement to bed or wheelchair, bed rest for 




increased risk for developing VTE 118. Additionally, immobilization as a risk factor for VTE 
can also be in the form of long-haul air travel 119.  
 
Pregnancy is associated with a 4-5 fold higher risk of VTE compared to non-pregnant 
women of similar age. The risk increases further to 20-fold in the postpartum period, 
compared to non-pregnant women 120,121. Pregnancy alters the hemostatic system to a more 
procoagulant state, characterized by an increase in several coagulation factors (FVII, FVIII, 
and FX) and a decrease in the natural anticoagulant protein S, leading to acquired APC 
resistance 122 . The alterations to the hemostatic system favoring a more procoagulant state 
during pregnancy are thought to be an important measure in minimizing potentially lethal 
blood loss during child birth. The risk of VTE during pregnancy is also increased due to 
mechanical changes caused by the expanding uterus leading to stasis by the increased intra-
abdominal pressure and compression of the vena cava 123.  
 
The use of exogenous hormone supplements, that is combined oral contraceptives (COC) or 
hormone replacement therapy, increases the risk of VTE by causing alterations to coagulation 
and fibrinolysis leading to an overall more procoagulant state 124,125. The risk of VTE 
increases 3-4 fold for COC users, and 2-4 fold for those undergoing hormone replacement 
therapy, compared to non-users. For both types of hormone supplements the increase in risk is 
most profound in the first months of use 124,125. The combined effect of COC use and the 
genetic risk factor FVL has been shown to account for a 35-fold higher risk of VTE, 
compared to non-users without FVL 126. Similarly, it has been reported that other genetic risk 
factors (non-O blood group, SNP rs2289252 in FXI), as well as environmental factors 
(smoking, high BMI) additionally increase the risk of VTE in women using COC 127,128.  
 
1.4 Treatment of VTE 
Anticoagulant treatment is associated with a 90% risk reduction for recurrent events and all-
cause mortality following two weeks treatment compared to no treatment 5. VTE treatment 
can be divided into the three following phases; acute (first 5-10 days), long-term (first 3 
months) and extended (beyond 3 months). Generally, all DVT and PE patients are treated for 
3 months with anticoagulation. However, decisions regarding extended treatment need to 




antagonists (VKA), low molecular weight heparin (LMWH) and unfractionated heparin were 
for a long time the treatment options of choice, but in recent years additional options are 
available in the form of direct oral anticoagulants (DOACs). In 2014 the first DOAC, the 
direct thrombin inhibitor Dabigatran, was approved for the treatment of VTE in the United 
States. Shortly after, the first direct factor Xa inhibitors, namely Rivaroxaban, Apixaban and 
Edoxaban were launched and included in the 2016 American College of Chest Physicians’ 
(ACCP) guidelines 130. Several randomized controlled trials (RCTs) have compared the use of 
DOACs to LMWH and Warfarin and concluded that they are non-inferior when it comes to 
efficacy in preventing recurrent events and VTE-related deaths. However, the RCTs report 
diverging results regarding the risk of major bleeding ranging from statistically significant 
lowered risk 131,132 to no difference between the study drugs 133-136. To date, there is no 
treatment or prophylactic option that effectively reduces VTE without the accompanying risk 
of major bleeding.   
 
1.5 The coagulation system 
Blood is a liquid that circulates in the vasculature under pressure. In case of injury to the 
vasculature it is important to minimize blood loss by rapidly converting liquid blood into a 
gel-like clot to serve as a plug. 137. Blood consists of a cell portion including erythrocytes, 
leukocytes and platelets, as well as a plasma portion containing soluble proteins which act 
together to form a fibrin clot. Hemostasis is the normal process where the clotting cascade 
prevents blood loss following vascular damage. It can further be divided into primary 
hemostasis covering platelet activation, aggregation and adhesion at the site of injury, and 
secondary hemostasis covering the activation of the coagulation factors, the formation of 
fibrin and plug stabilization. Thrombosis, on the other hand, is the formation of a blood clot 
caused by coagulation triggered inside the lumen of a blood vessel, often in the absence of 
tissue damage 137,138.  
 
In 1964 two research groups proposed at about the same time a cascade or waterfall model for 
blood coagulation. The models were based on a series of steps in which one coagulation 
factor would lead to the activation of the following factor, and so on, resulting in the 
generation of thrombin and the formation of a fibrin clot 139,140. Initially, all coagulation 




active enzyme. However, this concept has later been modified after some of the coagulation 
factors, like FVa and FVIIIa, were found to serve as cofactors for other coagulation factors 
and not hold enzymatic activity individually 141. The coagulation system is comprised of the 
intrinsic and extrinsic pathways that merge into the common pathway with FX activation to 
FXa. FXa activates prothrombin to thrombin, which culminates in the formation of cross-
linked fibrin (Figure 4) 142.  
 
 
Figure 4. Simplified overview of the intrinsic (blue), extrinsic (orange), and common 
pathway (red) of the coagulation system. (Adapted from Mackman N., J Clin Invest 2012 8) 
 
The extrinsic pathway is also known as the tissue factor pathway. TF is an integral 
membrane protein expressed by specific cells within the vessel wall and surrounding the 
blood vessels, like periocytes, vascular smooth cells, and adventitial fibroblasts. TF is also 
expressed by monocytes under pathological conditions 138. TF deficiency in humans has never 




underscoring the fact that TF is essential to hemostasis 138. TF initiates the coagulation 
cascade by binding with high affinity to the circulating coagulation factor FVII and the trace 
amounts (~1%) of circulating activated FVII(a) 143. The inactive zymogen FVII is rapidly 
converted to FVIIa after complexing with TF. Negatively charged phospholipids, like 
phosphatidylserine expressed on the surface of damaged cells, activated platelets and 
microvesicles are crucial for the assembly of both the extrinsic and the intrinsic tenase 
complex 137,138. The activity of the extrinsic tenase complex increases by several orders of 
magnitude in the presence of negatively charged surfaces 144. In the absence of an appropriate 
surface, most coagulation enzymes show low activity with their substrate within a biologically 
relevant time frame. The TF:FVIIa complex activates its substrates FIX and FX to FIXa and 
FXa, respectively. Thrombin is subsequently formed in small amounts leading to the 
activation of cofactors FV and FVIII. In order for the coagulation cascade to propagate 
further, both FIXa and FXa need an appropriate surface in order to assemble together with 
their individual cofactors, FVIIIa with FIXa, and FVa with FXa. The prothrombinase 
complex, FXa-FVa, activates prothrombin to thrombin 137,138. With the formation of large 
amounts of thrombin fibrinogen is cleaved to fibrin monomers. The monomers polymerize 
spontaneously and FXIIIa cross-links the fibrin chains in order to stabilize the clot 145.  
 
The intrinsic pathway of the coagulation system is activated by FXII coming in contact with 
negatively charged artificial surfaces. For in vivo activation of the intrinsic pathway, several 
potential activators are proposed like platelet-derived polyphosphates 146 and extracellular 
nucleic acids 147,148. The activation of FXII leads to the formation of small amounts of FXIIa. 
A positive feedback loop is initiated by FXIIa activating prekallikrein (PK) to kallikrein, 
which again activates FXII. FXIIa further activates FXI to FXIa. FXIa activates FIX to FIXa, 
which together with cofactor FVIIIa forms the intrinsic tenase complex. This activates FX to 
FXa in the common pathway, leading to the generation of thrombin and ultimately the 
formation of fibrin 137,149. Interestingly, neither mice nor humans deficient in FXII suffer from 
defects in hemostasis 150, suggesting that the intrinsic pathway does not contribute 
significantly to hemostasis. However, several studies have suggested a role for FXII and the 






Excessive clotting is harmful to the host, hence coagulation must be tightly regulated through 
the natural anticoagulants TFPI, AT and protein C. TFPI directly inhibits FXa, and therefore 
the activity of the prothrombinase (FXa/FVa) complex. TFPI also inhibits the TF/FVIIa 
complex. TFPI is the only endogenous protein that effectively inhibits these complexes under 
physiological conditions 154. No human deficient in TFPI has ever been reported, emphasizing 
the importance of TFPI in hemostasis. Observations from mouse studies show that TFPI 
deficiency leads to death in utero, strongly suggesting that TFPI deficiency is not compatible 
with life 155. Antithrombin, another natural anticoagulant, primarily inhibits FXa and thrombin 
in the common pathway, as well as the TF/FVIIa complex in the presence of heparin 156. 
Heparin and heparin-like glycosaminoglycans enhance the anticoagulant activity of AT by 
100 to 1000-fold 157,158. APC bound to its cofactor protein S, inhibits FVa and FVIIIa 159. 
Defects in the regulation of coagulation can lead to either bleeding events or thrombosis 
160,161. As previously discussed, deficiencies in AT, protein C and protein S are established 





1.6 Extracellular vesicles  
Our knowledge on EVs has grown immensely during the last decades from the first 
observations of “thromboplastic substances” 162 and “platelet dust”163 to the vast knowledge 
of EVs that we hold today. As early as 1946 Chargaff and West published their observations 
of “thromboplastic substances” in blood affecting coagulation. These substances were 
sedimentable by high speed centrifugation, and the sedimentation of these substances resulted 
in prolonged plasma clotting time 162. In 1967 Peter Wolf published his findings on what he 
named “platelet dust”. The platelet dust could be separated by ultracentrifugation, was rich in 
phospholipids and described to hold coagulant properties like Platelet Factor 3 163. With time 
and advances in technology and methodology numerous papers have been published on the 
topic of EVs 164.  
 
EVs are small vesicles that are released from a parental cell either by direct budding from the 
plasma membrane or by fusion of multivesicular bodies with the plasma membrane releasing 
small vesicles into the extracellular space (Figure 5). EVs are enclosed by a phospholipid 
bilayer membrane, which distinguishes them from other membrane vesicles like lipoproteins 
9,23. From an evolutionary perspective, the secretion of bi-layered membrane vesicles seems to 
be a common and conserved process. The release of EVs has been reported for both 
eukaryotic as well as prokaryotic cells. In humans, EVs have been isolated and studied in 
most bodily fluids like blood, urine, breast milk, saliva, amniotic fluid and semen 9,23,165. 
Several different names have been proposed for the vesicles, and for a long time a common 
consensus was lacking. This gave rise to a vast nomenclature either referring to their size 
(using the prefixes micro or nano for microparticles, microvesicles, nanoparticles, 
nanovesicles), to a proposed function (calcifying matrix vesicles), the cell or tissue they 
derived from (prostosomes, oncosomes), or by their presence outside of a cell (using the 
prefixes exo or ecto for exosomes, ectosomes) 165. However, the most commonly used 
subgroups are exosomes, microvesicles (MVs) and apoptotic bodies. Exosomes are the 
smallest of the EVs ranging from 30 to 100 nm and are released into the extracellular space by 
multivesicular bodies fusing with the plasma membrane. Microvesicles range in size from 100 
to 1000 nm and bud directly from the plasma membrane. Apoptotic bodies are the largest of 
the released vesicles and have been described to range from 1000 to 5000 nm. These bud off 





Figure 5. Overview of the different types of membrane vesicles released by eukaryotic cells. 
Microvesicles and apoptotic bodies are released by direct budding from the plasma membrane 
(PM), while exosomes are released by fusion of internal multivesicular bodies (MVB) with 
the PM. (Used and modified with permission of Annual Reviews, Inc., from Biogenesis, 
secretion, and intercellular interactions of exosomes and other extracellular vesicle. 
Colombo, M., Raposo, G., and Théry C. Annu Rev Cell Dev Biol, 2014. 30: p. 255-89 165; 
permission conveyed through Copyright Clearance Center, Inc.) 
 
EVs are important as they are able to transfer information from one cell to another, and 
influence the recipient cell function. EVs can transfer messages in the form of proteins, lipids, 
nucleic acids (mRNA, microRNA) and sugars 9,23,166. The phospholipid bilayer membrane 
surrounding the vesicle protects the message molecule and allows for the vesicle to travel 
with the biological fluid to sites remote to the parental cell 23. The release of EVs is a natural 
process 167, however most of the attention in research has been focused on the role of EVs in 
disease states. Pathological mechanisms known to trigger EV release include inflammation, 
shear stress, inducers of apoptosis, as well as activation of the coagulation system and the 





1.6.1 Formation and uptake of EVs 
The cytoplasmic membrane of eukaryotic cells has an asymmetric distribution of 
phospholipids, where negatively charged phospholipids like PS are located in the inner leaflet 
of the membrane of resting cells (Figure 6). There are three important enzymes that maintain 
the lipid asymmetry of the membrane: flippase, floppase and scramblase 166,169. The formation 
of EVs is initiated by an increase in the cytosolic concentration of calcium ions, which in turn 
activates scramblase. This results in a loss of membrane phospholipid asymmetry by 
increased scramblase activity together with the activation of floppase and the inactivation of 
flippase. PS is subsequently translocated to the outer leaflet of the membrane and exposed to 
the surroundings. Calpain, a calcium-dependent proteolytic enzyme is also activated, and 
causes a calcium dependent degradation of various proteins, allowing for the outward budding 
of MV from the membrane 166,169. The importance of proper enzymatic maintenance of the 
lipid asymmetry of the membrane is emphasized by the rare bleeding disorder Scott 
syndrome. Scott syndrome is characterized by a dramatic impairment of the procoagulant 
activity of stimulated platelets due to a functional defect in the surface exposure of anionic 
phospholipids 170. Scramblase is found to be defective and thereby unable to translocate PS 
from the inner to the outer leaflet of the membrane of activated platelets in addition to causing 
impaired membrane vesiculation. 166,170.   
 
Figure 6. The cytoplasmic membrane of eukaryotic cells has an asymmetric distribution of 




inner leaflet of the membrane of resting cells. During EV formation the negatively charged 
phospholipids are translocated to the outer leaflet of the membrane and exposed to the 
surroundings. (Modified from Schindler S. M., Microparticles: A New Perspective in Central 
Nervous System Disorders, BioMed Res Int 2014 171. Printed with permission through the 
Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/). 
 
The biogenesis of exosomes starts with the inward budding of the endosomal membranes 
generating intraluminal vesicles (ILV) within large multivesicular bodies (MVBs) (Figure 5). 
Cytosolic components are engulfed within the ILV, while transmembrane proteins are 
incorporated into the invaginating membrane 172. Intracellular MVB can either be subjected to 
proteosomal degradation in the lysosomes, or fuse with the plasma membrane. Upon fusion 
with the plasma membrane, the MVBs release their contents (ILV) into the extracellular 
space. The intraluminal vesicles are referred to as exosomes as they are released from the 
MVB and into the extracellular space 172,173.  
 
Several mechanisms has been proposed for EV uptake into cells, including phagocytosis, 
clathrin- and caveolin-mediated endocytosis, macropinocytosis and plasma or endosomal 
membrane fusion 174. EV uptake by the target cell may depend on the type of recipient cell 
and its physiological state, as well as ligand-receptor recognition by the EV and the target cell 
173. Different mechanisms for EV internalization has been described, with clathrin-dependent 
endocytosis or phagocytosis in neurons, caveolin-mediated endocytosis in epithelial cells and 
cholesterol and lipid raft dependent endocytosis in tumors 173. In addition, EVs can exert their 
functional effect on the target cell through direct receptor-ligand interaction 173. The level of 
EVs in circulation reflects the balance between generation and clearance. Studies differ with 
regard to the reported half-life of EVs 23. A study conducted in rabbits reported that biotin-
labelled platelet-derived EVs which were reintroduced into the animal were cleared within 10 
minutes from the circulation 175. In rats, red blood cell derived EVs which were labelled and 
injected into the animal, were found to be 91% cleared from circulation within 30 minutes 176. 
A similar clearance of 90% within half an hour was also reported for EVs derived from 
splenocytes 177, and B16 melanoma cells 178 in mouse models. The biodistribution of EVs 
varies with the cellular origin of the EVs. Melanoma-derived EVs were mainly taken up by 




(44.9%) followed by bone (22.5%), skin (9.7%), muscle (5.8%), spleen (3.4%), kidney (2.7%) 
and lung (1.8%) 176.  
 
1.6.2 EVs and coagulation   
EVs are procoagulant due to their surface expression of procoagulant proteins such as TF and 
negatively charged phospholipids (mainly phosphatidylserine, PS), which explains their role 
in coagulation activation. In contrast to TFs vital role in activating coagulation, elevated 
levels of TF+EVs are only found in certain disease states such as certain cancers or 
disseminated intravascular coagulation (DIC) 19-22. During EV formation the phospholipid 
asymmetry in the cell surface membrane is distorted and PS is exposed on the surface of the 
EV. PS facilitates the assembly of coagulation factors FVII, IX and X, as well as prothrombin 
on the EV surface, and it has been shown that the cleavage of factor X by soluble TF-VIIa 
showed a more than 100-fold enhanced reaction rate in the presence of phospholipids 144,179. 
PS binds to the γ-carboxyglutamic acid (GLA) domains located at the N-terminal of 
coagulation factors FVII, IX, X and prothrombin. PS binds in a reversible and calcium-
dependent manner to the GLA domains 180. The impact of PS+EVs on coagulation can be 
assessed directly in plasma using a PPL activity clotting assay.  
 
1.6.3 EVs and VTE 
Several studies have investigated the association between plasma levels of EVs and VTE. 
While some report elevated plasma levels of EVs 181,182, others focus on the expression of 
particular antigens 11,19, the procoagulant activity 20, or a combination of the above 21,181,182. 
However, the relationship between EVs and VTE is to date still best understood in cancer 
patients 19-22.  
 
There are limited original papers on the relationship between EV procoagulant activity as 
measured by clotting assays, and VTE. However, in a cross-sectional study including 100 
patients referred to the Emergency Department under suspicion of VTE, plasma clotting time 
was assessed by the STA Procoag PPL assay. It was found that PPL clotting time did not 
discriminate between patients with (n=31) and without VTE 183. Still, the lack of 
discriminatory diagnostic power by the PPL assay may have been diluted by other conditions 




exclude the potential of plasma clotting time as a potential predictive biomarker of VTE. Still, 
circumstantial evidence supports an association between procoagulant plasma clotting time 
and future risk of VTE. First, the procoagulant clotting time is inversely associated with 
annexin V+ EVs 184,185 and the plasma levels of EVs are associated with VTE risk in most 181, 
but not all studies 186. Second, in a cross-sectional study including 100 samples from healthy 
individuals and patients with obstructive sleep apnea, plasma clotting time presented strong 
and inverse correlations to parameters of thrombin generation. This was measured using the 
Calibrated Automated Thrombogram method with the addition of minimal amounts of 
phospholipids and TF (1 pM) to trigger thrombin generation 185. Several studies have shown 
that parameters of the thrombogram are associated with incident 187-189 and recurrent 190 VTE. 
Third, carriers of rare (e.g. deficiencies of antithrombin, protein C and S) 191 and common 
(e.g. factor V Leiden and the prothrombin mutation G20210A) 192,193 prothrombotic genotypes 
had significantly shorter plasma clotting time than non-carriers, providing indirect evidence 
for lower risk of VTE with prolonged plasma clotting time. However, most of the current 
studies are cross-sectional or retrospective, making it difficult to deduce whether EVs play a 
causal role of the disease or are merely a consequence of it. In addition, methodological 






2. Aims of the thesis 
 
The overall aim of the present thesis was to develop an easily available and reproducible FXa-
dependent clotting assay to measure plasma procoagulant phospholipid (PPL) activity, and 
investigate the association between plasma PPL activity and the risk of VTE.  
 
The specific aims were:  
I. To investigate the impact of plasma preparation, assessed by freezing plasma before 
(PPP) or after (PFP) a second high-speed centrifugation, various anticoagulants in 
commercial blood collection tubes (Citrate, EDTA, CTAD, and Heparin), and fasting 
status on plasma concentration and size distribution of EVs using Nanoparticle 
Tracking Analysis (NTA) and scanning electron microscopy (SEM). 
 
II. To develop a modified PPL-dependent clotting assay, capable of measuring the PPL 
activity in human plasma and cell supernatants of in vitro experiments, by removing 
PPL from plasma by sequential centrifugation, including final ultracentrifugation.  
 
III. To investigate the association between plasma PPL clotting time and the risk of 
incident VTE in a nested case-control study derived from the general population.  
 
IV. To investigate the impact of rosuvastatin treatment on plasma PPL activity in 
individuals with a previous history of VTE in a randomized controlled trial, and 
explore the effect of rosuvastatin treatment on total- and platelet-derived EV counts 





3. Methods   
3.1 Study populations 
For the papers included in the current thesis, different study populations were used including 
healthy volunteers (paper I and II), a nested case-control study derived from a population-
based cohort (paper III) and a randomized controlled trial (paper IV). The two latter 
populations will be further addressed in this section.   
 
3.1.1. The Tromsø study  
The Tromsø study is a single-center population-based cohort study with repeated health 
surveys on the inhabitants of the municipality of Tromsø 194. Tromsø is the largest city in 
northern Norway with a population of about 77,000 inhabitants. The first Tromsø study was 
conducted in 1974 to investigate why there was such high mortality from cardiovascular 
disease among young men in Norway, and particularly in the northern part of the country. The 
University of Tromsø was fundamental in the creation, as well as the continuation of the 
health surveys, resulting in numerous research findings made available through publications 
and doctoral thesis. Overall, more than 45,000 unique individuals, aged 25-97 years, have 
participated in one or more of the Tromsø studies. The participation rates for the studies have 
been high, ranging from 65-85% 194. To date seven surveys have been completed, with an 
eighth survey planned for 2024-25.   
 
The fourth survey of the Tromsø study (Tromsø 4) was conducted in 1994-95. All inhabitants 
of the municipality of Tromsø aged 25 years or older were invited to participate in the study. 
Tromsø 4 is the largest of the studies with 27,158 participating individuals, and a participation 
rate of 77%. The participants were followed from the date of inclusion in 1994-95 and until 
migration from the municipality, death or end of follow-up (September 1, 2007). Baseline 
information was collected through self-administered questionnaires, blood sampling, and 
physical examinations. The questionnaires assessed aspects of the participant’s general health, 
lifestyle, diet, medication use, and the occurrence of particular disease states in the immediate 
family (arterial cardiovascular diseases and cancer). All participants had their height (to the 
nearest cm) and weight (to the nearest 0.5 kg) measured, wearing light clothing and no shoes. 
Body mass index (BMI) was calculated using weight in kilograms divided by height in meters 
squared (kg/m2). Non-fasting blood samples were collected by venipuncture of an antecubital 




acid (K3-EDTA 40 µL, 0.37 mol/L per tube) (Becton Dickinson, Meylan Cedex, France). Cell 
counts were performed using a Coulter Counter (Coulter Electronics, Luton, UK). Platelet 
poor plasma (PPP) was prepared by centrifugation at 3000 x g for 10 minutes at room 
temperature. Plasma aliquots were transferred to 1 mL cryovials (Greiner Laboratechnik, 
Nürtringen, Germany) and stored at -80°C until analysis 34,194. The Regional Committee for 
Medical and Health Research Ethics, North Norway (REC Nord) approved the study, and all 
participants provided informed written consent.   
 
Identification and validation of the VTE events 
All incident VTE events occurring among the participants from inclusion and until the end of 
follow-up were identified by searching the hospital discharge diagnosis registry, autopsy 
registry and the radiology procedure registry at the University Hospital of North Norway 
(UNN). UNN is the sole provider of all hospital-based and outpatient medical care in the 
region, including all relevant diagnostic radiology and treatment of VTE. International 
Classification of Diseases (ICD), revision 9 (ISC-9), codes 325, 415.1, 451, 452, 453, 671.3, 
671.4 and 671.9 were used to identify VTE events occurring from 1994 to 1998, while 
revision 10 (ICD-10) codes I26, I80, I81, I82, I67.6, O22.3, O22.5, O87.1, and O87.3 were 
used for the time period 1998 to 2007. After the identification of events, trained personnel 
reviewed the medical records for every potential VTE case for validation. VTE events from 
the hospital discharge diagnosis registry and the radiology procedure registry were recorded 
and found valid only if all of the following criteria were met: 
1. Clinical signs and symptoms of DVT or PE, or both, were present 
2. The event was objectively confirmed by a diagnostic procedure (compression 
ultrasound, venography, computed tomography, perfusion-ventilation scan, pulmonary 
angiography, or autopsy) 
3. A physician noted the diagnosis of DVT or PE in the patient’s medical record  
4. Treatment was initiated (anticoagulant medication, thrombolysis, vascular surgery) 
unless contraindications were specified 
VTE cases from the autopsy registry were recorded if VTE was indicated as the cause of 





The confirmed VTE events were further classified as a DVT or PE, and in the case of both 
present, the event was classified as a PE. A VTE was classified as provoked if one of the 
following risk factors were found in the medical records up to 8 weeks preceding diagnosis; 
major surgery, trauma, active cancer, acute medical conditions like acute myocardial 
infarction, ischemic stroke or major infectious disease, immobilization defined as bed 
confinement exceeding 3 days, wheelchair confinement or long haul travel exceeding 4 hours 
within two weeks before VTE event, or other factors specified in the medical records to be 
provoking, like plaster cast or intravascular catheter. For unprovoked events, none of the 
above mentioned risk factors were present 34.  
 
Paper III is based on a nested case control study derived from the 4th survey of the Tromsø 
study. There were 462 individuals who experienced a VTE event during the follow-up period 
(1994-2007). For each case, two age- and sex-matched controls, who were alive at the index 
date of the corresponding VTE-case were randomly sampled from the source cohort (n=924). 
In total, 349 (140 cases and 209 controls) lacked plasma samples and 67 (26 VTE cases and 
41 controls) had plasma samples of insufficient quality (e.g. due to hemolysis). Hence, our 
study population consisted of 296 subjects with incident VTE and 674 age- and sex-matched 
controls. We measured the PPL clotting time in all samples using our modified FXa-
dependent clotting assay as described in detail previously 195. Information on age, sex, BMI, 
previous cardiovascular disease and cancer were obtained from the Tromsø study.  
 
3.1.2 The Statins Reduce Thrombophilia (START) Trial  
STAtins Reduce Thrombophilia, or the START trial (NCT01613794), is a multicenter, 
randomized, controlled, open label clinical trial aimed to investigate the impact of 
rosuvastatin treatment on the coagulation profile of individuals with a previous history of 
VTE. The study has been described in detail elsewhere 196-199. In brief, participants were 
recruited from three Dutch anticoagulation clinics (Leiden, Hoofddorp, and Rotterdam) which 
monitor anticoagulant treatment of VTE patients within a geographical area. Subjects with 
confirmed initial or recurrent symptomatic proximal DVT or PE allowed to stop oral 
anticoagulation treatment by their treating physician and aged 18 years or older, were invited 
to participate. Exclusion criteria were the following; individuals already using statins or other 




based on information provided by the instruction leaflet of the drug manufacturer. Participants 
were randomly assigned to either 20 mg/day of rosuvastatin or no study medication for the 
28-day study duration. The random allocation sequence was implemented by a central 
telephone, and the sequence was concealed until interventions were assigned. Adherence to 
the study protocol was assessed in two ways. First, participants in the treatment group took 
the first tablet of rosuvastatin in the presence of an investigator. Second, compliance to 
treatment was assessed by measurements of total cholesterol levels at baseline and at study 
end in all participants. The START trial was approved by the Medical Ethics Committee of 
the Leiden University Medical Center, Leiden, the Netherlands, and all study participants 
gave written informed consent prior to participation.  
 
The study baseline was set as the last regular visit of the participants to the anticoagulation 
clinic. All participants were screened on acquired risk factors for VTE through a 
questionnaire, in addition to being tested on kidney and liver function. The participants had 
stopped using their vitamin K antagonist one month prior to baseline blood draw to allow a 
wear off of the anticoagulant drugs. Non-fasting blood samples were collected in Vacutainer 
tubes containing 3.2% sodium citrate (Becton Dickinson, Meylan Cedex, France) at baseline 
and at study end (i.e. 28 days later). Samples were centrifuged at 2,500 x g for 15 minutes at 
18°C and platelet poor plasma (PPP) was stored at -80°C until analysis. 
 
In paper IV we measured the PPL clotting time in plasma samples from 125 participants who 
received rosuvastatin treatment and 120 participants from the control group. Measurements 
were performed using our modified FXa-dependent clotting assay previously described 195. In 
addition, we measured total and platelet-derived microvesicle counts using a sensitive flow 
cytometer (CytoFLEX, Beckman Coulter) in a selection of the trial participants (40 from the 







3.2 Methods used for EV measurements  
3.2.1 Isolation of EVs   
EVs can be isolated from their source fluid by several methods, such as ultracentrifugation 
(UC), size-exclusion chromatography, ultrafiltration, sucrose-gradient UC, density-gradient 
UC, or by a combination of the above 200. Precipitating agents like PEG and other commercial 
reagents have been suggested as rapid methods to use in order to enrich EVs from a biological 
fluid. However, these reagents also co-precipitate contaminant like lipoproteins 200,201. 
Choosing the method of EV isolation is a process of considering the pros and cons of each 
method while keeping in mind the source of the biological fluid, the input volume, the 
downstream application (required degree of purity), and the number of samples to be 
processed. For the work in the current thesis, the biological fluids used have been human 
blood and blood plasma. EVs have either been measured directly in plasma (PPL activity and 
CAT assay) or isolated by ultracentrifugation (20,000 x g for 30 minutes) and resuspended in 
buffer for subsequent analysis (NTA, flow cytometry, and electron microscopy).  
 
Ultracentrifugation is considered the gold standard for EV isolation. Blood is first centrifuged 
by one or more low-speed centrifugations to remove cells and cell debris and to generate 
plasma. Larger EVs (microvesicles) are most commonly pelleted from plasma by 
centrifugation speeds in the range of 10,000-20,000 x g for approximately 30 minutes. 
Smaller EVs (exosomes) are pelleted at a higher speed (100,000-120,000 x g) for a longer 
duration of  time (from 1 hour and longer) 200. Ultracentrifugation as a method cannot be used 
to absolutely discriminate between EV sizes, since sedimentation also will depend on the 
density and cargo of a vesicle, as well as the distance it needs to travel to be pelleted 200. To 
overcome the latter obstacle, it has been recommended to dilute biological fluids with PBS in 
order to alter the viscosity of the sample fluid and thereby enhance the sedimentation of EVs 
202. Ultracentrifugation has been described to induce aggregation of EVs as a result of the high 
speed applied 203. The method will also to some extent co-isolate contaminants from the 
source fluid. However, it is a relatively quick and easy isolation procedure with the possibility 
of high throughput of samples, and it requires minimal sample handling. The importance of 
reporting all aspects of EV isolation, in order to ensure reproducibility of study findings 
procedures has been stressed. The physical separation of vesicles not only depends on the g 
force applied, but also the type of rotor used (fixed angle, swinging bucket), the pelleting 




3.2.2 Quantification and size distribution of EVs 
Nanoparticle tracking analysis (NTA) is an advanced technique allowing for direct and 
real-time visualization and analysis of vesicles in solution. The technique combines the light 
scattering properties of vesicles with their Brownian motion in order to determine the size 
distribution and concentration. The technique is unique in that each particle is individually 
tracked and analyzed. In brief, the sample of interest, in this case vesicles in suspension, is 
inserted into a sample chamber. The vesicles are then visualized using a conventional optical 
microscope connected to a video camera. The sample is recorded by the camera for a set 
period of time, typically 60s, and for a number of repeats, and video files are generated. The 
software uses the videos generated to track individual vesicles frame-by-frame as they move 
in the sample chamber throughout the length of the video. The size is determined using the 
mean squared displacement to calculate their theoretical hydrodynamic diameter using the 
Stokes Einstein equation. NTA also estimates the concentration of vesicles in the sample 
204,205.  
 
The NanoSight (Malvern, UK) instruments are the most commonly used NTA instruments in 
the EV field. According to the manufacturer they offer a detection range of approximately 10-
1000 nm. The detection range depends on the refractive index of the particles or vesicles in 
question. Analyzing particles at the lowest end of this range is possible only for particles 
composed of materials with high refractive index, for example gold and silver, while 
biological vesicles have a lower refractive index. The upper size limit is restricted by the 
limited Brownian motion of large particles. The viscosity of the solvent also influences the 
movement of particles, and it too plays a part in determining the upper size limit for a specific 
system 205. All the models of the NanoSight instruments are based on the same principle of 
detection, but the more advanced models also offer measurements in fluorescence mode 
(NS300 and NS500) and measurements of single particle zeta potential (NS500) 206.  
 
The advantages of NTA are that it is a rapid method that provides information on both the size 
and count of individual vesicles in a sample. The method discriminates well between size 
populations in heterogeneous samples 207, which biological samples most often are. As NTA 
measures vesicles in suspension, it does not require major handling or processing of a sample 




disadvantages, NTA is unable to identify the phenotype of the vesicles measured. The later 
models of NanoSight (NS300 and NS500) introduced a fluorescence mode allowing for the 
detection of labelled vesicles. However, labelling for NTA require fluorophores that are 
bright, photostable and small in size, so it does not add substantially to the size of the EV 
itself. Another disadvantage of the method is that NTA is not able to discriminate between 
true EVs and other spherical vesicles or particles in a sample, for example lipoproteins or 
contamination of chemical particles from the reagents used 205,206. Therefore, an absolute 
requirement for obtaining correct measurements using NanoSight is the removal of 
contaminating particles from buffers, reagents and culture media used.  
 
There are several publications evaluating the performance of the NanoSight instruments 204-
208, as well as publication comparing their performance to other established methods like flow 
cytometry and electron microscopy 205,209. NanoSight was shown to be a sensitive instrument 
able to accurately determine the size distribution of both monodisperse and polydisperse 
samples 205,207. The coefficients of variation (CV) for NTA have been reported for intra-day 
variation to range from 1-7% for size measurements, and 5-12% for concentration, while the 
inter-day variations ranged from 1-9% for size and 5-18% for concentration measurements 
208,210.   
 
NanoSight NS300 (Malvern, UK) was used in paper I to evaluate the effect of various pre-
analytical conditions on the concentration and size distribution of EVs isolated from human 
plasma by ultracentrifugation. Samples of isolated EVs were diluted (50–100×) in particle-
free Dulbecco’s phosphate buffered saline without CaCl2 and MgCl2 (Sigma-Aldrich, St. 
Louis, MO, USA), and manually inserted into the sample chamber using a 1 ml syringe. The 
samples were recorded at ambient temperature with automatic temperature monitoring. Three 
separate dilutions of the samples were used for analysis. Each dilution was recorded 3 times 
for 60 seconds each at camera level 16 (highest magnification of the microscope). The sample 
was refreshed between the captures, and the sample chamber was cleaned between each 
sample. The nine resulting videos were analyzed with NTA software version 3.0 at detection 






Flow Cytometry is an established and commonly used method for the simultaneous 
measuring of multiple physical characteristics of a single cell, like size and granularity. In 
addition, fluorescent labelling of specific antigens using antibodies provides additional 
information on subpopulations in a sample 211. The main principle of flow cytometry is the 
light scattering and fluorescence emission generated by a cell or vesicle. The main 
components of a flow cytometer are fluidics, optics, detectors and a computer. The fluidics 
are responsible for transporting the sample through the instrument. The sample in question 
(i.e. cells or vesicles in solution) is diluted by sheath fluid in the instrument, and the cells or 
vesicles are made to align in a single file fashion by pressure differences when passing 
through the laser beam in the flow chamber. The optical system consists of a laser, lenses and 
collection optics. The laser beam is directed at the fluid stream with a single line of cells or 
vesicles, and light is scattered as the laser light strikes the cell or vesicle. Two types of light 
scatter occur, forward scatter (FSC) and side scatter (SSC). FSC is used as a measure of the 
cell/vesicle size, while SSC is a measure of cell granularity or internal complexity. In flow 
cytometers there is a variety of laser configurations able to excite a number of different 
fluorophores. The collection optics are lenses designed to collect the light emitted from the 
interaction between the laser beam and the cell/vesicle, as well as a system of optical mirrors 
and filters (long pass, short pass or band pass filters) that separate and direct specified 
wavelengths to the designated optical detectors. The light signals are converted into voltages 
by photodetectors and then into digital signals for computer processing 211.  
 
As EVs are only a fraction of the size of cells, analyzing EVs using conventional flow 
cytometers is rather challenging. Conventional flow cytometers have been reported to have a 
lower detection limit of approximately 300-500 nm for polystyrene beads 212. However, 
biological vesicles have a lower refractive index than beads, and the main population of EVs 
are below the detection limit of conventional flow cytometers 209,213-215. Specialized flow 
cytometers, on the other hand, have been reported to be able to detect 100 nm beads, 
corresponding to a biological vesicle of about 160-220 nm 212. Flow cytometry is a relatively 
easy method and the conventional instruments are commonly found in research laboratories 
making it an accessible method. Flow cytometry is useful as it provides information on 
multiple aspects of individual vesicles in solution. However, a major disadvantage is that 




In paper IV we used the sensitive flow cytometer CytoFLEX (Beckman Coulter, 
Indianapolis, USA) to determine the concentration of total EVs and platelet-derived EVs in 60 
plasma samples (40 from treatment group, 20 from control group) from the START trial. EVs 
were isolated from plasma by ultracentrifugation at 20,000 x g for 30 minutes, and stained for 
phosphatidylserine with FITC-labeled bovine lactadherin (Haematologic Technologies, 
Vermont, USA) and the platelet marker CD41 with APC-H7 clone HIP8 (Biolegend, San 
Diego, USA). EV pellets were incubated with either antibody or isotype control mixture for 
20 min at 4°C in the dark. Samples were washed with 1 ml pre-filtered DPBS and centrifuged 
at 20,000 x g for 30 minutes at 4°C. The EV pellet was resuspended in Dulbecco's phosphate-
buffered saline without Ca2+/Mg2+ (Thermo Fisher Scientific). The EV gate was set using 
Rosetta calibration beads (Exometry, Amsterdam, The Netherlands), and data analysis were 
performed using the software CytExpert 2.0 (Beckman Coulter, Indianapolis, USA). EVs 
were defined according to size and lactadherin-positive staining. The total number of EVs was 
calculated from the number of detected lactadherin-positive events in a sample, and further 
converted to EV number per microliter plasma (EV/µl) using the original volume of analyzed 
plasma (150 µl).  
 
3.2.3 Measurements of EV activity  
The activity of EVs, or their contribution to coagulation, can be measured using different 
assays. For the work in the current thesis, emphasis has been given to EV procoagulant 
activity driven by negatively charged phospholipids, measured using a modified FXa-
dependent clotting assay.  
 
Procoagulant phospholipid (PPL) activity clotting assays are based on the ability of 
procoagulant phospholipids to accelerate the conversion of prothrombin to thrombin with 
subsequent fibrin formation. An equal volume of sample plasma is mixed with PPL-free 
plasma provided as a reagent by the assay, and the assay read-out is seconds of clotting time. 
The reaction is triggered by the addition of FXa in excess together with calcium 216,217. This 
eliminates the influence of coagulation factors upstream of FXa, leaving the PPL provided by 
the sample as the rate-limiting factor. Hence, procoagulant plasma clotting time should be 
considered as the potential to facilitate coagulation activation when blood is exposed to 
triggers of the coagulation system. Clotting assays offer a complex reaction as they measure 




physiological end-point. In addition, clotting assays do not rely on a particular instrument as 
they can be performed on a variety of routine coagulation analyzers.  
 
There are currently two main clotting assays commercially available, the STA-Procoag-PPL 
assay from Diagnostica Stago and the XACT assay from Haematex. The two assays use the 
same principal for testing the PPL activity of a plasma sample. For both assays, the 
phospholipid-free plasma provided as a reagent is chemically treated with phospholipase in 
order to remove PPL. For the XACT assay, they specify that this is achieved by the use of 
snake phospholipase 217, while it is not specified for the Stago assay [Diagnostica Stago, 
Asnières sur Seine Cedex, France]. Additionally, the origin of PPL-depleted plasma differs 
between the assays. While porcine plasma is used in the XACT assay, the Stago assay uses 
human plasma 216,217. The reasoning for using plasma from a different species was to try to 
overcome the effect of lupus anticoagulant on PPL measurements. The coagulation factors in 
the porcine plasma will not be inactivated by lupus anticoagulant, and therefore the assay 
sensitivity would remain the same 218. Both the Stago and the XACT assay use FXa of bovine 
origin 216,218. The XACT assay initially reported adjustment of the FXa concentration to give a 
clotting time of 100 seconds 218, but later standardized this to a concentration of 0.01 U/ml 217. 
The Stago assay similarly provides a bovine FXa solution of the same concentration 
[Diagnostica Stago, Asnières sur Seine Cedex, France]. The two PPL assays differ with regard 
to the use of a phospholipid calibrator. The XACT assay solves this problem by the inclusion 
of a synthetic PPL calibrator, while the Stago assay leaves it up to the users to create a 
reference range and standards for the clotting time 218 [Diagnostica Stago, Asnières sur Seine 
Cedex, France]. The benefit of including a standardized phospholipid calibrator is that the 
clotting times measured can then be converted into a unit of phospholipids.  
 
A way of measuring the degree of variability of an assay is by the coefficient of variability 
(CV). The Stago assay reports intra-assay CVs of 0.3% and 0.6% for the two samples tested, 
and inter-assay CVs of 1.3% and 2.1% [Diagnostica Stago, Asnières sur Seine Cedex, 
France]. Slightly higher CVs were reported by van Dreden and colleagues in the XACT assay, 
with intra-assay CVs of 3.3% and 3.1% for normal pooled plasma and patient plasma, 




The commercial assays are sensitive, easy to use and portray low CVs. However, when 
running larger series of samples, using the commercial assays becomes quite costly. Given the 
importance of PS and PS+EVs in coagulation activation, there is a need for a cost-effective 
assay with the possibility of between-laboratory comparisons of data. We therefore set out to 
modify a FXa-dependent clotting assay. We assumed that the vast majority of procoagulant 
phospholipids in plasma were EV-bound, and we examined whether sequential centrifugation, 
including final ultracentrifugation, might substitute phospholipase treatment for the 
production of a suitable assay plasma. We additionally chose to include a standardized 
phospholipid reagent (UPTT, BioData Corporation, Horsham, Pennsylvania, USA) to allow 
for clotting times to be converted into a standardized unit of phospholipids.  
 
In paper II we developed a modified FXa-dependent clotting assay by substituting 
chemically phospholipid depleted plasma with PPL depleted plasma obtained by 
ultracentrifugation. We tested several aspects of the assay performance, like the influence of 
individual coagulation factors, postprandial lipoproteins and plasma centrifugation protocols. 
The modified PPL assay was compared to the commercial PPL assay STA-Procoag-PPL from 
Stago Diagnostica. The two PPL assays displayed similar sensitivity to exogenously added 
standardized phospholipids, and the PPL activity measured by the modified assay strongly 
correlates with the results from the commercial assay. The intra-day and between-days 
coefficients of variation ranged from 2–4% depending on the PPL activity in the sample. The 
modified PPL assay was insensitive to postprandial lipoprotein levels in plasma, as well as to 
TF+EVs isolated from stimulated whole blood.  
 
In paper III and IV, we used the modified PPL assay to measure the PPL activity of plasma 
samples from a nested case-control study derived from the general population (paper III) and 
a randomized controlled trial (paper IV). In brief, 25 μl sample plasma was mixed with 25 μl 
phospholipid-depleted plasma (PPLDP). PPLDP was generated from pooled citrated PFP (n = 
18), centrifuged at 100,000 x g for 60 minutes at 16°C (Beckman Optima LE-80K 
Ultracentrifuge, rotor SW40TI, Beckman Coulter, Indianapolis, Indiana, USA), aliquoted and 
stored at -80°C until use. The mixture of sample and PPLDP was incubated for 2 minutes at 
37°C, before the reaction was initiated by the addition of 100 μl pre-warmed factor Xa 




chloride and 20 mM HEPES buffer (pH 7.0). Clotting tests were carried out in duplicates on a 
StarT4 instrument from Diagnostica Stago (Asnières sur Seine Cedex, France) and measured 
in seconds of clotting time or converted into phospholipid activity in mU/ml by the use of a 
UPTT calibrator.  
 
The Calibrated Automated Thrombogram (CAT) is a method to measure thrombin 
generation in clotting plasma, either with or without platelets present in the sample (PRP, PPP 
or PFP). The method has previously been described by Hemker et al. 219,220. The CAT assay is 
a general physiologic function test of the thrombotic hemostatic system, and can be used to 
measure both thrombotic and bleeding tendencies. The CAT assay can detect deficiencies in 
all coagulation factors (except FXIII), as well as the effect of anticoagulant treatments (VKA, 
heparin and heparin-like, direct inhibitors). The assay CVs for endogenous thrombin potential 
(ETP) has been described to range from 15-19% for inter-individual variability, and from 4.5-
7.4% for intra-individual variability, depending on the sample type (PPP or PRP, respectively) 
219.  
 
The general principle of the CAT assay is that a plasma sample, or plasma diluted with buffer, 
is mixed with trigger(s), e.g. TF and phospholipids, in the wells of a 96-well plate. The 
concentration of TF and phospholipids can be altered according to the objective of the 
experiment. For each plasma sample used, additional wells are needed where a thrombin 
calibrator is added to plasma. The thrombin calibrator is used to correct for the inner filter 
effect, donor-to-donor variability in the color of plasma, substrate depletion and instrumental 
differences. The plate is then incubated in the instrument at 37°C for 10 minutes. The reaction 
is initiated by the addition of calcium and a fluorogenic substrate dispensed into the wells by 
the instrument. Thrombin activity is calculated as a function of time by comparing the 
fluorescent signal from the sample well to that of a known stable concentration of thrombin 
activity in a parallel non-clotting sample (the calibrator well). A computer software will then 
calculate thrombin generation parameters like lag time (LG) (min), the time to peak (tPeak) 
(min), the peak of thrombin generation (peak) (nM), the area under the thrombin generation 







Figure 7. Overview of the most commonly used thrombin generation parameters; lag time 
(min), the time to peak (tPeak) (min), the peak of thrombin generation (Peak) (nM), and the 
area under the thrombin generation curve, that is the endogenous thrombin potential 
(nM*min) (ETP). (Adapted from Hemker, H.C., Pathophysiol Haemost Thromb 2003 and 
2002 219,220). 
 
In paper III we used the CAT assay to measure thrombin generation of plasma samples. 
Thrombin generation was measured in a Fluoroscan Ascent Fluorometer (Thermolabsystems 
OY, Vantaa, Finland). Fluorescence intensity was detected at wavelengths of 355 nm 
(excitation filter) and 460 nm (emission filter). Forty µl of plasma was mixed with 40 µl 
Hepes buffer (20 mM Hepes and 140 mM NaCl) and pipetted into the wells of round bottom 
96-well microtiter plates (Immulon, Lab Consult, Lillestrøm, Norway). Ten µl of TF solution 
(final concentration of 3 pM) (Innovin, Bade Behring) and 10 µl of a standardized 
phospholipid in solution (diluted 1:20) (UPTT, BioData Corporation, Horsham, Pennsylvania, 
USA.) were added as triggers. Both TF and UPTT were diluted to the stated concentrations in 




phospholipid depleted plasma (PPLDP) added in ratios of 100:0, 80:20, 60:40, 40:60, 20:80, 
10:90, and 0:100, respectively. For each experiment, a fresh mixture of 2.5 mM fluorogenic 
substrate (Z-Gly-Gly-Arg-AMC from Bachem, Bubendorf, Switzerland), 0.1 M CaCl2, 20 
mM Hepes (Sigma Aldrich, St Louis, USA) and 60 mg/ml BSA (A-7030, Sigma Aldrich) 
with pH 7.35 was prepared. Each dilution of PFP/PPLDP was assigned its own calibrator 
(Thrombinoscope BV, Maastricht, The Netherlands). The computer software calculated lag 
time (LG) (min), the time to peak (TTP) (min), the peak of thrombin generation (PEK) (nM) 
and the area under the thrombin generation curve (nM*min) and endogenous thrombin 
potential (ETP). Plasma samples were run in duplicates and each experiment was repeated 
three times. 
 
3.2.4 Electron microscopy  
Transmission electron microscopy (TEM) is used to image, phenotype and count EVs. 
TEM is able to detect and characterize individual EVs. TEM is highly sensitive with an 
imaging resolution down to 1 nm 209. Thus, using immuno-gold labelling for TEM, proteins 
on the EV surface can be detected. TEM is a useful method to visualize and confirm the 
presence of biological vesicles with a bi-layered membrane after an EV isolation technique 
has been applied.  However, electron microscopy is a labor-intensive method and does not 
allow for high-throughput of samples. EV sample preparation requires chemical fixation and 
dehydration, which potentially alter the morphology of the EVs. Additionally, limited and 
non-uniform adhesion of vesicles to the grid surface may affect the read-out on size 
distribution 214,221.  
 
Scanning electron microscopy (SEM) is also used to characterize individual EVs. SEM uses 
an electron laser beam to scan the surface of a vesicle and generates information on its 
topography. Similarly to TEM, EV samples are processed before analysis by fixation and 
dehydration. Immobilized samples are spray-coated with a thin layer of conductive material 
like cobber or gold before imaging, which might affect the surface structure of EVs 222.  
 
In paper I we used both TEM and SEM to investigate EVs isolated from human plasma by 
ultracentrifugation. For TEM, EVs were isolated by ultracentrifugation, resuspended in buffer 




colloidal gold particles. The substrate was prepared by adsorbing 15 nm gold particles 
(Department cell biology, University of Utrecht, the Netherlands) on formvar/carbon coated 
copper specimen grids and then the gold-coated grids were embedded in a thin layer of epoxy 
resin between two layers of Aclar film and polymerized at 60 °C for 48 hours. The EV 
suspension was placed on the gold-loaded, epoxy-embedded specimen grids and in 1% 
glutaraldehyde, postfixated in 1% OsO4 and stained with 1% aqueous uranyl acetate. The 
EVs on the epoxy-embedded grids were dehydrated in a graded series of ethanol, infiltrated in 
an Epon Equivalent (AGAR 100, DDSA, MNA and DMP-30, Agar Scientific, UK) and 
polymerized at 60 °C for 48 hrs. Ultrathin sections of the embedded EVs were prepared using 
Ultracut S ultramicrotome (Lieca Microsystems, Vienna, Austria) and a Diatome diamond 
knife (Diatome, Biel, Switzerland). Images using a JEOL JEM 1010 transmission electron 
microscope (Tokyo, Japan) were acquired with a Morada camera system (Olympus Soft 
Imageing System, Münster, Germany). 
 
For immune-gold labelling the EVs were fixed with 1% buffered glutaraldehyde and adsorbed 
onto carbon-formvar coated specimen grids before immunolabelling. Unspecific labelling was 
blocked on 0.1% cold water fish skin gelatin (CWFSG) (Sigma G-7765) and 1.5% bovine 
serum albumin. Samples were incubated with anti-annexin V (Anx5) antibody (abcam, Cat# 
ab14196), diluted in Anx5 binding buffer (BD Pharmingen, Cat#556454) and protein A-gold 
(University of Utrecht, The Netherlands). All immune-reagents were diluted in CWFSG and 
the grids washed in PBS between each step. The grids were finally fixed in 1% 
glutaraldehyde, washed in distilled water and dried in 1.8% Methylcellulose containing 0.3% 
uranyl acetate. 
 
For SEM analysis, isolated EVs were negatively stained on formvar/carbon coated copper 
grids. The grids floated on sample drops for 30 minutes, and were treated with 1% 
glutaraldehyde, washed in PBS and ddH2O and contrasted/dried with the addition of 1.8% 
methyl cellulose and 0.3% uranyl acetate. EV size measurements were performed using the 
iTEM software (Olympus Soft Imaging Solutions, Münster, Germany) by measuring the 
diameter of at least 200 EV from the SEM pictures. The start and end of every diameter was 




specimen holder and coated with gold/palladium before SEM examination. The images were 
obtained using a Zeiss Merlin VP compact scanning microscope. 
 
3.3 Statistical analysis  
All statistical analyses were conducted using either SPSS for Windows (SPSS Inc., Chicago, 
Illinois, USA), GraphPad Prism for Windows (GraphPad Software, San Diego, California, 
USA) or R for Windows (The R Foundation for Statistical Computing c/o Institute for 
Statistics and Mathematics, Vienna, Austria). 
 
In paper I, median values and interquartile ranges for continuous data (EV concentrations) 
were presented, as data was not normally distributed. To test for differences in EV 
concentrations between anticoagulants we used Friedman’s test for non-parametric and 
dependent continuous data. Bar graphs were used to display (i) EV concentrations according 
to size categories of EVs (<100 nm, 100–199 nm, 200–299 nm, 300–1000 nm), and (ii) mean 
sizes of EVs measured by NTA and SEM in the different anticoagulants. The correlation 
between triglycerides and EV concentrations as well as VLDL and EV concentrations was 
calculated using Pearson’s correlation coefficient. All analyses were performed using IBM 
SPSS Statistics version 22. 
 
In paper II all statistical analyses were performed in Graph Pad Prism 9.0. ANOVA was used 
to test for differences in performance between the modified PPL assay and the STA-Procoag- 
PPL assay. 
 
In paper III statistical analyses were performed using R (Version 4.0.4). Unconditional 
logistic regression models were used to estimate odds ratios for VTE with 95% confidence 
intervals with plasma procoagulant phospholipid clotting time (PPLCT) used as a continuous 
variable, discretized to quartiles and dichotomized according to PPLCT  ≤ 25th percentile 
versus PPLCT  > 95th percentile. The analyses were adjusted for age, sex and BMI. The PPLCT 




As the follow-up time in the source cohort was long (more than 12 years for many 
persons), the results based on baseline PPLCT measurements could be influenced by 
regression dilution bias. To investigate this, we performed analyses where we restricted the 
maximum time from blood sampling in Tromsø 4 to the VTE events, while keeping all 
controls in the analyses. The logistic regression analyses on time restrictions were set to 
require at least 10 VTE events, and odds ratios were generated at every 0.1 year increase and 
plotted as a function of time from blood sampling to VTE. 
 
In paper IV statistical analysis were performed using R (Version 4.0.3). Descriptive statistics 
were used to describe the baseline difference between the intervention and the control group. 
For the results tables, the treatment and non-treatment group, as well as subgroups, were 
compared using two-sample t-tests with equal variance assumed and standard multivariate 
linear regression models adjusting for age and sex. Pearson’s correlation coefficient was used 






4. Main results 
4.1 Paper I: Impact of preanalytical conditions on plasma concentration and size distribution 
of extracellular vesicles using Nanoparticle Tracking Analysis  
 
EVs are most often subjected to several pre-analytical handling steps before analysis. Optimal 
pre-analytical handling is therefore crucial to ensure valid measurements of parameters such 
as plasma concentration and size distribution of EVs.  
In this study we aimed to investigate the impact of plasma preparation, various 
anticoagulants, including citrate, EDTA, CTAD, and heparin, as well as fasting status on the 
concentration and size distribution of EVs measured by Nanoparticle Tracking Analysis and 
scanning electron microscopy.  
Blood was drawn from 10 healthy volunteers to investigate the impact of plasma 
preparation and anticoagulants. We also used plasma samples from 40 individuals from a 
previous population-based study to investigate the impact of postprandial lipidemia. 
Transmission electron microscopy was used to confirm the presence of EVs. The plasma 
concentrations of EVs were measured by NTA after isolation by high-speed centrifugation. 
The size distributions of the plasma EVs were determined using NTA and SEM.  
TEM confirmed the presence of EVs after isolation by high-speed centrifugation from 
plasma. TEM and SEM-analyses showed that the EVs kept a spherical morphology after high-
speed centrifugation. The plasma concentrations and size distributions of EVs were 
essentially similar for the various anticoagulants investigated. We found no statistical 
difference in either size or concentration of EVs measured by NTA, when plasma was 
prepared as PPP or PFP before freezing. Plasma levels of EVs were not significantly altered 
in response to a high-fat meal, but the mean sizes of VLDL particles were increased and 
interfered with EV measurements.  
Isolation of EVs from plasma by high-speed centrifugation yielded similar 
concentrations and size distributions of EVs for the four anticoagulants tested. We found no 
statistical difference in concentration nor size of EVs when plasma was prepared as PPP or 
PFP before freezing. Plasma VLDL particles interfered with EV measurements particularly 




4.2 Paper II: A modified clot-based assay to measure negatively charged procoagulant 
phospholipids  
 
The interest in PPL activity has increased during recent years, mainly due to the increased 
understanding of the role of EVs in thrombosis and hemostasis. There are currently two 
commercial PPL-dependent clotting assays available, the STA-Procoag-PPL assay from 
Diagnostica Stago (Asnières sur Seine Cedex, France) and the XACT assay from Haematex 
(Hornsby, NSW, Australia). Both assays use chemical phospholipase treatment to deplete 
phospholipids from the reagent plasma.  
The purpose of our study was to modify the PPL assay by substituting the chemically 
phospholipid depleted plasma with PPL depleted plasma obtained by ultracentrifugation This 
in order to get readily access to a sensitive and reliable assay to measure PPL activity in 
human plasma and cell supernatants.  
The performance of the assay was tested, including the influence of individual 
coagulation factors and postprandial lipoproteins and compared to a commercial PPL assay 
(STA-Procoag- PPL assay). The two PPL assays displayed similar sensitivity to exogenously 
added standardized phospholipids. The PPL activity measured by the modified assay strongly 
correlates with the results from the commercial assay. The intraday- and between-days 
coefficients of variation ranged from 2–4% depending on the PPL activity in the sample. The 
modified PPL assay was insensitive to postprandial lipoprotein levels in plasma, as well as to 
TF+EVs from stimulated whole blood.  
Our findings showed that the modified assay performed equally to the comparator, and 
was insensitive to postprandial lipoproteins and TF+ EVs. In addition, we introduced a 
standardized PPL reagent (UPTT) which allowed for clotting times to be converted into a 
standardized unit of phospholipids. These modifications led to the establishment of an 





4.3 Paper III: Plasma Procoagulant Phospholipid Clotting Time is Inversely Associated with 
Future Risk of Incident Venous Thromboembolism 
 
Several observational studies have reported elevated plasma levels of EVs in VTE. Negatively 
charged procoagulant phospholipids, and phosphatidylserine in particular, are expressed on 
the surface membrane of EVs and are vital to coagulation. However, no previous study has 
investigated the association between plasma PPLCT and future risk of VTE.  
In this study we aimed to investigate the association between plasma PPLCT and the 
risk of incident VTE in a nested case-control study.  
We conducted a nested case-control study using 296 VTE patients and 674 age- and 
sex-matched controls derived from a general population cohort (The Tromsø Study 1994-
2007). PPLCT was measured in platelet-free plasma using our modified factor Xa-dependent 
clotting assay (Paper II). Logistic regression was used to estimate odds ratio (OR) with 95% 
confidence intervals (CI) for VTE with PPLCT modelled as a continuous variable, across 
quartiles and in dichotomized analyses.  
There was a weak inverse association between plasma PPLCT and risk of VTE per one 
standard deviation increase of PPLCT (OR 0.93, 95% CI 0.80-1.07) and when comparing those 
with PPLCT in the highest quartile (OR 0.89, 95% CI 0.60-1.30) with those in the lowest 
quartile. The inverse association was stronger when the analyses were restricted to samples 
taken shortly before the event. Subjects with PPLCT > 95th percentile had substantially 
lowered OR for VTE (OR 0.35, 95% CI 0.13-0.81). The risk estimates by categories of 
plasma PPLCT were similar for deep vein thrombosis and pulmonary embolism.  
In conclusion, our results indicate an inverse association between plasma PPLCT and 
the risk of future VTE. Our findings suggest that high plasma PPLCT is associated with 





4.4 Paper IV: Rosuvastatin treatment decreases plasma procoagulant phospholipid activity 
after a VTE: A randomized controlled trial  
 
VTE is a frequent cardiovascular disease with severe complications, including recurrence and 
death. There is a great need for preventive treatment options against recurrence as 
anticoagulation is accompanied by increased bleeding risk. Statins are reported to reduce the 
risk of incident and recurrent VTE, but the mechanisms are elusive. Procoagulant 
phospholipids, and phosphatidylserine in particular, are crucial for efficient coagulation 
activation, but no studies have investigated the effect of statin treatment on plasma PPL 
activity.  
In this study we aimed to investigate the impact of rosuvastatin treatment on plasma 
PPL activity and levels of EVs in subjects with a history of VTE.  
Participants of the STAtins Reduce Thrombophilia (START) trial (NCT01613794) 
were randomized to either 20 mg/day of rosuvastatin treatment or no treatment for 28-days. 
Plasma sample were collected at baseline and study end. The PPL activity was measured in 
samples from 245 participants using our FXa-dependent clotting assay (Paper II). The levels 
of total and platelet-derived EVs were measured in a selection of the participants using a 
sensitive flow cytometer.  
Rosuvastatin treatment yielded an overall 22% (95% CI -38.2 to -5.8) reduction in 
PPL activity, and 37% (95% CI -62.9 to -11.2) reduction in PPL activity in participants with a 
history of pulmonary embolism. The effect of rosuvastatin on plasma PPL activity was not 
explained by changes in total cholesterol nor change in plasma levels of total- or platelet-
derived EVs measured by flow cytometry. 
In conclusion, rosuvastatin treatment caused a substantial decrease in plasma PPL 
activity, suggesting that a PPL-dependent attenuation of coagulation activation may contribute 





5. General discussion 
5.1 Methodological considerations 
 
5.1.1 Study design 
Cohort studies follow a defined population from inclusion (baseline) and until the outcome 
of interest or other censoring events occur (death, end of study). Participants are classified 
according to the status of exposure(s), allowing for differences in outcome to be investigated 
based on exposure status (non-exposed vs exposed) during follow-up. With a cohort design 
one can estimate both absolute risk and relative risk. Cohort studies are useful tools to 
investigate common diseases, while other study designs are more suitable for rare outcomes 
223. Cohort studies are generally comprised of large participant pools and follow the 
participants for a long time. A major strength of the cohort study design is the clear temporal 
sequence between exposure and outcome, which is the most important prerequisite for 
determining causality. However, according to the Bradford Hill criteria for causation, 
additional criteria should also be considered including experimental evidence, the strength of 
the observed association, consistency across studies, biological gradient (dose-response) and 
biological plausibility 224. Challenges with this study design include selection bias, 
confounders and bias by differential loss to follow-up (missing data) 223.  
 
Case-control studies have a retrospective design. A group with the outcome of interest (case) 
is compared to a group without the outcome (control). The selected controls should be 
representative of the population from which the cases were drawn. The information on 
exposure status is registered for both groups, and odds ratios are estimated for the proportion 
of cases with an exposure compared to the proportion of controls with the same exposure. 
This determines the relative importance of the exposure with respect to the presence or 
absence of the outcome 223. Since the cases included in a study are chosen based on the fact 
that they have the outcome of interest, case-control studies are cost-effective and require a 
smaller sample size than for example cohort studies. The case-control study design allows for 
multiple exposures to be investigated, while the outcome of interest is limited. It can also be 
applied to investigate rare outcomes. Challenges with case-control studies include selection 
bias, recall bias and confounding. An additional potential challenge with case-control studies 
is reverse causality. Reverse causality is a temporal bias where the outcome of interest causes 
alterations in the exposure of interest. The observed association would then be the opposite of 




Nested case-control studies encompass subjects sampled, or “nested”, from within a cohort 
study, hence the name. Random sampling of controls from the cohort strengthens the 
probability of the controls being representative for the general population. Nested case-control 
studies are both cost- and time-effective, as well as maintaining the temporal sequence of 
exposure-outcome. In addition, this study design allows for better control of confounding 
(age, sex) by the matching of cases and controls. A limitation with nested case-control studies 
is that we are unable to estimate absolute risk 223.  
 
In paper III we used a nested case-control study derived from a prospective population-based 
cohort study. In the Tromsø study participants were followed until a VTE event, death, 
migration from the municipality, withdrawal from the study, or end of study. The exposure 
statuses were recorded and blood samples were drawn at inclusion in the study. For the nested 
case-control study, two age- and sex-matched controls, alive at the index date of the VTE 
event were sampled from the cohort for each case included.  
 
Randomized controlled trials (RCTs) are considered the gold standard of study designs 
when it comes to determining causal relationships, as they provide experimental evidence, an 
important Bradford Hill criteria for causation 224. In a RCT the participants are randomly 
assigned to groups (control or intervention), followed for a set period of time and compared 
with each other according to the preset study outcomes. RCTs allow for the manipulation of 
exposures in a controlled environment. Proper participant randomization is crucial in order to 
ensure that all covariates, apart from the exposure, are randomly distributed among the study 
groups, thus minimize confounding. When controlling for confounding and bias, we allow for 
the estimation of true associations between the exposure and the outcome. RCTs have a high 
internal validity, but the strict inclusion criteria might reduce their external validity. 
Challenges with RCTs are that they are resource demanding, time consuming, and may not 
always be possible to conduct or ethically acceptable 225.   
 
In paper IV we used a randomized controlled study design. The STAtins Reduce 
Thrombophilia (START) trial, is a multicenter, randomized, controlled, open label clinical 




a previous history of VTE was investigated. Participants were randomly assigned to either 20 
mg/day of rosuvastatin treatment or no study treatment for the 28-day study period. 
Participants were randomized by using a random allocation sequence implemented by a 
central telephone. The sequence was concealed until interventions were assigned. Adherence 
to the study protocol was assessed in two ways. First, participants in the treatment group took 
the first tablet of rosuvastatin in the presence of an investigator. Second, compliance to 
treatment was assessed by measurements of total cholesterol levels at baseline and at study 
end in all participants. The START trial was approved by the Medical Ethics Committee of 
the Leiden University Medical Center, Leiden, the Netherlands, and all study participants 
gave written informed consent prior to participation. 
 
5.1.2 Bias  
Bias is systematic error(s) in the design or execution of a study leading to incorrect estimates 
of a true association between exposure and outcome. Several systematic errors have been 
described, however most of the biases relate to the selection of participants (selection bias), 
measurements performed and the classification of exposure and outcome (information bias), 
or the presence of confounding factors 226.  
 
Selection bias is a result of any errors in selecting the study participants and/or from factors 
affecting the study participation 227. Selection bias affects the relationship between the 
included participants and the non-participants or non-responders with regards to exposure and 
disease status. As we often do not know the exposure-disease status of the non-participants, 
selection bias can most often only be hypothesized. Selection bias can further be divided into 
non-response bias, incidence-prevalence bias, loss to follow-up bias, confounding by 
indication bias and volunteer bias 227. Cohort studies are less likely to be affected by selection 
bias as all of the participants are included in the study before the outcome of interest occur. 
Still, cohort studies are prone to non-response bias, implying that the participants of the study 
differ from the non-participants. Individuals who choose to participate in cohort studies are 
generally thought to be healthier than non-participants. This is because it is unlikely that 
individuals who are immobilized or institutionalized due to disease or illness of any kind 
would attend health surveys. Cohort studies are also prone to the loss to follow-up bias. If the 




differential loss to follow-up, where the exposure affects the probability of completing the 
study, will result in study bias 227.  
 
The 4th survey of the Tromsø study had a high attendance rate of 77% of the invited 
population (aged 25 years and older). Generally, the participation rates for epidemiological 
studies have declined during the last decades 228. This was similarly observed for the Tromsø 
study, with participation rates ranging from 81%-85% for the first three of the surveys (1974-
1987) and declining to 65%-77% for the last four studies (1994-2016) 194. We know that the 
non-participants of the Tromsø study tended to be male, unmarried, and younger than 35 
years old or older than 80 years 194. The profile of the non-participants are in line with 
previous findings that those more likely to not participate in epidemiological studies were 
male, unmarried, at extremes of age (younger or older), have a lower level of education and 
be of lower socioeconomic status 228. As the incidence of VTE is low in the younger 
population, and the participation rate of Tromsø 4 is quite high, we presume that the selection 
bias as well as the non-responder bias would be low in our study.  
 
In the START trial participants were randomly assigned to the treatment group or the control 
group. Generally, randomization is implemented to reduce the effect of bias in a study. 
However, in our study the distribution of age and sex were unevenly distributed among the 
study groups. The control group had more men (69.2% vs 53.6%) and the participants in this 
group were slightly older than the treatment group (59 years vs 57 years). However, adjusting 
for age and sex in statistical analysis did not alter the results, indicating that the impact of 
selection bias is low. In addition, participants were compared to themselves (baseline vs 
study-end samples) for analyses. As participants were recruited from an outpatient setting, it 
limits the risk of confounding diseases at randomization, limiting selection bias in our study. 
For each study group, a low number of participants were excluded after randomization, six in 
the treatment group and four in the control group. However, none of the participants were lost 
to follow-up. Two participants in the treatment group was excluded due to not starting the 
study drug.  
Information bias occurs during data collection and is the result of the systematic tendency to 
erroneously place participants in different exposure and outcome categories. The accuracy of 




A common source of misclassification in clinical practice is the inaccuracy of diagnostic tests 
227. Misclassification bias is the most important type of information bias, and can be divided 
into differential or non-differential misclassification. Non-differential misclassification is 
when the probability of misclassifying the exposure is not related to the outcome (disease), or 
the other way around. The ability of the diagnostic test to determine exposure status is the 
same for cases and controls, and they are both equally likely to be misclassified according to 
disease status. In the case of differential misclassification, the performance of the diagnostic 
test for the exposure identification differs between cases and controls. Recall bias is an 
example of differential misclassification where the cases are more likely to remember relevant 
exposures compared to the controls 227.  
 
In paper III, information on the exposure status was obtained from blood samples which 
were drawn at study inclusion in 1994-95 and stored at -80°C until analysis. Information on 
the participants from the Tromsø study were derived from self-administered questionnaires. 
As blood samples and the questionnaires (exposure information) were collected before the 
outcome (VTE event) occurred, potential misclassification in our study is likely to be 
unrelated to the outcome (non-differential). Non-differential misclassification tends to lead to 
an underestimation of an association 226. Potential sources of information bias include 
measurements obtained by the Tromsø study personnel, our laboratory measurements and 
instrument errors. The PPL assay is a sensitive method to determine PPL clotting time of a 
sample. The assay was found to display low intra- and inter-series coefficients of variations 
(CV) ranging from 2.8% to 4.1% 195. In addition, the technician carrying out the PPL assay 
measurements was blinded to the identity and case-control status of the samples in order to 
reduce the potential information bias. The outcome of our study, VTE events, are also prone 
to information bias. All events were identified by searching the hospital discharge diagnosis 
registry, autopsy registry and the radiology procedure registry at the University Hospital of 
North Norway (UNN). The events were thoroughly validated by multiple criteria such as 
presence of symptoms, objective confirmation by diagnostic procedures, and the initiation of 
treatment. The strict criteria implemented for an event to be found valid and included in the 
study will reduce the probability of false positive cases, and reduce study bias. Potential 





In paper IV, using the START trial, we measured the exposure (PPL activity) in plasma 
samples collected at baseline and study-end. As mentioned in the section above, the PPL 
assay is a sensitive method which displays low intra- and inter-day CVs. The technicians 
conducting the laboratory analyses were blinded to sample treatment. In the trial neither the 
patients nor the physicians were blinded to study treatment. However, it is unlikely that 
knowledge of the treatment would affect the laboratory outcomes (PPL clotting time). For the 
statistical analysis performed, the participants are compared to themselves (baseline vs study-
end).   
 
Regression dilution bias is a type of information bias affecting longitudinal studies assessing 
the association between the baseline measurements of a continuous modifiable variable and 
the risk of an outcome 227. The exposure status of modifiable risk factors might change during 
follow-up. If not accounted for it may introduce regression dilution bias to a study resulting in 
an underestimation of the true association between the exposure and outcome 229.  
 
In paper III, the follow-up time in the source cohort was more than 12 years for several of 
the participants (from 1994 to September 1st 2007). Because of the long follow-up time in our 
study, we chose to investigate the potential impact of regression dilution bias. Statistical 
analyses were performed where we restricted the maximum time from blood sampling in 
Tromsø 4 to the VTE events, still keeping all controls in the analyses. The logistic regression 
analyses on time restrictions were set to require at least 10 VTE events, and odds ratios were 
generated at every 0.1 year increase and plotted as a function of time from blood sampling to 
VTE. We do observe regression dilution bias in our study, and found that the inverse 
association between high plasma PPLCT and VTE was stronger with shortened time between 
the blood sampling and the VTE events. Our exposure (PPLCT) was subject to variation over 
the long follow-up time, making our results prone to underestimation of the true association 







Validity can be divided into internal or external validity. The internal validity of a study is 
the extent to which the observed results in fact reflect the true association within the study 
population investigated. External validity, or generalizability of a study, describes to what 
extent the study findings can be applied to subjects beyond the investigated study population. 
External validity depends on internal validity, but internal validity does not necessary result in 
external validity 226. Bias will reduce the validity of a study. Population-based cohort studies 
generally have high external validity, while RCTs have low external validity, but a high 
internal validity. For extrapolation of the findings from RCTs the inclusion criteria should be 
as general as the study allows, while at the same time maintaining scientific precision 225.  
 
In paper III the mean age of the VTE cases was 68 years, and the proportion of men and 
women was approximately the same (47% male, 53% women). Both mean age at VTE and 
the sex distribution in our study were comparable to reports from a pooled Scandinavian 
cohort (Norway and Sweden)230. Similarly, the proportions of DVT (58.8%) and PE (41.2%) 
in our study, have also been reported by others 230. The VTE cases in our study are seemingly 
representative of VTE cases in the general population, strengthening the external validity of 
our study. In our nested case-control study two controls, matched for age, sex and time, where 
chosen for each VTE case. The controls were sampled from the same parent cohort (Tromsø 
4). However, with knowledge of that the non-participants of the Tromsø study tended to be 
male, unmarried, and younger than 35 years or older than 80 years, our study generalizability 
will be decreased for individuals belonging to these subgroups. In addition, the inhabitants of 
the municipality of Tromsø, hence the invited population, are predominantly Caucasian, with 
a Sami minority 194. As we know that the incidence of VTE differs with regard to ethnicity, 
the generalizability of our findings to other ethnicities is not known. High internal validity in 
our study is supported by the high participation rate (77%) in the cohort study, as well as the 
strict criteria for the validation of the included VTE events. In addition, the PPL assay is a 
sensitive method to determine PPL clotting time, and it displays low intra- and inter-series 
coefficients of variations (CV) ranging from 2.8% to 4.1% 195. The technician carrying out the 
PPL assay measurements was blinded to the case-control status of the samples, strengthening 





In paper IV, our study design (RCT) suggests high internal validity, but often holds a low 
external validity. The participants in our study were recruited from three different 
anticoagulation clinics in the Netherlands (Leiden, Hoofddorp, and Rotterdam). Participants 
were included in the trial if they were 18 years or older, had an initial or recurrent confirmed 
symptomatic proximal DVT or PE, and were allowed to stop oral anticoagulant treatment by 
their treating physician. The exclusion criteria were; individuals already using statins or lipid 
lowering drugs or any contraindications for using 20 mg/day of rosuvastatin for the duration 
of the study 196. Strict inclusion criteria ensure that the study participants are as similar as 
possible before randomization to reduce study bias and increase internal validity. In addition, 
the study participants were compared to themselves for statistical analysis. However, the strict 
inclusion criteria affect the degree of generalizability of our study. The included participants 
from both study groups were slightly younger than the mean age of VTE found in studies 
derived from the general population (57 and 59 years versus 68 years). Of the 245 participants 
included in our study the majority were male (61%), and 75% of the participants had 
cardiovascular risk factors. The participants included were allowed to stop anticoagulant 
treatment, possibly distinguishing them from other VTE patients. Still, a wide age range (19 
to 83 years of age) was observed in the participants.  
 
5.1.4 Confounding  
A confounder is a variable that is both associated with the exposure and the outcome, but is 
not an intermediate variable in the causal pathway between the exposure and outcome 231. If a 
confounder is unevenly distributed across the exposure status, the association will be 
distorted. The presence of confounding may strengthen, weaken or even reverse the studied 
association. The type of study design will impact the degree of potential confounding in a 
study. For RCTs the participants are randomly assigned to the study groups which reduces the 
risk of confounding by (ideally) causing an even distribution of confounders in the treatment 
and control group. However, associations found in RCTs may be confounded if exposures, by 
random, are unevenly distributed between the groups. In paper IV, we observed that the age 
and sex distribution were unevenly distributed among the study groups. We therefore adjusted 
the statistical analysis for age and sex, but the adjustments did not alter the observed effect. In 
addition, the participants of the trial were recruited from an outpatient setting, limiting the risk 
of confounding by other diseases. Furthermore, participants were compared with themselves 




The presence of confounding is a concern for observational studies since the non-random 
allocation to a study group may result in an uneven distribution of confounding factors among 
the groups. Strategies to overcome confounding include multivariable regression analysis, 
matching and stratification. Pairwise matching is a way of controlling for confounding at an 
early stage of a study. In a case-control study participants can be matched according to status 
of the known confounder, for example smoking status. Stratification is a way of controlling 
for confounding after the study has been completed. The confounding variable can be divided 
into subgroups for analysis. However, stratification will reduce the statistical power 232. 
Multivariable regression analysis is a way of estimating an association between exposure and 
outcome, while controlling for one or more confounding variables. In paper III, the cases and 
controls were matched on age and sex. For analysis, PPL activity was stratified into four 
groups (quartiles) of clotting time, and the logistic regression analysis was run as crude 
analysis as well as analysis adjusted for age, sex and BMI. It is important to acknowledge that 
despite applying various methods for dealing with confounding factors in our study, residual 
confounding may still affect our results. Residual confounding occurs when unrecognized 
(unknown or unmeasured) confounders exist, which in turn could potentially impact the 
observed associations. Residual confounding is recognized as a challenge in observational 
studies 233. The associations described in our study could potentially be affected by 






5.2 Discussion of the main results 
 
5.2.1 The impact of preanalytical conditions on plasma concentration and size distribution of 
EVs 
In paper I we assessed the impact of preanalytical conditions, such as centrifugation steps for 
plasma preparation and EV isolation, the choice of anticoagulant, and fasting status on plasma 
concentration and size distribution of EVs. As a proof of concept, we used TEM (negative 
staining and ultrathin sectioning) to confirm the presence of bilayer membrane vesicles (i.e.  
EVs) after isolation from plasma by ultracentrifugation. A bilayer membrane was 
demonstrated in the majority of vesicles from the isolated EV pellets, confirming the presence 
of EVs. As suggested in the statement paper from the International Society for Extracellular 
Vesicles (ISEV) 164, we chose to apply several different methods, including NTA, SEM and 
TEM, for investigating the presence of EVs, their concentration and size. EV isolation by 
ultracentrifugation has been described to induce aggregation and alter the shape of the EVs 
203. However, in our study we did not observe EV aggregation or great variation in the 
morphology of the EVs, assessed by TEM and SEM. The main EV population was spherical, 
and the EV population investigated by electron microscopy was relatively pure, given that the 
presence of monolayer vesicles (lipoproteins) was a rare finding. However, knowing that the 
EV sample preparation for TEM and SEM require chemical fixation and dehydration, the 
observed size and morphology should be interpreted with that in mind. We therefore applied a 
second method for size determination of the isolated EV population. Interestingly, we found 
similar size distributions of plasma EVs measured by NTA and SEM. Both methods found the 
majority of EVs to be below 200 nm in diameter, and the presence of larger vesicles (>300 
nm) were rarely observed. The mean size of the EVs were slightly smaller using SEM 
compared to NTA, and the size distribution measured by SEM was shifted towards smaller 
EVs (<199 nm). NTA and electron microscopy have previously been found to provide similar 
size measurements, where the differences observed could be explained by differences in the 
lower detection threshold (minimum detectable size) 205,209.    
 
In our study we observed that the mean diameter of EVs was between 80-90 nm, which was 
similar to findings in other studies 205,209. In our study, the majority of the EVs isolated by 
ultracentrifugation were in the smaller size categories (<100 nm: 76.4% to 78.2%). Only a 




the observed EVs were below 300 nm. The discrepancies observed for EV concentrations 
measured by flow cytometry and NTA may partly be explained by the fact that the lower 
detection limit of conventional flow cytometers is approximately 300-500 nm.  
 
We observed that the plasma concentration and size distribution of EVs were similar in 
plasma isolated from blood with various anticoagulants (citrate, EDTA, heparin and CTAD). 
Neither the total plasma concentration, nor the concentrations of EV subgroups defined by 
size (<100 nm, 100–199 nm, 200–299 nm and 300–1000 nm) differed significantly between 
the anticoagulants. However, although not statistically significant, blood anticoagulated with 
sodium citrate showed the lowest plasma concentration of EVs across all size categories, 
whereas heparinized plasma yielded an almost 2-fold higher concentration of large EVs (300–
1000 nm) compared to the other anticoagulants. The impact of different anticoagulants on 
plasma concentration of EVs has previously been investigated by several studies 234-237. It was 
similarly found that heparin gave a higher concentration of EVs compared to citrate or CTAD 
234,235. We observed that EDTA displayed the highest plasma concentrations of EVs, 
supporting the notion that EDTA promotes the formation of ex vivo microvesicles possibly 
due to platelet activation 236. Citrate, a weaker calcium chelator than EDTA, displayed the 
lowest median concentrations of EVs across all size categories. Calcium chelators, such as 
citrate and EDTA, make the ex vivo calcium unavailable to the coagulation system and 
prevents leukocyte and platelet degranulation. Calcium plays an important role in the 
phospholipid re-modelling of the membrane during EV formation. Therefore, calcium 
chelating anticoagulants are believed to prevent vesiculation, to a certain extent 236. However, 
differences in EV concentration are observed with regard to the type of chelator used, 
suggesting that other mechanisms are involved. EDTA is known to additionally affect 
platelets by inducing a P-selectin dependent platelet activation process, dissociate the platelet 
integrin αIIbβ3 complex, and result in pseudo-thrombocytopenia and platelet aggregates on 
blood smears 234,236. The use of heparin for EV research was reported as not recommended 
due to its impact on platelet activation and aggregation. As heparin does not chelate free 
calcium it will not prevent EV generation by platelets after blood collection 236. Our findings 
of a lower EV concentration in samples with citrate may indicate that in vitro vesiculation 
potentially occurs to a larger extent with the other anticoagulants, and supports the 





The impact of freezing PPP compared to PFP on concentration and size distribution of 
plasma-derived EVs was also evaluated in our study. Lacroix and colleagues showed that the 
choice of centrifugation protocol for the preparation of plasma impacted the levels of EVs, 
measured by flow cytometry 234. The impact of residual platelets and platelet debris poses the 
risk of generating artifactual platelet-derived EVs. It has been shown that if platelets are 
insufficiently depleted before freezing, the EV count is affected after thawing 238. Double 
centrifugation prior to freezing has been shown to decrease the number of annexin V positive 
EVs, as well as platelet-derived EVs when measured by flow cytometry 238. In addition, 
freeze-thaw cycles are known to alter the number of platelet derived EVs 239,240. However, in 
our study, no statistical differences in total concentration and size distribution of EVs between 
plasmas prepared as PPP and PFP before freezing were observed for any of the anticoagulants 
used (citrate, EDTA, CTAD and heparin), measured by NTA.  
 
NTA as a method does not allow for the distinction between EVs and other particles within 
the same size range in plasma. Triglyceride-rich lipoproteins (chylomicrons, chylomicron 
remnants and very-low-density lipoproteins) are in molar excess, but of similar size to cell-
derived EVs 241-243, and therefore detectable by light scattering. Previous studies showed that 
the plasma concentration of EVs measured by NTA was strongly correlated to the plasma 
concentration of triglycerides 210, and that the concentration of EVs declined by more than 
98% when only vesicles labelled with a cell tracker dye were counted 205. It is important to 
avoid the interference of triglyceride-rich lipoproteins on NTA measurements of EVs. As 
previously described in the methods section, ultracentrifugation as a method cannot be used to 
absolutely discriminate between EV sizes, since sedimentation also will depend on the density 
and cargo of a vesicle, as well as the distance it needs to travel to be pelleted 200. It has 
therefore been recommended to dilute biological fluids with PBS in order to alter the viscosity 
of the sample fluid and thereby enhance the sedimentation of EVs 202. In our study we diluted 
PFP in Dulbecco’s phosphate buffered saline without CaCl2 and MgCl2 when we isolated EVs 
by ultracentrifugation. This was done in order to facilitate a better separation of the plasma 
constituents. In our study, the median concentrations of EVs isolated from plasma varied 
between 1.6–2.0×1010/mL with an interquartile range from 1.3 to 2.7×1010/mL, which is in 





We observed that the ingestion of a standardized high-fat meal was accompanied by a 
significant increase in serum triglycerides which peaked at 4 hours and returned to baseline 
levels within 8 hours after the meal. However, the postprandial lipidemia was not 
accompanied by significant changes in the concentration of EVs in plasma determined by 
NTA. Similarly, the plasma concentration of VLDL particles did not change from the fasting 
to the postprandial state, but the median diameter of VLDL particles increased from 42 ± 6 
nm in fasting plasma to 55 ± 9 nm in postprandial plasma samples. Serum triglycerides and 
the concentration of VLDL particles in plasma collected 4 hours after ingestion of the meal 
showed a strong correlation with the plasma concentration of EVs and explained 59–66% of 
the variation in plasma EVs. These findings suggest that the particle count, measured by 
NTA, was influenced by VLDL particles under postprandial conditions. Still, our findings 
provide several lines of evidence for at least partial separation of EVs from triglyceride-rich 
lipoproteins by high-speed centrifugation of plasma. First, the concentration of triglycerides in 
the plasma supernatant remained unchanged after high-speed centrifugation, suggesting that 
VLDL-particles in fasting blood samples were not pelleted and mainly remained floating. 
Second, even though serum triglycerides and the concentration of VLDL particles in plasma 
from fasting individuals displayed a moderate correlation with the plasma concentration of 
EVs, it only explained 13–19% of the variation in plasma EVs, suggesting that the particle 
count, measured by NTA, was not dominated by VLDL particles. Third, we developed a 
novel procedure to section the EVs, and could thereby clearly visualize the bilayer 
phospholipid membrane which distinguishes EVs from lipoproteins. Fourth, the results of our 
TEM analysis confirmed that the majority of isolated vesicles in our samples were in fact EVs 






5.2.2. A modified clot-based assay to measure negatively charged procoagulant phospholipids 
In paper II, we thoroughly validated a modified and easy to use PPL assay for the 
measurement of procoagulant phospholipids in test specimens (plasma samples or isolated 
EVs) and compared its performance with the commercial STA-Procoag-PPL assay from 
Stago Diagnostica. Our primary modification included preparation of PPL-depleted plasma by 
ultracentrifugation to remove EVs, which are assumed to be the main source of negatively 
charged phospholipids in plasma. This modification allowed for the establishment of an 
accessible in-house assay with comparable performance to the commercial assay. The 
addition of a standardized phospholipid reagent (UPTT) allows for clotting times to be 
converted into a standardized unit of phospholipids. 
 
There are currently two main clotting assays commercially available, the STA-Procoag-PPL 
assay from Diagnostica Stago and the XACT assay from Haematex, as previously mentioned 
in the methods section. Both assays are well established in research as reliable tools for 
assessing PPL activity in human plasma, and they have been used as tools for measuring the 
PPL activity in disease states 191,244-246, for the determination of pre-analytical parameters 
affecting EVs 234, and quality control of cell storage 247. The clotting assay, as a method, is 
favorable to use since it offers the measurement of PPL activity directly in plasma, compared 
to the antibody mediated capture based chromogenic assays. Clotting assays offer the 
measurement of a complex reaction with a physiological end-point, and can be performed on 
a variety of routine coagulation analyzers. However, for large scale application of clotting 
assay, the commercial options become quite costly.  
 
The commercial assays are based on the ability of procoagulant phospholipids to accelerate 
the conversion of prothrombin to thrombin with subsequent fibrin formation. Experimentally, 
equal volumes of sample plasma are mixed with PPL depleted plasma, provided as a reagent 
by the assay. The reaction is triggered by the addition of FXa in excess, together with 
calcium, and clotting time is measured. In both of the commercial assays, the phospholipid 
depleted plasma provided as a reagent is chemically treated with phospholipase in order to 
remove PPL. However, assuming that the vast majority of procoagulant phospholipids in 
plasma are EV-bound, we examined whether ultracentrifugation of plasma might substitute 




concept, we subjected plasma to sequential centrifugation steps, with increasing g power and 
time, which resulted in prolongation of the PPLCT. The notion of a procoagulant property of 
plasma, removable by centrifugation is in line with the observations of “thromboplastic 
substance” by Chargaff and West in 1946 162, and “platelet dust” by Wolf in 1967 163. The 
removal of EVs by ultracentrifugation, hence the reduced PPL activity, did not affect the 
ability of the depleted plasma to clot when subjected to standard coagulation test (activated 
partial thromboplastin time, aPTT and prothrombin time, PT). Moreover, the clotting time of 
the PPL-depleted plasma we generated by ultracentrifugation was comparable to the depleted 
plasma provided by the commercial assay, supporting its use in the modified assay. As plasma 
depleted of PPL is an essential reagent in the modified assay, the importance of not 
introducing assay variations is critical. We demonstrated that three independent batches of 
PPL-depleted plasma prepared from the same donors performed similarly, supporting the use 
of ultracentrifugation as a method for PPL depletion. 
 
The performance of our modified assay was compared to the Stago assay using both dilutions 
of a standardized phospholipid reagent (UPTT) and samples from ten individuals. Our study 
provides evidence for comparable performance of the modified assay with regard to 
sensitivity and measurement of levels of PPL in plasma samples. Our modified PPL assay 
displayed minor variation in the assay performance. CVs obtained using the standards from 
the Stago STA-Procoag-PPL or in-house pooled PFP range from 2.8 to 4.1%, well within 
recommended acceptable limits for within-day and between-day variability. Similar results 
were shown by van Dreden and colleagues in the XACT assay, with intra-assay CVs of 3.3% 
and 3.1% for normal pooled plasma and patient plasma, respectively, and inter-assay CVs of 
3.9% and 4.2%. We showed that the PPL activity measured in the modified assay was largely 
dependent on PS in the test sample by blocking with lactadherin. The abundance of PS on the 
EV surface is often used to characterize EVs by exploiting the ability of annexin A5 or 
lactadherin to bind PS on the outer leaflet of the membrane. Lactadherin has been 
demonstrated to be an effective anticoagulant blocking the activity of PS and inhibiting the 
procoagulant activity of blood cells, endothelial cells and EVs by 80% 248. In our experiment, 
PPLCT was prolonged with increasing concentrations of lactadherin to the extent that it was no 
longer measurable in the assay. Aung et al. similarly showed that pre-treatment of packed red 





The effect of pre-analytical parameters such as the plasma centrifugation protocol and the 
impact of postprandial lipemia on PPL activity was investigated in this study. It was 
previously reported by Lacroix and colleagues that the choice of centrifugation protocol for 
the preparation of PFP influenced the PPLCT after a freeze-thaw cycle. Similarly, we observed 
that a common protocol for PFP preparation (3000 × g for 10 minutes followed by 13,500 × g 
for 2 minutes) yielded a 24% shorter PPLCT than PFP prepared as recommended by ISTH 
(2,500 x g for 15 minutes twice). Hence, the plasma centrifugation protocol should be taken 
into consideration when comparing plasma PPLCT between studies. An additional pre-
analytical challenge for population-based studies is the availability of fasting blood samples 
as the PPL activity in plasma may be affected by plasma levels of triglyceride-rich 
lipoproteins. We therefore tested the PPL activity in plasma isolated before and four hours 
after a high fat meal on the modified PPL assay. We observed that the PPLCT was unchanged 
in fasting and postprandial plasma, while an increase in triglycerides was observed. This 
suggests that PPLCT is independent of postprandial lipemia and that there is no need to use 
fasting blood samples to obtain reliable PPL activity in plasma samples. Our findings are 
supported by Silveira et. al. who reported no effect of postprandial lipemia on the overall PPL 
measures, using the STA-Procoag PPL assay 249. It was also shown by Mørk and colleagues 
that even a non-standardized meal and a shorter time interval between the ingestion of the 
meal and blood draw (75 min) resulted in no change in PPL between fasting and postprandial 
samples measured by the Stago assay 250.  
 
The inter-individual variability of coagulation factors in the test samples may affect the 
degree of activation measured by the modified assay. We know that procoagulant 
phospholipids, with PS in particular, affect the activity of both the intrinsic and extrinsic 
tenase and prothrombinase complexes, as well as the activation of FXI by thrombin 251. We 
therefore tested a wide range of FVIIa and FVa concentrations, where high concentrations of 
coagulation factors proved to shorten the clotting time in the modified PPL assay. However, 
these effects occurred only at supra-physiological concentrations significantly higher than 
those observed in vivo. While TF is thought to be a major procoagulant factor found in EVs, 
only minute quantities of TF are normally present in human plasma. Therefore, we also 
investigated the effect of TF on the modified PPL assay. It was previously shown by Connor 
and coworkers that the XACT assay was insensitive to increasing concentrations (0–0.1%) of 




TF after LPS stimulation (pathophysiological conditions) did not affect the clotting time in 
our assay. However, we observed a dose-dependent decrease in the clotting times with 
increasing supra-physiological concentrations of relipidated TF. Taken together, our findings 
suggest that the modified PPL assay is not influenced by physiological concentrations of the 
clotting factors or TF+EVs in the test samples. 
 
An assay designed for large-scale applications should be reproducible over time, and it should 
be possible to compare the results between different laboratories. To solve the latter challenge 
we proposed the introduction of the UPTT reagent, which is an inexpensive standardized 
preparation of rabbit brain cephalin, allowing for clotting times to be converted into a 
standardized unit of phospholipids. The XACT assay solves this problem by the inclusion of a 
synthetic PPL calibrator 218, while the Stago assay leaves it up to the users to create a 
reference range and standards for the clotting time.  
 
There are two main considerations with the modified PPL assay. First, the results will be 
influenced by the presence of lupus anticoagulants as well as high concentrations of 
coagulation factors which may lead to falsely prolonged or shortened clotting times. This is 
common for all plasma-based assays, and should be accounted for when interpreting the 
results. Second, pre-analytical conditions and inter-individual variations might influence 
plasma concentrations of coagulation factors in PPL depleted plasma. However, our modified 







5.2.3 PPL clotting time and the risk of future incident VTE 
In paper III, we investigated the association between plasma PPLCT and the risk of future VTE 
in a nested case-control study derived from a population-based cohort study. We found that 
prolonged PPLCT displayed a modest protective effect on VTE risk both when PPLCT was 
used as a continuous and as a categorized variable in the logistic regression models. In 
addition, we show that subjects with extremely prolonged PPLCT (above the 95
th percentile) 
had lowered risk of VTE (OR 0.35, CI 95% 0.13-0.81) compared to those with PPLCT in the 
lowest quartile. We observed similar results in subgroup analysis for PE and DVT. However, 
our results appeared to be influenced by regression dilution bias, as the ORs for VTE by 
plasma PPLCT decreased substantially with shortened time between blood collection and the 
VTE events.   
 
Our study is, to the best of our knowledge, the first to investigate the association between 
plasma PPLCT and the risk of future VTE in the general population. In a paper by Riva and 
coworkers, they report their findings from a hospital based cross-sectional study exploring 
PPLCT in relation to VTE. They measured the PPLCT of 100 patients referred to the 
Emergency Department under suspicion of VTE using the commercial STA Procoag PPL 
assay from Diagnostica Stago. They reported that PPLCT did not discriminate between 
patients with (n=31) and without VTE in their study 183. However, the lack of discriminatory 
diagnostic power by the PPL assay may have been diluted by other conditions associated with 
shortened PPLCT among the acute medical patients without VTE admitted to the hospital. 
Since our study population as well as study design differ, we believe that their findings does 
not exclude the potential association between plasma PPLCT and the risk of future VTE.  
 
Ayers and colleagues published a cross-sectional study investigating if EV count, assessed by 
flow cytometry, correlated with their functional capacity 185. They measured the plasma 
PPLCT in 53 healthy individuals and 47 patients with obstructive sleep apnea, using the STA 
Procoag PPL assay, as well as thrombin generation by the calibrated automated thrombogram 
(CAT). They found that plasma PPLCT showed strong inverse correlations to parameters of 
thrombin generation, such as ETP (Spearman r=-0.77) and peak thrombin concentration 
(Spearman r= -0.72), using the addition of minimal amounts of phospholipids and TF (1 pM) 




relationship between plasma PPLCT and parameters of the CAT assay. The PPLCT correlated 
strongly with both lag time (r= 0.99, p= <0.0001) and ETP (r= -0.98, p= <0.0001). 
 
An association between plasma PPLCT and the risk of future VTE is supported by 
circumstantial evidence. First, the PPLCT is inversely associated with annexin V-positive EVs 
184,185 and high plasma levels of EVs are associated with VTE risk in most 11,19,181,252 but not 
all studies 182,186. Second, in a cross-sectional study including plasma samples from 100 
healthy individuals and patients with obstructive sleep apnea, plasma PPLCT showed strong 
and inverse correlations to parameters of thrombin generation, such as ETP and peak 
thrombin concentration, using the CAT assay 185. Accordingly, we demonstrated a clear dose-
response relationship between plasma PPLCT and parameters of the CAT assay. In addition, 
several studies have shown that parameters of the CAT assay, particularly lag-time and ETP, 
are associated with incident 187-189,253,254 and recurrent 190,255,256 VTE. Third, carriers of rare 
(e.g. deficiencies of antithrombin, protein C and S) 191 and common (e.g. factor V Leiden and 
the prothrombin mutation G20210A) 192,193 prothrombotic genotypes had significantly shorter 
plasma PPLCT than non-carriers, providing indirect evidence for lower risk of VTE with 
prolonged plasma PPLCT.    
 
The plasma levels of modifiable biomarkers such as PPLCT, are expected to change over time. 
Fluctuations in the exposure variable during follow-up will lead to the phenomenon called 
regression dilution bias 257, which usually results in an underestimation of the true association 
between exposure and outcome. We therefore chose to estimate the ORs for VTE among 
subjects with the highest (highest quartile) versus lowest (lowest quartile) plasma PPLCT as a 
function of time between blood sampling and the VTE events. We observed that the inverse 
association between high plasma PPLCT and VTE was stronger with shortened time between 
the blood sampling and the VTE events. In subgroup analysis the ORs for DVT and PE as a 
function of time between blood sampling and events showed similar patterns as the ORs for 
overall VTE. The explicit impact of regression dilution in our study may indicate that we 
report an underestimation of the true association between PPLCT and the risk of future VTE. 
Regression dilution has in a similar manner previously been reported to impact other 
modifiable biomarkers such as the terminal complement complex (TCC) 258 and mannose-





Strengths of our study include recruitment of VTE patients from a population-based cohort 
with age- and sex-matched controls from the same source population where blood samples 
were collected prior to the VTE event. This allows assumptions on the direction of the 
observed association between plasma PPLCT and VTE. Additionally, the modified FXa-
dependent PPL clotting assay is highly sensitive and displayed a low CV of ≤ 4%. A 
limitation of our study is that plasma samples used were collected in 1994/95 and stored at -
80°C until analysis more than 20 years later. The long storage time, as well as freezing and 
thawing, might possibly affect the plasma PPLCT. However, it is unlikely that it would impact 
our end results, as the potential effects would be similar for both cases and controls. 
Moreover, the PPL levels were only measured in baseline samples, while potential changes 
during follow-up were not accounted for. This might lead to an underestimation of the true 
association between plasma levels of PPLCT and VTE risk due to regression dilution bias 
257. 
In our study, some plasma samples were excluded due to either missing samples or poor 









5.2.4 PPL activity and rosuvastatin treatment after a VTE event  
In paper IV we investigated the effect of rosuvastatin treatment on plasma PPL activity, 
measured by a FXa-dependent PPL clotting assay in patients with a previous history of VTE. 
We observed that statin treatment caused a 22% reduction in PPL activity for all VTE patients 
and 37% reduction in PPL activity for PE patients compared to no treatment. The observed 
effect of rosuvastatin on PPL activity was not explained by changes in serum levels of total 
cholesterol or a parallel change in plasma levels of total- and platelet-derived microvesicles 
by statin treatment, measured by flow cytometry. The results from our study support the 
beneficial effect of statin treatment on coagulation factors and thrombin generation potential 
in plasma. As the presence of negatively charged phospholipids augment the activity of the 
extrinsic tenase complex TF-FVIIa by several orders of magnitude 144, the combined effect of 
reduced PPL activity and modest decline in several coagulation factors may reduce 
coagulation activation and contribute to the explanation of why rosuvastatin treatment lower 
the risk of VTE 260.  
 
Clinical studies have previously shown that statin treatment, with simvastatin 261, atorvastatin 
262,263, or cerivastatin 264 caused a beneficial effect on the coagulation system by a moderate 
lowering of specific coagulation factors and thrombin generation. In previous publications 
from the START trial, rosuvastatin treatment showed favorable effects on the hemostatic 
system by reducing plasma levels of coagulation factors FVII, FVIII, and FXI by 4-6% 196, D-
dimer by 3% 196 and lowering the ex vivo thrombin generation potential by 10% 198. 
Additionally, rosuvastatin treatment was found to increase the fibrinolytic potential assessed 
by shortening of the mean plasma clot lysis time and a decrease in both plasmin inhibitor 
levels and thrombin-activatable fibrinolysis inhibitor (TAFI) activity 197. The treatment effects 
of rosuvastatin on thrombin generation and plasma D-dimer levels were mainly driven by an 
increase among non-statin users 196,198. In contrast, we found a more profound beneficial 
effect of rosuvastatin treatment that was mainly driven by a significant decline in the PPL 
activity among rosuvastatin users accompanied by a minor increase in the PPL activity among 
the non-users. The increase in hemostatic factors among non-statin users in our and previous 
studies from the START trial may be interpreted as a consequence of the rebound 





Previous studies have demonstrated that plasma PPL activity is mainly due to the presence of 
EVs  184,185, and most 186,191-193,267 but not all 268 case-control studies have reported increased 
EV-related plasma PPL activity in VTE patients compared to controls. Therefore, our findings 
of a profound decrease in PPL activity by statin treatment may contribute to the explanation 
behind the reduction of incident and recurrent VTE by statin treatment 260,269-276. 
Microvesicles (MVs) are larger EVs (100-1000 nm in diameter), which bud directly from the 
plasma membrane of activated cells, and express surface markers of their cell of origin 179,277. 
The largest proportion of MVs in circulating blood is derived from platelets 278,279 and the 
subsequent procoagulant activity in plasma is mediated by platelet-derived MVs (PDMVs) 
267,278. A strong inverse correlation has also been reported between PPL clotting time and 
lactadherin positive EVs measured in PPP from healthy control subjects and patients with 
obstructive sleep apnoea (OSA), though the strength of the correlations was mainly driven by 
the OSA patients 185. We therefore hypothesized that the reduction we observed in plasma 
PPL activity following rosuvastatin treatment was caused by a parallel decline in plasma MV 
levels, and particularly platelet-derived MVs. In order to test our hypothesis, we isolated EVs 
from platelet free plasma and measured the total count (lactadherin-positive) and platelet-
derived MVs (lactadherin- and CD41-positive) by flow cytometry. Although we found that 
statin treatment lowered the PPL activity in the treatment group, we did not observe a 
reduction in total EV count, or platelet-derived EVs for comparisons between – or within 
study groups.  
 
In our study, rosuvastatin treatment did not affect plasma MV levels in patients with a 
previous history of VTE. Contradicting our findings, previous observational studies have 
shown that patients with arterial cardiovascular diseases or risk factors (hyperlipidemia in 
particular) had higher plasma MV levels than control individuals, and that statin treatment 
lowered plasma MV levels in most, but not all studies 280-285. Several factors may contribute to 
explain our findings. First, the effect of statin treatment on plasma MV levels may be limited 
to individuals with arterial cardiovascular diseases and risk factors, and not transferrable to 
VTE patients. Second, one might speculate that statin treatment could differentially influence 
EV formation from various intravascular cells and the subsequent process of externalization 
of PS to the outer leaflet of the cell membrane during EV formation 286. Accordingly, in a 
placebo-controlled randomized double-blinded crossover study, the treatment of 19 patients 




reduction in plasma MV levels expressing CD62P- and CD61-positive MVs without affecting 
plasma levels of lactadherin-positive EVs 283. Third, a well-recognized limitation of flow 
cytometry as a method is the detection limit of the instrument. Even a sensitive flow 
cytometer will still only detect vesicles above approximately 200 nm in diameter, and thereby 
exclude the majority of EVs. Vesicles larger than 200 nm in diameter have been reported to 
only account for a minority of the EV population (< 5%) 287. This may imply that a possible 
decrease in plasma EVs after statin treatment could have been masked by the unchanged level 
of the EVs >200 nm in diameter.  
 
Some aspects of our randomized controlled trial need special considerations. Neither the 
patients nor the physicians were blinded to treatment. However, it is unlikely that knowledge 
of the treatment would affect the laboratory outcomes. Furthermore, the technicians 
conducting the laboratory analyses were blinded to sample treatment. In addition, despite 
randomization, the distribution of age and sex was uneven between the study arms. We 
decided a priori to adjust analysis for age and sex as potential confounders, and adjustments 
did not influence the observed treatment effect. Even though results from subgroup analysis 
revealed the most pronounced decrease in plasma PPL activity in individuals with a history of 
PE, they should be interpreted with caution as the study was not originally powered to analyze 
differences in subgroups 196. Lastly, as participants were recruited from an outpatient setting, 
it limits the risk of confounding diseases at randomization, and for analyses, participants were 









I. Isolation of EVs from plasma by high-speed centrifugation yielded similar 
concentrations and size distributions of EVs for the four anticoagulants tested (citrate, 
EDTA, CTAD and heparin). We found no statistical difference in concentration or 
size of EVs (measured by NTA) when plasma was prepared as PPP or PFP before 
freezing. Plasma VLDL particles interfered with EV measurements assessed by NTA, 
particularly under postprandial conditions due to an increase in the median particle 
diameter of VLDLs exceeding the lower detection limit of NTA.  
 
II. The use of sequential centrifugation, including final ultracentrifugation, to deplete 
plasma of procoagulant phospholipids performed equal to enzymatic depletion of 
phospholipids from plasma in a FXa-based clotting assay to determine PPL clotting 
times. In addition, we introduced a standardized PPL reagent (UPTT) which allows for 
clotting times to be converted into a standardized unit of phospholipids. These 
modifications allowed us to establish a sensitive and reproducible in-house assay. 
 
III. Results from our nested case-control study indicate an inverse association between 
plasma PPLCT (measured by a modified FXa-dependent PPL clotting assay) and the 
risk of future VTE. Subjects with PPLCT above the 95th percentile had particularly low 
risk of future VTE and the results were strongly influenced by regression dilution bias. 
 
IV. Rosuvastatin treatment caused a substantial decrease in plasma PPL activity, 
suggesting that PPL-dependent attenuation of coagulation activation may contribute to 
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Impact of preanalytical conditions 
on plasma concentration and size 
distribution of extracellular vesicles 
using Nanoparticle Tracking 
Analysis
Simin Jamaly1, Cathrine Ramberg1,2, Randi Olsen3, Nadezhda Latysheva1, Paul Webster4, 
Timofey Sovershaev1,2, Sigrid K. Brækkan1,2 & John-Bjarne Hansen1,2
Optimal pre-analytical handling is essential for valid measurements of plasma concentration and 
size distribution of extracellular vesicles (EVs). We investigated the impact of plasma preparation, 
various anticoagulants (Citrate, EDTA, CTAD, Heparin), and fasting status on concentration and size 
distribution of EVs measured by Nanoparticle Tracking Analysis (NTA). Blood was drawn from 10 
healthy volunteers to investigate the impact of plasma preparation and anticoagulants, and from 
40 individuals from a population-based study to investigate the impact of postprandial lipidemia. 
Plasma concentration of EVs was measured by NTA after isolation by high-speed centrifugation, and 
size distribution of EVs was determined using NTA and scanning electron microscopy (SEM). Plasma 
concentrations and size distributions of EVs were essentially similar for the various anticoagulants. 
Transmission electron microscopy (TEM) confirmed the presence of EVs. TEM and SEM-analyses showed 
that the EVs retained spherical morphology after high-speed centrifugation. Plasma EVs were not 
changed in postprandial lipidemia, but the mean sizes of VLDL particles were increased and interfered 
with EV measurements (explained 66% of the variation in EVs-concentration in the postprandial phase). 
Optimization of procedures for separating VLDL particles and EVs is therefore needed before NTA-
assessment of EVs can be used as biomarkers of disease.
Extracellular vesicles (EVs), including exosomes (30–100 nm in diameter) and microvesicles (100–1000 nm in 
diameter), are bilayer membrane vesicles released from various cells into their surroundings1. The EVs are char-
acterized by their size, mechanism of cellular release, and their content of proteins, RNA, and DNA molecules 
derived from the parental cell2. The functional properties of EVs are dependent on the cellular origin and patho-
logical conditions3,4. Elevated plasma levels of EVs, and microvesicles in particular, have been associated with 
several disease states such as atherosclerosis5,6, diabetes7, cancer8,9, arterial cardiovascular diseases10–12 and venous 
thromboembolism13,14. Although the majority of EVs in plasma have diameters below 200 nm15,16, most studies 
relating plasma levels of EVs with diseases have been carried out using flow cytometry for EV measurements 
with lower detection limits above 200 nm. Therefore, it would be attractive to use Nanoparticle Tracking Analysis 
(NTA) to determine plasma concentration of EVs in the size range of 50–1000 nm15,17 in order to assess associa-
tions between the predominantly smaller EVs and disease states.
Measurement of plasma EVs by NTA could possibly provide novel information on the role of EVs as poten-
tial biomarkers of risk, diagnosis, and prognosis of various diseases. However, the clinical application is cur-
rently hampered by methodological concerns related to NTA assessment of EVs. In human plasma, more than 
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98% of the particles detected by NTA are very low density lipoprotein (VLDL) particles15,18, and the measured 
particle concentrations are associated with the triglyceride concentration both under fasting and postprandial 
conditions19. Isolation of EVs from plasma is therefore an essential pre-analytical step before NTA measurement. 
However, isolation of EVs by differential centrifugation may affect EV morphology, promote aggregation of EVs, 
and to some extent pellet lipoproteins20–22. In clinical and epidemiological studies, plasma is most often prepared 
by single centrifugation at 1500–3000 × g for 10–20 min, yielding platelet poor plasma (PPP), before storage in 
biobanks. High-speed centrifugation to achieve platelet free plasma (PFP) from PPP prior to freezing has been 
shown to lower the concentration of platelet-derived EVs compared to plasma subjected only to lower speed 
centrifugation (PPP) before freezing23. However, it is not known whether high-speed centrifugation after thaw-
ing of PPP would affect concentration and size distribution of plasma derived EVs compared to PFP prepared by 
double centrifugation (including one low and one high-speed centrifugation step) before freezing. Furthermore, 
previous studies comparing the impact of various anticoagulants on plasma concentrations of EVs, assessed by 
flow cytometry, have shown higher levels of EVs in heparin than in sodium citrate, acid-citrate dextrose (ACD) 
or sodium citrate theophylline adenosine dipyridamole (CTAD)24,25.
Pre-analytical conditions such as centrifugation steps, choice of anticoagulant, and fasting status may impact 
the plasma concentration and size distribution of EVs determined by NTA. We therefore aimed to investigate the 
impact of plasma preparation, assessed by freezing plasma before (PPP) or after (PFP) a second high-speed cen-
trifugation, various anticoagulants in commercial blood collection tubes (Citrate, EDTA, CTAD, and Heparin), 
and fasting status on plasma concentration and size distribution of EVs using NTA and SEM.
Material and Methods
Study participants. Ten healthy volunteers (5 men and 5 women, aged 28–55 years) were recruited from 
the research staff, and they donated blood used to investigate the method of blood collection, centrifugation 
steps for plasma preparation and EV isolation, and choice of anticoagulant on the concentration and size dis-
tribution of plasma EVs. The study was approved by the regional ethical committee (REK Nord), and was con-
ducted in accordance with relevant guidelines and regulations. Informed written consent was obtained from all 
participants.
Forty healthy subjects, 20 to 80 years of age, were recruited from a general population-based study (the 
Tromsø study) in order to investigate whether fasting and postprandial lipoproteins would affect the concentra-
tion and size distribution of plasma EVs. They underwent a screening visit including a complete medical history, 
physical examination, a self-administrated questionnaire which also included dietary habits, physical exercise, 
and alcohol consumption, and blood samples were taken with special emphasis on exclusion criteria. Exclusion 
criteria were any of the following conditions: regular use of lipid-lowering drugs (statins, resins or nicotinic 
acid derivates), estrogen supplementation or oral anticoagulants, cancer or other serious life-threatening medical 
conditions, present or previous cardiovascular diseases, recurrent venous thrombosis, diabetes mellitus, hypothy-
roidism, renal, hepatic, or psychiatric disease, and current abuse of alcohol or drugs. Informed written consent 
was obtained from all participants, and the Regional Committee for Research Ethics approved the study. The 
study was performed at the Clinical Research Unit at the University Hospital of North-Norway.
Blood collection. Blood was drawn from an antecubital vein using a 21 Gauge needle in the morning 
(08:30 am). Tourniquet was only used to find a vein and was opened after needle insertion. Blood was drawn 
into regular commercially available blood collection tubes (BD Vacutainers) (BD Bioscience, New Jersey, US) 
with the following anticoagulants; Sodium citrate (2.7 ml, REF363048), Sodium heparin (6.0 ml, REF367876), 
Ethylenediaminetetraacetic acid (K2E-EDTA) (6.0 ml, REF367864) and buffered Sodium Citrate Theophylline 
Adenosine Dipyridamole (CTAD) (4.5 ml, REF367599). The first few millilitres of blood were drawn into a 
dummy tube that was discarded afterwards. The blood collection tubes were gently inverted several times in 
order to mix anticoagulants with blood. The blood collection tubes were not transported, as blood collection 
and plasma preparation was performed in the same laboratory. The blood collection tubes were held in upright 
racks until centrifuged at room temperature. Blood cell counts were performed at baseline using Micros60 (ABX 
Diagnostics, Montpellier, France).
Plasma and EV Preparation. Platelet poor plasma (PPP) was prepared from anticoagulated whole blood 
by centrifugation at 3000 × g for 10 minutes at room temperature within 30 minutes after blood collection. PPP 
was then either subjected to a second high-speed centrifugation at 13,500 × g for 2 minutes to achieve platelet free 
plasma (PFP) or aliquoted and stored at −70 °C for at least 48 hours. After thawing, PPP was then centrifuged 
at 13,500 × g for 2 minutes to get rid of platelets and cell debris. PFP was then diluted with Hanks/Hepes buffer 
(130 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl2, 0.8 mM MgSO4, 0.44 mM Na2HPO4, 20 mM HEPES, pH 7.4) (1:10 
dilution) (to be used for electron microscopy) or sterile filtered Dulbecco’s phosphate buffered saline (DPBS) 
without CaCl2 and MgCl2 (Sigma-Aldrich, St. Luis, MO, USA) (1:20 dilution) (to be used for EV concentration 
and size distribution)26. EVs were pelleted from PFP by centrifugation at 20,000 g for 30 minutes at room tem-
perature (Beckman OptimaTM LE-80K Ultracentrifuge, swinging bucket rotor SW 40 TI). The supernatant was 
discarded and the EV pellet re-suspended in DPBS, snap frozen27 and stored at −70 °C until further analysis. 
For electron microscopy the EV pellet was re-suspended in double filtered Hanks/Hepes buffer and fixed in 4% 
formaldehyde until further analysis.
Nanoparticle Tracking Analysis (NTA). EV concentration and size distribution were determined using 
NanoSight NS300 (Malvern Instruments Ltd., Worcestershire, UK) equipped with a 488 nm blue laser and a 
CMOS camera. EV samples were thawed in 37 °C water immediately prior to analysis and diluted (50–100×) in 
DPBS. Samples were manually introduced to the instrument using a syringe. Samples were captured at ambient 
www.nature.com/scientificreports/
3SCIENTIFIC REPORTS |         (2018) 8:17216  | DOI:10.1038/s41598-018-35401-8
temperature with automatic temperature monitoring. Three separate dilutions of the samples were used for anal-
ysis. Each dilution was captured 3 times 60 seconds (camera level 16), and the sample was refreshed between cap-
tures. The gasket was cleaned between each sample. The nine resulting videos were analysed with NTA software 
version 3.0 (detection threshold 5). Mean values for concentration and size distribution were calculated.
Transmission Electron Microscopy (TEM). TEM was performed on isolated EVs. The EV pellets were 
re-suspended in 50 µl of Hanks/Hepes buffer and fixed in 4% formaldehyde in 200 ml Hepes overnight.
TEM of Ultrathin sections. To improve localization of EVs for TEM, the EVs were adsorbed onto an epoxy 
resin substrate containing colloidal gold particles. The substrate was prepared by adsorbing 15 nm gold particles 
(Department cell biology, University of Utrecht, the Netherlands) on formvar/carbon coated copper specimen 
grids and then embedded the gold-coated grids in a thin layer of epoxy resin between two layers of Aclar film and 
polymerized at 60 °C for 48 hours. The EV suspension was placed on the gold-loaded, epoxy-embedded specimen 
grids and in 1% glutaraldehyde, postfixated in 1% OsO4 and stained with 1% aqueous uranyl acetate. The EVs 
on the epoxy-embedded grids were dehydrated in a graded series of ethanol, infiltrated in an Epon Equivalent 
(AGAR 100, DDSA, MNA and DMP-30, Agar Scientific, UK) and polymerized at 60 °C for 48 hrs. Ultrathin 
sections of the embedded EVs were prepared using Ultracut S ultramicrotome (Lieca Microsystems, Vienna, 
Austria) and a Diatome diamond knife (Diatome, Biel, Switzerland). Images using a JEOL JEM 1010 transmis-
sion electron microscope (Tokyo, Japan) were acquired with a Morada camera system (Olympus Soft Imageing 
System, Münster, Germany).
Immune electron microscopy. EV’s were fixed with 1% buffered glutaraldehyde and adsorbed onto 
carbon-formvar coated specimen grids before immunolabelling. In short, unspecific labelling was blocked on 
0.1% cold water fish skin gelatin (CWFSG) (Sigma G-7765) and 1.5% bovine serum albumin. Samples were 
incubated with anti-annexin V (Anx5) antibody (abcam, Cat# ab14196), diluted in Anx5 binding buffer (BD 
Pharmingen, Cat#556454) and protein A-gold (University of Utrecht, The Netherlands). All immunoreagents 
were diluted in CWFSG and the grids washed in PBS between each step. The grids were finally fixed in 1% glutar-
aldehyde, washed in distilled water and dried in 1.8% Methylcellulose containing 0.3% uranyl acetate.
Scanning Electron Microscopy (SEM). To obtain an overview of the morphology and measure particle 
size of EV samples, isolated EVs were prepared for SEM analysis. To study the surface size, shape, and features 
of EVs, they were negatively stained on formvar/carbon coated copper grids. Grids floated on sample drops for 
30 minutes were treated with 1% glutaraldehyde, washed in PBS and ddH2O and contrasted/dried with the addi-
tion of 1.8% methyl cellulose and 0.3% uranyl acetate according to Tokuyasu28,29. EV size measurements were 
performed in the iTEM program (Olympus Soft Imaging Solutions, Münster, Germany) by measuring shortest 
diameter of at least 200 EV on SEM pictures. The start and end of every diameter was set manually and the 
diameter was calculated by the program. Grid were mounted on specimen holder and coated with gold/palla-
dium before examination in the SEM. The images were obtained using a Zeizz Merlin VP compact scanning 
microscope.
Fat tolerance test. A fat-tolerance test was conducted using a test meal prepared from standard porridge 
cream containing 70% of calories from fat of which 66% saturated fat, 32% monounsaturated fat and 2% polyun-
saturated fat. The test meals were served with two teaspoons of sugar, cinnamon, and two glasses (150 ml each) 
of sugar-free juice. The test meals were freshly prepared each morning. A weight-adjusted meal (1 gram fat per 
kg body weight) was served at 8:00 a.m. and consumed over a 15-minutes period. The participants were allowed 
to drink 350 ml calorie-free beverages and eat an apple during the following 8 hrs. Blood was drawn from an 
antecubital vein in the morning at 7:45 a.m., after a 12 hour overnight fast and a 48 hour refrain of exhaustive 
physical exercise and alcohol consumption, and then 2, 4, 6, and 8 hours after the meal, using a 19-gauge needle 
in a vacutainer system with minimal stasis for serum and plasma preparations. Blood for plasma preparation was 
collected into 4.5 ml vacutainers (Becton Dickinson, Meylan Cedex, France) containing 0.129 M sodium citrate 
(1 vol anticoagulant and 9 vol whole blood) or EDTA (K3 – EDTA 40 µl, 0.37 mol/L per tube) as anticoagulant. 
Serum was prepared by clotting whole blood in a glass tube at room temperature for 1 hour. Serum and plasma 
was prepared by centrifugation at 2000 g for 15 minutes at 22 °C, transferred into cryovials (Greiner laboratech-
nik, Nürtringen, Germany) in aliquots of 1 ml and stored at −70 °C until further analysis.
Serum lipids were analyzed on an ABX Pentra 400 (Horiba ABX Diagnostics, Montpellier, France) with rea-
gents from Horiba ABX Diagnostics (Montpellier, France). Proton nuclear magnetic resonance (NMR) spec-
troscopy was used to determine mean particle sizes of the main lipoprotein classes (very-low-density lipoprotein 
(VLDL), low-density-lipoprotein (LDL), and high-density lipoprotein (HDL)) along with concentrations of 10 
lipoprotein subclasses (chylomicron/large VLDL, medium VLDL, small VLDL, intermediate-density lipoprotein 
(IDL), large LDL, small LDL also reported as medium small LDL and very small LDL, large HDL, medium HDL, 
and small HDL) in fasting and 4-hours postprandial citrated plasma at LipoScience Inc., Railegh, NC, USA. 
Plasma concentrations of EVs in fasting and 4-hours postprandial citrated plasmas were determined using NTA 
as previously described.
Statistics. Median values and interquartile ranges for continuous data (EV concentrations) were presented 
as data was not normally distributed. To test for differences in EV concentrations between anticoagulants, we 
used Friedman’s test for non-parametric and dependent continuous data. Bar graphs were used to display (i) 
EV concentrations according to size categories of EVs (<100 nm, 100–199 nm, 200–299 nm, 300–1000 nm), 
and (ii) mean sizes of EVs measured by NTA and SEM in the different anticoagulants. The correlation between 
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triglycerides and EV concentrations, as well as VLDL and EV concentrations, was calculated using Pearson corre-
lation coefficient. All analyses were performed using IBM SPSS Statistics version 22 (Armonk, NY, USA).
Results
The baseline characteristics of the ten healthy volunteers (aged 28–55 years) recruited from the research staff and 
the forty subjects (aged 28–76 years) recruited from the general population health study are shown in Table 1.
The impact of freezing PPP compared to PFP on concentration and size distribution of plasma-derived EVs 
is shown in Fig. 1, panel A–D. There were no statistical differences in total concentration and size distribution of 
EVs between plasmas prepared as PPP and PFP before freezing in any of the anticoagulants used (Fig. 1).
The impact of the four different anticoagulants on concentration and size distribution of plasma EVs are 
displayed in Table 2. Neither the total plasma concentration, nor concentrations of EVs within defined size 
categories (<100 nm, 100–199 nm, 200–299 nm and 300–1000 nm) differed significantly between the antico-
agulants. However, although not statistically significant, blood anticoagulated with sodium citrate showed the 
lowest plasma concentration of EVs across all size categories, whereas heparinized plasma yielded an almost 
2-fold higher concentration of large EVs (300–1000 nm) compared to the other anticoagulants (Table 2). The 
majority of EVs were in the smaller size categories (<100 nm: 76.4% to 78.2%, 100–199 nm: 18.0% to 20.2%, 
200–299 nm: 2.7% to 3.5%, 300–1000 nm: 0.7% to 1.3%) and the size distribution did not differ between antico-
agulants (Table 2).
The mean size of the EVs was marginally lower (Fig. 2, upper panel) and the size distribution was shifted 
towards smaller EVs (<199 nm) when EVs were sized by SEM compared to NTA (Fig. 2, lower panel). Similar to 
NTA, the majority of EVs determined by SEM were below 200 nm in diameter and large vesicles were rarely seen.
TEM was applied to confirm the presence of EVs after isolation by high-speed centrifugation from plasma 
samples. TEM of negatively stained (Fig. 3A) and ultrathin sections (Fig. 3B) revealed that the majority of isolated 
vesicles were EVs, characterized by the bilayer phospholipid membrane. Even though concern has been raised 
about EV aggregation and morphological changes as a result of high-speed centrifugation, we could not identify 
EV aggregates, nor large variations in the EV morphologies, as the main proportion of vesicles identified were 
spherical (Fig. 3C) and presented uneven non-smooth surfaces (Fig. 3D). Lipoprotein vesicles, characterized by 
the lack of a bilayer surface membrane, were rarely seen.
In order to determine if the concentration of triglycerides would change, and lipoproteins would sediment 
with EVs after a high speed centrifugation (20,000 × g for 30 minutes), we measured the levels of plasma lipopro-
teins before and after centrifugation, in both diluted and undiluted plasma. We found that the plasma concen-
tration of triglycerides was equal before and after high-speed centrifugation for both undiluted and diluted (1:5 
in DPBS) plasma (Fig. 4, panel A). Despite the minimal sedimentation of VLDL particles by high-speed centrif-
ugation due to unchanged plasma concentration of triglycerides, we found moderate correlations between EVs 
and plasma concentrations of triglycerides (Fig. 4, panel B) and VLDL particles (Fig. 4, panel C) under fasting 
conditions. Concentrations of serum triglycerides and VLDL particles explained (r2) 13% and 19%, respectively, 
of the plasma variation of EVs.
Ingestion of a standardized high-fat meal (1 g/kg body weight) was accompanied by a significant increase 
in serum triglycerides, which peaked at 4 hours, and returned to baseline levels within 8 hours after the meal 
(Fig. 5A). The postprandial lipidemia was not accompanied by significant changes in the concentration of EVs 
in plasma determined by NTA (Fig. 5A). Similarly, the plasma concentration of VLDL particles did not change 
from the fasting to the postprandial state (Fig. 5B), but the median diameter of VLDL particles increased from 
42 ± 6 nm in fasting plasma to 55 ± 9 nm in postprandial plasma (p < 0.0001) (Fig. 5C). However, serum triglyc-
erides and the concentration of VLDL particles in plasma collected 4 hours after ingestion of the meal showed a 
strong correlation with the plasma concentration of EVs and explained 59–66% of the variation in plasma EVs 





Women, n (%) 5 (50) 20 (50)
Age (years) 41 ± 9 56 ± 14
Body mass index (kg/m2) 28.0 ± 4.0
Haemoglobin (g/dL) 13.9 ± 1.2 14.4 ± 1.3
Leukocytes (109/L) 5.1 ± 0.9 6.3 ± 1.7
Platelet count (109/L) 229 ± 47 249 ± 62
Total cholesterol (mmol/L) 5.69 ± 1.35
HDL cholesterol (mmol/L) 1.32 ± 0.45
Triglycerides (mmol/L) 1.33 ± 0.82
Table 1. Characteristics of the volunteers recruited from the research staff (n = 10) and the participants of the 
cohort study (n = 40). Values are means ± standard deviations or numbers with percentage in brackets.
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Figure 1. Panels of bar graphs showing concentrations across size categories of plasma EVs frozen before 
(platelet poor plasma, PPP) and after (platelet free plasma, PFP) high-speed centrifugation in order to get rid 
of cell debris and platelets. After thawing, plasmas frozen as PPP were subjected to high-speed centrifugation 
before isolation of plasma EVs. The panels represent blood anticoagulated with citrate (panel A), CTAD (panel 
B), EDTA (panel C), and heparin (panel D). EV concentrations were measured by nanoparticle tracking 
analysis (NTA).Values are means with standard error of the means (SEM) (n = 10 in each group). EDTA: 
Ethylenediaminetetraacetic acid, CTAD: sodium citrate theophylline adenosine dipyridamole.
EV size category Citrate EDTA CTAD Heparin p
<100 nm 1133 (1066–2034) 1514 (1074–2039) 1420 (928–1926) 1314 (928–2207) 0.1
100–199 nm 262 (200–450) 402 (270–443) 319 (265–474) 313 (287–372) 0.2
200–299 nm 41 (19–71) 53 (38–65) 63 (40–105) 54 (35–76) 0.7
300–1000 nm 13 (2–20) 14 (6–19) 13 (5–36) 22 (9–52) 0.5
Total Concentration 1588 (1331–2403) 2017 (1510–2528) 1980 (1320–2514) 1658 (1342–2700) 0.2
Table 2. Plasma concentration (107 per mL) of extracellular vesicles (EVs) according to type of anticoagulant 
and size categories of EV.Values are expressed as median values with interquartile ranges (n = 10). Values 
are expressed as medians and interquartile ranges, nm: nanometer, EV: Extracellular vesicle, EDTA: 
Ethylenediaminetetraacetic acid, CTAD: sodium citrate theophylline adenosine dipyridamole.
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Discussion
We aimed to investigate the impact of various preanalytical conditions such as centrifugation steps for plasma 
preparation and EV isolation, choice of anticoagulant, and fasting status on plasma concentration and size dis-
tribution of EVs determined by NTA. The size distribution of plasma EVs was similar when determined by NTA 
and SEM, and the majority of EVs were round-shaped. The plasma concentration and size distribution of EVs 
were essentially similar in plasmas isolated from blood with various anticoagulants, even though the plasma 
concentration of large EVs was almost 2-fold higher in heparinized plasma compared to the other anticoagulants. 
A bilayer membrane of EVs was demonstrated in the majority of particles in the EV pellet by two separate TEM 
methods. The plasma concentration and size distribution of EVs, isolated from plasma by high-speed centrifuga-
tion and determined by NTA, were similar in blood collected before and 4 hours after ingestion of a high-fat meal. 
Even though triglyceride levels remained unchanged after high-speed centrifugation, serum concentrations of 
triglycerides and plasma concentrations of VLDL particles correlated with the concentration of EVs, particularly 
in the postprandial state.
Isolation of EVs from plasma by high-speed centrifugation may elicit shape change, aggregates and/or damage 
of EVs. In our study, the mean diameter of EVs isolated from plasma by high-speed centrifugation was 80–90 nm. 
Our results were very similar to those reported by Dragovic et al. who measured vesicles directly in plasma after 
labelling with a specific cell tracker dye17. We used two independent methods (NTA and SEM) to determine the 
size distribution of the EV fraction, and the results were similar for the two methods. NTA assessment of the size 
distribution revealed that only 3.5–5% of the EVs had a diameter above 200 nm, and that only 0.7–1.3% of the 
EVs had a diameter above 300 nm. The low proportion of EVs with a diameter above 2–300 nm, which is the lower 
detection limit of conventional flow cytometers, may explain the huge differences in observed plasma concentra-
tions of EVs measured by flow cytometry and NTA.
Previous studies comparing the impact of various anticoagulants on plasma concentrations of EVs assessed by 
flow cytometry, have shown higher levels of EVs in heparin than in sodium citrate, ACD or CTAD as anticoagu-
lants24,25. In line with these studies, we found that the plasma level of large EVs (>300 nm), which is detectable by 
flow cytometry, was 2-fold higher in plasma anticoagulated by heparin compared to plasma containing the other 
anticoagulants. In our study, blood anticoagulated with EDTA, a stronger chelator than citrate, displayed highest 
Figure 2. Bar graphs displaying mean sizes of plasma EVs measured by nanoparticle tracking analysis (NTA) 
and scanning electron microscopy (SEM) (upper panel) and size distribution (lower panel) across categories of 
various blood anticoagulants (upper panel). Values are means with standard error of the means (upper panel) 
or proportions (lower panel). EDTA: Ethylenediaminetetraacetic acid, CTAD: sodium citrate theophylline 
adenosine dipyridamole.
www.nature.com/scientificreports/
7SCIENTIFIC REPORTS |         (2018) 8:17216  | DOI:10.1038/s41598-018-35401-8
plasma concentrations of EVs, supporting the notion that EDTA promotes formation of artefactual microvesicles 
due to platelet activation30. Citrated plasma displayed the lowest median concentrations of EVs across all size 
categories. Citrate plays a role in membrane phospholipid remodelling and may thereby partially inhibit vesicu-
lation30. Our findings of a lower EV concentration in samples with citrate indicates that in vitro vesiculation may 
occur to a larger extent with the other anticoagulants, and support the recommended use of citrate as anticoag-
ulant for studies on EVs.
Previous studies using Nanoparticle Tracking Analysis of PFP have reported a particle concentration of 
approximately 1.5 × 1012/mL in plasma17. However, NTA does not allow for distinction between EVs and other 
particles within the same size range in plasma. Triglyceride-rich lipoproteins (chylomicrons and very-low-density 
lipoproteins) are in molar excess, but of similar size to cell-derived EVs18,31,32, and can be detected in light scatter. 
Previous studies showed that the apparent plasma concentration of EVs measured by NTA was highly correlated 
to the plasma concentration of triglycerides19, and that the concentration of EVs declined by more than 98% when 
only vesicles labelled with a cell tracker dye were counted17. To avoid interference of triglyceride-rich lipoproteins 
on the NTA measurements of EVs, we isolated EVs from plasma by high-speed centrifugation and re-suspended 
the pellet in a particle-free buffer. In our study, the median concentrations of EVs isolated from plasma varied 
between 1.6–2.0 × 1010/mL with an interquartile range from 1.3 to 2.7 × 1010/mL, which is in line with the results 
based on specific labelling of EVs by a cell tracker dye17.
Our findings provide several lines of evidence for at least partial separation of EVs from triglyceride-rich 
lipoproteins by high-speed centrifugation of plasma. First, the concentration of triglycerides in the plasma super-
natant remained unchanged after high-speed centrifugation, suggesting that VLDL-particles in fasting blood 
samples were not pelleted and mainly remained floating. Second, even though serum triglycerides and the con-
centration of VLDL particles in plasma from fasting individuals displayed a moderate correlation with the plasma 
Figure 3. Visualization of Extracellular Vesicles (EVs) by scanning electron microscopy (SEM) and 
transmission electron microscopy (TEM). (Panel A) EVs with phospholipid bilayer membrane after ultra-thin 
sectioning of the Epon blocks. (Panel B) Representative transmission electron micrograph of purified, negatively 
stained annexin positive and negative bilayer membrane extracellular vesicles. (Panel C) Representative 
transmission electron micrograph of plasma purified, negatively stained EVs. (Panel D) Representative 
micrograph of an EV by SEM, isolated from EDTA peripheral blood of a healthy donor at the working distance 
of 2.6 mm and an accelerating voltage of 2.00 kV (Original magnification 61.12 KX). EVs were spherical and 
presented uneven non-smooth surfaces.
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concentration of EVs, it only explained 13–19% of the variation in plasma EVs, suggesting that the particle count, 
measured by NTA, was not dominated by VLDL particles. Third, we developed a novel procedure to section 
the EVs, and could thereby clearly visualize the bilayer phospholipid membrane which distinguishes EVs from 
lipoproteins. Fourth, the results of our TEM analysis confirmed that the majority of isolated vesicles in our sam-
ples were in fact EVs (characterized by the bilayer phospholipid membrane) and not lipoproteins or protein 
complexes.
Figure 4. Bar graphs showing concentration of triglycerides before and after high-speed centrifugation  
(20,000 × g for 30 minutes) in undiluted (PFP) and diluted (dPFP, diluted 1:5 in DPBS) samples (panel A, bar 
graphs are means with 1 standard deviation), and dot-plots showing correlations between plasma concentration 
of EVs and serum triglycerides (panel B) and plasma VLDL particles (panel C) under fasting conditions. 
Proton nuclear magnetic resonance (NMR) spectroscopy was used to determine mean particle sizes of the main 
lipoprotein classes, and EV concentration was measured by NTA.
www.nature.com/scientificreports/
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Ingestion of a standardized high-fat meal was accompanied by significant increase in serum triglycerides 
which peaked at 4 hours and returned to baseline levels 8 hours after the meal without affecting the plasma levels 
of EVs determined by NTA. However, serum triglycerides and the concentration of VLDL particles in plasma 
collected 4 hours after ingestion of the meal showed a strong correlation with the plasma concentration of EVs 
and explained 59–66% of the variation in plasma EVs. These findings suggest that the particle count, measured 
by NTA, was highly influenced by VLDL particles under postprandial conditions. The reason(s) for the apparent 
differential impact of VLDL particles on the vesicle count measured by NTA under fasting and postprandial con-
ditions is not known. Even though the plasma concentration of VLDL particles did not increase in postprandial 
plasma, the mean particle size increased significantly from 42 ± 6 nm in fasting plasma to 55 ± 9 nm in postpran-
dial plasma. With a detection limit of a particle diameter of around 50 nm for EVs by NTA17, even a marginal 
sedimentation of VLDL particles during high-speed centrifugation may affect the particle counts, particularly 
under postprandial conditions. Thus, our measurements of EVs isolated from plasma by high-speed centrifu-
gation, should be interpreted with caution due to a potential partial interference by VLDL particles, particularly 
Figure 5. Bar graphs showing concentrations of serum triglycerides and plasma EVs before (fasting) and every 
second hour after ingestion of a standardized high fat meal (panel A, bar graphs are means with 1 standard 
deviation, ***p < 0.0001 from fasting levels). Dot plots showing median and 25 to 75% percentiles of plasma 
concentration of VLDL particles (panel B) and mean sizes of VLDL particles (panel C); and dot plots showing 
correlations between plasma concentration of EVs (measured by NTA) and serum triglycerides (panel D) and 
plasma VLDL particles (panel E) 4 hours after ingestion of a standardized high fat meal.
www.nature.com/scientificreports/
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under postprandial conditions. Recently, Mørk et al. aimed to prevent VLDL interference during NTA measure-
ments of EVs by antibody-mediated removal of ApoB-exposing lipoproteins from plasma using magnetic beads33. 
However, antibody-mediated depletion of ApoB-containing lipoproteins (including VLDLs) was accompanied 
by removal of EVs most probably due to the formation of LDL-EV complexes22, and by a shift in particle size due 
to the formation of aggregates of antibodies and lipoproteins33. Future studies should optimize centrifugation 
procedures, antibody-mediated removal or combined procedures in order to separate EVs and VLDL particles, 
so that NTA can accurately and reliably be applied to measure plasma concentrations of EVs.
In conclusion, isolation of EVs from plasma by high-speed centrifugation yielded similar concentrations and 
size distributions of EVs for the four anticoagulants tested (citrate, EDTA, CTAD and heparin). We found no 
statistical difference in concentration nor size of EVs (measured by NTA) when plasma was prepared as PPP or 
PFP before freezing. Plasma VLDL particles interfered with EV measurements assessed by NTA, particularly 
under postprandial conditions due to an increase in the median particle diameter of VLDLs exceeding the lower 
detection limit of NTA. Future studies are warranted to optimize the separation of VLDL particles and EVs in 
plasma in order to promote the utility of EVs determined by NTA as potential biomarkers of risk, diagnosis and 
prognosis of diseases.
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A modified clot‑based assay 
to measure negatively charged 
procoagulant phospholipids
Cathrine Ramberg1*, S. Jamaly1, N. Latysheva1, L. Wilsgård1, T. Sovershaev1, O. Snir1 & 
J.‑B. Hansen1,2
Growing evidence supports a role for extracellular vesicles (EVs) in haemostasis and thrombosis due 
to exposure of negatively charged procoagulant phospholipids (PPL). Current commercial PPL‑
dependent clotting assays use chemically phospholipid depleted plasma to measure PPL activity. 
The purpose of our study was to modify the PPL assay by substituting the chemically phospholipid 
depleted plasma with PPL depleted plasma obtained by ultracentrifugation This in order to get 
readily access to a sensitive and reliable assay to measure PPL activity in human plasma and cell 
supernatants. The performance of the assay was tested, including the influence of individual 
coagulation factors and postprandial lipoproteins and compared to a commercial PPL assay (STA‑
Procoag‑PPL). The two PPL assays displayed similar sensitivity to exogenously added standardized 
phospholipids. The PPL activity measured by the modified assay strongly correlates with the results 
from the commercial assay. The intraday‑ and between‑days coefficients of variation ranged from 
2–4% depending on the PPL activity in the sample. The modified PPL assay was insensitive to 
postprandial lipoprotein levels in plasma, as well as to tissue factor (TF) positive EVs from stimulated 
whole blood. Our findings showed that the modified assay performed equal to the comparator, and 
was insensitive to postprandial lipoproteins and  TF+ EVs.
Procoagulant phospholipid (PPL) activity has regained interest in recent years, mainly due to the increased 
understanding of the role of extracellular vesicles (EVs) in thrombosis and  haemostasis1,2. As early as 1946, 
Chargaff and West observed that the clotting time of plasma was prolonged by applying high-speed centrifugation 
to remove “thromboplastic substances”3. Accordingly, Connor and colleagues demonstrated that the amount of 
annexin A5 positive EVs, measured by flow cytometry, showed a significant and inverse correlation with clot-
ting  time4. These findings suggest that EVs play a significant role in coagulation, apparently due to exposure of 
phospholipids, and phosphatidylserine (PS) in particular, on their surface. The increase in surface expression of 
negatively charged PPL will facilitate the assembly of coagulation factors upon cell activation or  apoptosis5. This 
is crucial for several stages of the coagulation pathway, namely the formation of the intrinsic and extrinsic tenase 
complexes, as well as the conversion of prothrombin to thrombin by coagulation factor Xa (FXa)6. The activity of 
the extrinsic tenase complex, the tissue factor (TF)—factor VIIa (FVIIa) complex, is increased by several orders 
of magnitude in the presence of negatively charged membrane  phospholipids7.
Several assays have been developed to measure the PPL activity in human plasma. While some are based on 
the ability of annexin A5 to bind PS in the presence of  Ca2+4,8, others are clot-based, utilizing the ability of PPL to 
accelerate the conversion of prothrombin to thrombin. Annexin A5-based assays are widely used, often in a flow 
cytometry setting, a method that is time consuming, requires expensive equipment and experienced personnel. 
In addition, annexin A5 is commonly used in chromogenic FXa assays, where the activity measured is based on 
the EVs exposing PS that are bound to the microplate. These EVs are then able to accelerate the cleavage of the 
chromogenic substrate by  FXa9.
Compared to FXa chromogenic assays, which measure procoagulant activity of EVs in a purified system, 
clotting assays involve a more complex reaction and a physiological end-point as they measure the PPL activity of 
plasma, and not only captured PS-positive  EVs9. To the best of our knowledge, there are currently two clot-based 
assays commercially available, the STA-Procoag-PPL assay from Diagnostica Stago (Asnières sur Seine Cedex, 
France) and the XACT assay from Haematex (Hornsby, NSW, Australia). Both assays use chemical phospholipase 
treatment to deplete phospholipids from plasma, but differ with regard to the phospholipase used, plasma origin, 
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and the use of a phospholipid calibrator. The XACT assay uses a snake  phospholipase10 and porcine plasma, while 
an unspecified phospholipase and human plasma is used for the Stago assay.
In this study, we aimed to develop a modified PPL-dependent clotting assay, capable of measuring the PPL 
activity in human plasma and cell supernatants of in vitro experiments, by removing PPL from plasma by 
sequential centrifugation, including final ultracentrifugation. The performance of the modified assay was then 
validated against the commercially available Stago STA-Procoag-PPL assay.
Results
Impact of stepwise EV depletion on PPL clotting times. The removal of PPL from plasma is fun-
damental for the clot-based assays. As EVs are the main source of PPL, we first tested whether sequential cen-
trifugation reliably depleted EVs from plasma. To achieve this, we compared the PPL clotting times  (PPLCT) of 
plasma samples (n = 6) subjected to sequential centrifugation procedures (Fig. 1). Plasma prepared by centrifu-
gation at 2500×g for 15 min caused clotting times of 51.8 ± 4.7 s (mean ± 1 SD). A second centrifugation step 
of 2500×g for 15 min resulted in a prolongation of the clotting times to 92.5 ± 6.3 s (mean ± 1 SD). Pelleting 
larger EVs (e.g. microvesicles) from platelet free plasma (PFP) by an additional spin of 20,000×g for 30 min at 
room temperature (RT) further prolonged the clotting times to 127.8 ± 16.9 s (mean ± 1 SD). The final spin at 
100,000×g for 60 min to remove the smallest and lightest EVs (e.g. exosomes) further prolonged the clotting 
times to 159.3 ± 7.1 s (mean ± 1 SD).
Procoagulant phospholipid depleted plasma (PPL depleted plasma) prepared from pooled PFP (2500×g for 
15 min twice) by ultracentrifugation (100,000×g for 60 min) resulted in a mean clotting time of 163.2 ± 7.5 s 
(mean ± 1 SD) (Supplementary Figure S1).
PPL depletion by ultracentrifugation does not affect standard coagulation assays. To test 
whether the preparation of PPL depleted plasma affected standard coagulation assays, we measured activated 
partial thromboplastin time (aPTT) and prothrombin time (PT). The aPTT was 30.2 (normal range 25–37 s) and 
PT 21.3 s, corresponding to a PT-INR of 1.00 (normal range < 1.1).
Comparison of the modified PPL assay and the STA‑Procoag‑PPL assay. In order to demon-
strate that PPL depleted plasma prepared by ultracentrifugation was comparable to enzymatic depletion of PPL, 
we tested the sensitivity of the STA-Procoag-PPL assay and the modified PPL assay using serial dilutions of a 
standardized phospholipid reagent (UPTT reagent). The addition of UPTT shortened the clotting times in a 
concentration dependent manner (Fig. 2). The two assays performed similarly throughout the tested concentra-
tion range. Dilution curves of bovine FXa (bFXa) tested in PPL depleted plasma and pooled PFP supported the 
use of 0.1 U/ml bFXa for the modified PPL assay (Supplementary Figure S2). Despite a ten-fold lower concentra-
tion of bFXa used in the STA-Procoag-PPL assay, it consistently displayed shortened clotting times compared 
to the modified assay.
To compare the performance of the modified PPL and STA-Procoag-PPL assays, plasma samples from ten 
healthy blood donors were tested on both assays (Fig. 3). A strong correlation (r = 0.76, p < 0.01) was found 
Figure 1.  The effect of sequential centrifugation on plasma PPL clotting times. Citrated blood collected from 
6 healthy volunteers was subjected to consecutive centrifugations: 2500×g for 15 min to obtain platelet poor 
plasma (PPP), 2500×g for 15 min to obtain platelet free plasma (PFP), 20,000×g for 30 min and 100,000×g 
for 1 h to deplete for EVs. A sample of plasma after each centrifugation was analyzed with the modified PPL 
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between the assays, confirming their comparable performance.  PPLCT measured by the modified assay were 
consistently longer than for the STA-Procoag-PPL assay.
Assay reproducibility. To assess the coefficients of variation (CV) of the modified PPL assay, we used the 
two plasma standards provided by the STA-Procoag-PPL assay, one resulting in  PPLCT of 16 s. and the other 
 PPLCT of 54 s, as well as a pooled PFP sample with  PPLCT of 85 s. The day-to-day CV for the Stago standards 
(n = 30) was 3.9% and 3.2%, respectively, whereas the within-a-day CV (n = 20) was 3.7% and 2.8%, respectively. 
Pooled PFP had a day-to-day CV of 4.1% and a within-a-day CV of 3.3%.
The reproducibility of three independent preparations of PPL depleted plasma from the same six donors was 
tested, and demonstrated highly comparable  PPLCT measurements without the addition of UPTT and with the 
addition of two different concentrations of UPTT (PPL depleted plasma without UPTT: 163.2 ± 7.5 s, 1:3200 U/
ml of UPTT: 102.3 ± 5.7 s, 1:100 U/ml of UPTT: 30.6 ± 0.9 s) (Supplementary Figure S1).
Impact of different PFP preparation protocols on PPLCT. We wanted to investigate to what extent 
two different centrifugation protocols (Protocol A: 2500×g for 15 min twice; protocol B: 3000×g for 10 min fol-
lowed by 13,500×g for 2 min) affected  PPLCT (Fig. 4). Plasmas obtained by protocol A from 10 healthy individu-
als displayed prolonged  PPLCT compared to plasmas obtained by protocol B (101.2 ± 10.9 s versus 76.5 ± 9.1 s, 
p < 0.0001).
Postprandial lipemia does not affect PPLCT in the modified PPL assay. To test the sensitivity of 
the modified PPL assay to postprandial lipemia, we compared the  PPLCT of PFP prepared from blood collected 
before (0 h) and 4 h after a standardized high fat meal (1 g fat/kg body weight) (Fig. 5). This caused a prompt 
Figure 2.  Comparison of the clotting times obtained by the STA-Procoag-PPL and the modified PPL assays 
using a standardized phospholipid reagent (UPTT reagent). Serial dilutions of UPTT (from 1/50 to 1/12,800), 
was added to PPL depleted plasma and tested on the modified PPL assay (closed circles) and the STA- Procoag-
PPL assay (empty circles). Values are means of three experiments ± 1 SD.
Figure 3.  Comparison of PPL clotting times  (PPLCT) measured by the modified PPL assay (closed circles) and 
the STA-Procoag-PPL kit (empty circles). Platelet free plasmas from 10 healthy individuals were tested on both 
assays and the  PPLCT is presented in seconds (s). Values are mean of duplicate measurements.
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increase in total serum triglycerides that peaked after 4 h and almost reached baseline concentrations 8 h after 
the  meal11. However, postprandial lipemia was not accompanied by a significant change in the  PPLCT of fasting 
and postprandial plasma samples (51.1 ± 12.4 s and 48.9 ± 9.3 s, respectively). This indicates that the modified 
PPL assay was insensitive to postprandial lipemia measured in PPP samples subjected to a second high speed 
centrifugations after thawing, that generate mean CT values around 50 s.
The impact of FVIIa, FVa and surface PS on the modified PPL assay. Since the presence of coagu-
lation factors in human PPL depleted plasma may provide a source of preanalytical variation of the modified 
Figure 4.  The effect of platelet free plasma (PFP) preparation on clotting time. PFP from 10 volunteers were 
prepared using two different centrifugation protocols, (A) 2500×g for 15 min twice or (B) 3000×g for 10 min 
followed by 13,500×g. Clotting times were measured using the modified PPL assay. Panel (A) is a box plot of 
all ten volunteers combined for the two protocols, while panel (B) displays the individual values as mean of 
duplicate measures ± 1 SD.
Figure 5.  The effect of postprandial lipemia on plasma PPL activity. Serum triglycerides increased significantly 
after the ingestion of the standardized high fat meal without affecting the PPL activity. Dot plots are means ± 1 
SD, n = 40 for each group.
5
Vol.:(0123456789)
Scientific Reports |         (2021) 11:9341  | https://doi.org/10.1038/s41598-021-88835-y
www.nature.com/scientificreports/
PPL assay, we tested the assay with the addition of various concentrations of coagulation factors V/Va and VIIa 
(Fig. 6). The addition of FVa resulted in a dose dependent shortening of  PPLCT (Fig. 6A). The addition of increas-
ing levels of FVIIa had minor influence on  PPLCT, although the initial addition of 5 nM FVIIa slightly shortened 
the  PPLCT (Fig. 6B).
To further prove that coagulation in the modified assay is mainly driven by PPL, we used lactadherin to neu-
tralize the negatively charged phospholipids. Pretreatment with lactadherin reduced the  PPLCT dose-dependently 
of EVs derived both from A23187-stimulated PRP and EVs from unstimulated PRP (Fig. 6C). Pretreatment of 
Figure 6.  The effect of coagulation factors on the performance of the modified PPL assay. Exogenous 
coagulation factors were added to the reaction buffer in concentrations from 0.02 to 3.0 nM for FVa (panel A) 
and from 5 to 80 nM for FVIIa (panel B). Panel (C) shows the effect of lactadherin pretreatment on the PPL 
activity of PRP-derived EVs generated by stimulation of PRP by calcium ionophore A23187 for 15 min. Values 
are means ± 1 SD (n = 4).
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both PPL depleted plasma and PFP with 107 nM lactadherin drastically reduced their  PPLCT with clotting times 
exceeding the maximum clotting time of the coagulometer.
Blood‑borne TF has no effect on PPLCT in the modified PPL assay. Addition of recombinant relipi-
dated TF to PPL depleted plasma resulted in a dose-dependent shortening of clotting time (Fig. 7A). Since the 
artificial nature of TF and supra-pathological levels of TF may have caused the observed effect, we decided to test 
a more physiological source of TF. Whole blood was stimulated with a combination of LPS and  PMA12 to induce 
the release of  TF+ EVs from monocytes. Then, isolated EVs were run on the PPL assay with or without inhibitory 
TF antibody (clone HTF-1). As seen in Fig. 7B, stimulation of whole blood resulted in significant shortening of 
the clotting time. However, addition of anti-TF antibody (26 µg/ml final concentration) did not alter clotting 
times, suggesting that TF did not affect coagulation times in the modified PPL assay.
Discussion
The procoagulant potential of plasma phospholipids is modified under pathological conditions. Currently, two 
commercial assays, namely XACT and STA-Procoag PPL are widely used to monitor PPL activity plasma. We 
thoroughly validated a modified and easy to use PPL assay for the measurement of procoagulant phospholipids 
in test specimens (plasma samples or isolated EVs) and compared its performance with the STA-Procoag-PPL 
assay. Our primary modification included preparation of PPL-depleted plasma by ultracentrifugation to remove 
Figure 7.  The effect of TF on the modified PPL assay. Exogenous relipidated TF was added to the modified PPL 
assay in concentrations from 0.01 to 5.5 pM (panel A). Panel (B) illustrates the effects of EVs from LPS-PMA 
stimulated blood and inhibitory TF antibody on clotting times in the PPL assay. Values are means ± 1 SD (panel 
A,B) from three experiments.
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EVs, assumed to be the main source of negatively charged phospholipids in plasma. This modification allowed for 
the establishment of an accessible and in-house assay with a comparable performance to that of the commercial 
assay. The addition of a standardized phospholipid reagent (UPTT) allows for clotting times to be converted 
into a standardized unit of phospholipids.
The commercially available PPL assays are well established in research and provide a reliable tool for assessing 
PPL activity in human plasma. Such assays are dependent on chemically phospholipid depleted plasma provided 
by the assay as a reagent. Their performance has been assessed under different pre-analytical and experimental 
settings such as quality control of cell  storage13, plasma  EVs14,15, and monitoring of plasma EV levels in various 
disease  states16–19. Assuming that the vast majority of procoagulant phospholipids in plasma are EV-bound, we 
examined whether sequential centrifugation, including final ultracentrifugation, might substitute phospholipase 
treatment for production of a suitable assay plasma. Indeed, subjecting plasma to sequential centrifugation 
resulted in prolonged clotting times (i.e. reduced PPL activity), thus supporting that the major part of PPL activity 
in plasma is mediated by EVs, as originally suggested by Chargaff and  West3.
Since ultracentrifugation may leave residual amounts of PPL in the assay plasma, it was crucial to compare 
the properties of our PPL depleted plasma with the phospholipase-depleted plasma. Therefore, the performance 
of the modified PPL assay and the STA-Procoag-PPL assay were compared using a standardized UPTT reagent. 
The results revealed a high degree of coherence between assays. Further, measurement of endogenous plasma 
PPL in PFP obtained from 10 volunteers demonstrated strong correlations between assays assessed by  PPLCT. 
These findings support that the modified assay provide comparable performance to the STA-Procoag PPL assay 
with regard to sensitivity and measurement of levels of PPL in plasma.
It is important to note the effects of pre-analytical parameters on the performance of the modified PPL assay. 
Recently, Lacroix and colleagues used the STA-Procoag PPL assay to investigate the effect of different centrifuga-
tion protocols for PFP preparation on plasma  PPLCT14. They found that PFP prepared according to the Interna-
tional Society of Thrombosis and Haemostasis (ISTH) recommended protocol (2500×g for 15 min twice) yielded 
similar  PPLCT to another common centrifugation protocol (1500×g for 15 min followed by 13,500×g for 2 min) 
in fresh PFP. However, PFP obtained by the second, less intensive centrifugation protocol, displayed a substantial 
shortening of the  PPLCT after a freeze–thaw cycle (− 154%). A minor effect on PPL activity (− 5%) was observed 
when analyzing frozen-thawed PFP using the ISTH recommended centrifugation  protocol14. Accordingly, we 
found that a routine protocol for PFP preparation (3000×g for 10 min followed by 13,500×g for 2 min) yielded 
a 24% shorter  PPLCT than PFP prepared as recommended by ISTH. Hence, the plasma centrifugation protocol 
should be taken into consideration when comparing plasma  PPLCT between studies. As plasma depleted of PPL 
is an essential reagent in the modified assay, the importance of not introducing assay variations is critical. We 
demonstrated that three independent batches of PPL depleted plasma prepared from the same donors performed 
similarly, supporting the use of ultracentrifugation as a method for PPL depletion.
An additional pre-analytical challenge for population based studies is the availability of fasting blood samples 
as the PPL activity in plasma may be affected by plasma levels of triglyceride-rich lipoproteins. We therefore 
tested the PPL activity in plasma isolated before (0 h) and 4 h (4 h) after a high fat meal on the modified PPL assay. 
 PPLCT was unchanged in fasting and postprandial plasma, suggesting that  PPLCT is independent of postprandial 
lipemia and that there is no need to use fasting blood samples to obtain reliable PPL activity in plasma samples. 
Similar studies on the effect of lipemia should be repeated using more stringent pre-analytical conditions of 
plasma collection to see whether lipemia has a slight albeit detectable effect on the procoagulant properties of 
EVs. However, our findings are supported by Silveira et. al. who reported no effect of postprandial lipemia on the 
overall PPL measures, using the STA-Procoag PPL  assay20. Using the same assay, Mørk and colleagues showed 
that even a non-standardized meal and a shorter time interval between the ingestion of the meal and blood draw 
(75 min) resulted in no change in PPL between fasting and postprandial  samples21.
Procoagulant phospholipids, and PS in particular, affect the activity of both the intrinsic and extrinsic tenase 
and prothrombinase complexes, as well as the activation of FXI by  thrombin6. The inter-individual variability 
may affect the degree of activation of several coagulation factors in the test samples. We therefore tested a wide 
range of FVIIa and FVa concentrations, where high concentrations of coagulation factors proved to shorten the 
clotting time in the modified PPL assay. However, these effects occurred only at supra-physiological concentra-
tions significantly higher than those observed in vivo. Another aspect is the presence of TF. While only minute 
quantities are normally present in human plasma, TF is thought to be a major procoagulant factor found in 
 EVs22. Previously, Connor and coworkers showed that increasing concentrations (0–0.1%) of TF added to whole 
blood were insensitive to the XACT  assay4. Accordingly, we found that monocyte-derived EVs expressing TF 
after LPS stimulation (pathophysiological conditions) didn’t affect the clotting time in our assay. However, we 
observed a dose-dependent decrease in the clotting times with increasing supra-physiological concentrations of 
relipidated TF. Taken together, our findings suggest that the modified PPL assay is not influenced by physiological 
concentrations of the clotting factors in the test samples.
Over the last decade the interest in assays measuring the negatively charged phospholipid fraction of plasma 
has increased along with the growing interest and knowledge about EVs. Elevated levels of EVs, most frequently 
measured by flow cytometry, were found in venous  thromboembolism23–25, arterial cardiovascular  diseases25,26, 
 cancer27,28,  atherosclerosis29,30 and  diabetes31. In vascular disorders, the procoagulant properties of EVs are of par-
ticular interest. It has been shown that PS is the main phospholipid contributing to the procoagulant  function32.
The abundance of PS on the EV surface is often used to characterize EVs, by exploiting the ability of annexin 
A5 or lactadherin to bind PS on the outer leaflet of the membrane. Lactadherin is a small glycoprotein that binds 
PS in a calcium-independent manner and with higher affinity than annexin  A533. It has been demonstrated that 
lactadherin is an effective anticoagulant blocking the activity of PS, and inhibits the procoagulant activity of 
blood cells, endothelial cells and extracellular vesicles by 80%34. Here we showed that  PPLCT was prolonged with 
increasing concentrations of lactadherin to the extent that it was no longer measurable in the assay, implying that 
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the measured PPL activity is largely dependent on PS in the test samples. Similarly, using the XACT assay Aung 
et al. showed that pre-treatment of packed red blood cell supernatants by lactadherin prolonged clotting  times13.
Any assay designed for large-scale applications should be reproducible over time, and it should be possible 
to compare the results between different laboratories. To solve the latter challenge we propose the introduction 
of the UPTT reagent—an inexpensive standardized preparation of rabbit brain cephalin, which allows for clot-
ting times to be converted into a standardized unit of phospholipids. The XACT assay solves this problem by 
inclusion of a synthetic PPL calibrator, while the Stago assay leaves it up to the users to create a reference range 
and standards for the clotting  time35. Further, our modified PPL assay displayed minor variation in the assay 
performance. CVs obtained with either the standards from the Stago STA-Procoag-PPL or in-house pooled PFP 
range from 2.8 to 4.1%, well within recommended acceptable limits for within-day and between-day variability. 
Similar results were shown by van Dreden and colleagues in the XACT assay, with intra-assay CVs of 3.3% and 
3.1% for normal pooled plasma and patient plasma, respectively, and inter-assay CVs of 3.9% and 4.2%10.
There are two main considerations with the modified PPL assay. First, the results will be influenced by the 
presence of lupus anticoagulants as well as high concentrations of coagulation factors which may lead to falsely 
prolonged or shortened clotting times. This is common for all plasma-based assays, and should be accounted for 
when interpreting the results. The creators of the XACT assay tried to overcome this issue by using plasma of 
porcine origin. However, while it significantly decreased the assay sensitivity to some of the lupus anticoagulants, 
it failed to completely eliminate the  problem35. Second, pre-analytical conditions and inter-individual variations 
might impact plasma concentrations of coagulation factors in PPL depleted plasma. However, our modified assay 
seems to be unaffected by variations within the pathophysiological range.
In conclusion, the use of sequential centrifugation, including final ultracentrifugation, to deplete plasma of 
procoagulant phospholipids performed equal to enzymatic depletion of phospholipids from plasma in a FXa-
based clotting assay to determine PPL clotting times. In addition, we introduced a standardized PPL reagent 
(UPTT) which allows for clotting times to be converted into a standardized unit of phospholipids. These modi-
fications allowed us to establish an accessible and convenient in-house assay.
Materials and methods
Study subjects and sample preparations. For the calibration of the modified PPL assay, blood was 
drawn from healthy volunteers (n = 25) aged 25–79  years old, by venipuncture of an antecubital vein using 
a 21-gauge needle and minimal stasis. Blood was collected into 3  mL tubes containing 3.2% sodium citrate 
(0.109 M, 1:9 v/v)  (Vacuette®, Greiner Bio-One, Kremsmünster, Austria), 3 mL K2EDTA  Vacuette® tubes (Greiner 
Bio-One, Kremsmünster, Austria) for cell count or Fragmin (Sigma-Aldrich, St. Louis, Missouri, USA) for the 
Ca-ionophore experiments (preparation of EVs from PRP). The first 3 mL of blood were discarded. Blood was 
mixed with anticoagulant by gentle inversions of the tube. The samples were kept at room temperature (20–
24 °C) and processed within 15 min of collection. Blood was centrifuged twice at 2500×g for 15 min to obtain 
platelet free plasma (PFP). Both individual PFP samples and pooled PFP (n = 11) were prepared. PFP samples 
were aliquoted and stored at − 80 °C until use.
Procoagulant phospholipid depleted plasma (PPL depleted plasma) was prepared by sequentially centrifuging 
citrated blood (n = 18) using the following protocol: 2500×g for 15 min twice followed by 100,000×g for 60 min 
at 16 °C (Beckman Optima LE-80 K Ultracentrifuge, rotor SW40TI, Beckman Coulter, Indianapolis, Indiana, 
USA). Supernatants were pooled, aliquoted and stored at − 80 °C until further use.
Activated partial thromboplastin time (aPTT) and prothrombin time (PT-INR) were determined for the 
pooled PPL depleted plasma used in the modified assay. Both aPTT and PT-INR were measured on ACL TOP 
750 CTS (Instrumentation Laboratory, Bedford, MA, USA), using the kits SynthASil (Instrumentation Labora-
tory, Bedford, MA, USA), and STA-SPA + (Diagnostica Stago, Asnières sur Seine Cedex, France), respectively.
The reproducibility of three independent preparations of PPL depleted plasma from the same six donors were 
tested. Citrated PFP from six volunteers were centrifuged at 100,000×g for 60 min at 16 °C, pooled, aliquoted and 
frozen at − 80 °C.  PPLCT was measured using the modified PPL assay. Clotting tests were perform in PPL depleted 
plasma alone, or with UPTT added to mimic normal CT (1:3200 U/ml UPTT) and short CT (1:100 U/ml UPTT).
In order to investigate the impact of postprandial lipemia, forty study participants donated blood for plasma 
and serum analysis in a previously described  study11. Briefly, blood was drawn from an antecubital vein using 
a 19-gauge needle in a Vacutainer system with minimal stasis in the morning after 12 h fasting and then 2, 4, 6, 
and 8 h after a standardized high fat meal (1 g fat/kg body weight). Blood for plasma preparation was collected 
into 4.5-mL Vacutainers (Becton Dickinson, Meylan Cedex, France) containing 0.129 M sodium citrate (1:9 
v/v). Serum was prepared by letting blood clot for 1 h in a glass tube at room temperature. Plasma and serum 
were centrifuged at 2000×g for 15 min at 22 °C, transferred into cryovials (Greiner Labortechnik, Nürtringen, 
Germany) and stored at − 80 °C until further analysis. Blood samples collected before (fasting) and 4 h after the 
meal were selected for the present study. For analysis, samples were thawed, centrifuged 13,500×g for 2 min 
and measured on the modified PPL assay. Informed written consent was obtained from all participants, and 
the regional committee for medical and health research ethics (REC North) approved the study. The study was 
conducted in accordance with relevant guidelines and regulations.
Assay reagents. The UPTT reagent was purchased from BioData Corporation (Horsham, Pennsylvania, 
USA). Bovine FXa (bFXa), FVIIa, bovine FV/Va (bFV/Va) were purchased from Enzyme Research Labora-
tory (South Bend, Indiana, USA). Human recombinant tissue factor was purchased from Sekisui Diagnostics, 
LLC (Stamford, Connecticut, USA) and lactadherin from Haematologic Technologies Inc. (Essex Junction, Ver-
mont, USA). The STA-Procoag-PPL assay was purchased from Diagnostica Stago Inc. (Asnières sur Seine Cedex, 
France). All other chemicals were from Sigma-Aldrich (St. Louis, Missouri, USA).
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Test procedure for the modified PPL assay. Clotting tests were carried out in duplicate by using a 
Start Max instrument from Diagnostica Stago (Asnières sur Seine Cedex, France). Twenty five µl of test plasma 
or EV suspension was mixed with 25 µl of PPL depleted plasma in a Start-cuvette containing a steel ball, and 
pre-warmed for 2 min to 37 °C. The reaction was initiated by the addition of 100 µl of pre-warmed assay buffer 
with a cabled pipette that automatically starts the timer upon pipetting, and clotting time was measured. The 
assay buffer contains bFXa (0.1 U/ml) in 15 mM calcium chloride, 100 mM sodium chloride and 20 mM HEPES 
buffer (pH 7.0). The STA-Procoag-PPL assay (Asnières sur Seine Cedex, France) was performed according to 
the manufacturer’s protocol.
Assay calibration. Citrated blood samples from six individuals were subjected to sequential centrifuga-
tion in order to remove an increasing amount of EVs. The centrifugation protocol was as following; 2500×g for 
15 min, 2500×g for 15 min twice, 20,000×g for 30 min and 100,000×g for 60 min. Clotting time was measured 
after each centrifugation step.
Concentration of bFXa for the modified assay was determined by serially diluting bFXa from 0.01 to 2 U/ml. 
Clotting time was measured using the modified PPL assay. Pooled PFP added to PPL depleted plasma or PPL 
depleted plasma alone were used as test plasma.
Standardized UPTT reagent containing 0.1% of rabbit brain cephalin in a buffered solution was used as a 
calibrator. The UPTT reagent was reconstituted in milliQ water according to the manufacturer’s protocol, and 
set as 1 U/ml. To obtain a standard curve, serial dilutions of the UPTT reagent (1/50 to 1/12,800) in the assay 
buffer were added to phospholipid-depleted plasma. UPTT dilution curves were measured for both the modified 
PPL assay and STA-Procoag-PPL assay.
The effect of PFP preparation was tested using two different centrifugation protocols. Citrated blood samples 
from ten volunteers were split in two, one fractions was centrifuged 2500×g for 15 min twice (75,000g minutes) 
and the second fraction 3000×g for 10 min, followed by 13,500×g for 2 min (57,000g minutes). Clotting time 
was measured using the modified PPL assay.
The effect of coagulation factor V, VII, and blocking surface PS on PPL activity. The effect of 
varying levels of coagulation factors Va and VIIa were tested on the modified PPL assay. The coagulation factors 
were added to the reaction buffer in concentrations from 0.02 to 3.0 nM for FVa, and from 5 to 80 nM for FVIIa, 
and tested in pooled PFP.
The effect of lactadherin pretreatment of PRP-derived EVs on PPL activity was tested on the modified PPL 
assay. Plasma EVs were isolated from pooled citrated PFP, diluted with PBS (without  Ca2+ and  Mg2+) 1:3 v/v and 
centrifuged at 20,000×g for 30 min at 22 °C. The supernatant was discarded and the EV-pellet was resuspended 
in PPL depleted plasma. PRP-derived EVs were prepared by incubation of PRP (anticoagulated with Fragmin) 
with 10 µM of calcium ionophore A23187 for 15 min at 37 °C, followed by the isolation procedure described 
above. The concentrated EV suspension was serially diluted with PPL depleted plasma and assayed within 1 h.
The effect of TF and TF + EVs on PPL activity. Recombinant relipidated TF was added in the reaction 
buffer to pooled PFP in concentrations from 0.01 to 1.38 pM and clotting time was measured on the modified 
PPL assay.
Whole blood was stimulated with a combination of LPS (5 ng/ml, Dako, strain 026:B6, Difco Lab., Detroit, 
MI, USA) and PMA (30 ng/ml, Sigma-Aldrich, Oslo, Norway) at 37 °C for 4 h with gentle agitation. EVs were 
isolated as described above. TF activity was blocked with an inhibitory antibody at a final concentration of 26 µg/
ml (Purified Mouse Anti-Human CD142, Clone HTF-1, Catalog No.550252, BD Biosciences, Pharmingen, NJ). 
Clotting time was measured on the modified PPL assay.
Serum lipid analysis. Serum triglycerides were measured by the use of an enzymatic photometric method 
on the ABX Pentra 400 instrument (Horiba ABX Diagnostics, Montpellier, France).
Statistical analysis. Statistical analysis were performed in Graph Pad Prism 9.0.0 (GraphPad Software, Inc. 
La Jolla, CA, USA). ANOVA was used to test for differences in performance between the modified PPL assay and 
the STA-Procoag- PPL assay.
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Supplementary Figure S1. The batch-to-batch reproducibility of EVDP. Citrated blood 
samples from six volunteers were centrifuged twice at 2500xg for 15 minutes, then 100,000xg 
for 1hour to prepare EVDP. EVDP samples were pooled and stored at -80°C until analysis. 
Three separate batches were prepared and the clotting times (CT) were measured using the 
modified PPL assay for EVDP alone, and with the addition of UPPT concentrations of 1:3200 
(normal range CT) and 1:100 (short range CT). Values are mean of duplicate measurements ± 




Supplementary Figure S2. Bovine FXa dilution curve. Clotting times were measured from 
serial dilutions of bFXa added to EVDP alone, or in combination with pooled platelet free 
plasma (PFP). Clotting times for EVDP alone using 0.01 U/ml bFXa exceeded the range of the 
instrument (300 s) and artificial values of 301 seconds were plotted. Values are mean of three 
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 It is not known whether plasma levels of procoagulant phospholipids are associated 
with VTE risk 
 The association between PPL and risk of VTE was investigated in a nested case-
control study 
 PPL clotting time above the 95th percentile was associated with lower risk of future 
VTE 
 The association was stronger when analyses were restricted to samples taken shortly 





Background: Negatively charged procoagulant phospholipids, phosphatidylserine (PS) in 
particular, are vital to coagulation and expressed on the surface membrane of extracellular 
vesicles. No previous study has investigated the association between plasma procoagulant 
phospholipid clotting time (PPLCT) and future risk of venous thromboembolism (VTE).  
Objectives: To investigate the association between plasma PPLCT and the risk of incident 
VTE in a nested case-control study.  
Methods: We conducted a nested case-control study in 296 VTE patients and 674 age- and 
sex-matched controls derived from a general population cohort (The Tromsø Study 1994-
2007). PPLCT was measured in platelet free plasma using a modified factor Xa-dependent 
clotting assay. Logistic regression was used to estimate odds ratio (OR) with 95% confidence 
intervals (CI) for VTE with PPLCT modelled as a continuous variable, across quartiles and in 
dichotomized analyses.  
Results: There was a weak inverse association between plasma PPLCT and risk of VTE per 
one standard deviation increase of PPLCT (OR 0.93, 95% CI 0.80-1.07) and when comparing 
those with PPLCT in the highest quartile (OR 0.89, 95% CI 0.60-1.30) with those in the lowest 
quartile. Subjects with PPLCT > 95th percentile had substantially lowered OR for VTE (OR 
0.35, 95% CI 0.13-0.81).  The inverse association was stronger when the analyses were 
restricted to samples taken shortly before the event. The risk estimates by categories of 
plasma PPLCT were similar for deep vein thrombosis and pulmonary embolism.  
















Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a common disease with an annual incidence of 1-2 per 1000 individuals [1, 
2]. VTE is associated with severe short- and long-term complications, such as recurrent events 
[3], post-thrombotic syndrome (PTS) [4], post-PE syndrome [5] and death [6]. The incidence 
of VTE has been stable [7] or slightly increased during the last two decades [8, 9], and VTE 
has become a major economic burden and challenge to health care systems [10, 11]. 
Therefore, there is a great need to identify novel biomarkers to improve risk-stratification and 
unravel disease mechanisms to tailor preventive and treatment strategies with the long-term 
goal to lower the incidence of the disease.  
 
Phosphatidyl serine (PS) is a negatively charged phospholipid with procoagulant potential 
expressed at the surface of activated platelets and extracellular vesicles (EVs) [12]. The 
presence of PS on the membrane surface facilitates the assembly of coagulation factors VII 
(FVII), FIX, FX and prothrombin (FII) [13], and accelerates the activity of the TF:FVIIa 
complex by several orders of magnitude [14]. Furthermore, a strong relationship between 
plasma levels of  PS-positive EVs and procoagulant phospholipid (PPL) activity has been 
reported [15]. Hence, plasma PPL clotting time (PPLCT) may be considered as a measure for 
the potential to facilitate coagulation activation when blood is exposed to triggers of the 
coagulation system.  
 
As most [16-19], but not all [20] observational studies have reported elevated plasma levels of 
EVs in VTE, we hypothesized that prolonged PPLCT was associated with lowered risk of 
VTE. We therefore aimed to investigate the association between plasma PPLCT, measured by 
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a modified factor Xa-dependent clotting assay, and the risk of incident VTE in a nested case-
control study derived from the general population.  
 
MATERIAL AND METHODS 
Study population 
The Tromsø Study is a large prospective single-center population-based cohort study with 
repeated health surveys of inhabitants of Tromsø, Norway [21]. The study participants were 
recruited from the fourth survey (1994-95) of the Tromsø Study. All inhabitants aged 25 years 
and older living in the municipality of Tromsø were invited to participate, and 77% of those 
invited participated (n=27,158). The participants were followed from the date of inclusion 
until an adjudicated incident VTE event, migration, death, or end of follow-up (September 1, 
2007). All first lifetime events of VTE occurring among the participants in this period were 
identified using the hospital discharge diagnosis registry, the autopsy registry, and the 
radiology procedure registry from the University Hospital of North Norway (UNN), which is 
the sole provider of diagnostic radiology and treatment of VTE in the Tromsø area. Trained 
personnel adjudicated and recorded each VTE by extensively reviewing medical records. The 
identification and adjudication process of VTEs has previously been described in detail [22]. 
In short, the adjudication criteria for VTE were presence of signs and symptoms of DVT or 
PE combined with objective confirmation by radiological procedures, which resulted in 
initiation of treatment (unless contraindications were specified). A VTE occurring in the 
presence of one or more provoking factors was classified as provoked. Provoking factors 
were: surgery or trauma (within eight weeks before the event), acute medical condition (acute 
myocardial infarction, acute ischemic stroke, acute infections), immobilization (bed rest > 3 
days or confinement to wheelchair within the last 8 weeks, or long distance travel ≥4 hours 
9 
 
within the last 14 days), or other factors specifically described as provoking by a physician in 
the medical record (e.g. intravascular catheter).  
 
There were 462 individuals who experienced a VTE event during the follow-up period (1994-
2007). For each case, two age- and sex-matched controls, who were alive at the index date of 
the corresponding VTE-case, were randomly sampled from the source cohort (n=924). In 
total, 349 (140 cases and 209 controls) lacked plasma samples and 67 (26 VTE cases and 41 
controls) had plasma samples of insufficient quality (e.g. hemolysis). Hence, our study 
population consisted of 296 subjects with incident VTE and 674 age- and sex-matched 
controls. The regional committee for medical and health research ethics approved the study, 
and all participants provided informed written consent. 
 
Baseline measurements 
At inclusion in Tromsø 4 (1994/95), baseline information was collected by physical 
examinations, blood samples and self-administered questionnaires. All participants had their 
height (to the nearest cm) and weight (to the nearest 0.5 kg) measured, wearing light clothing 
and no shoes. Body mass index (BMI) was calculated using weight in kilograms divided by 
height in meters squared (kg/m2). Information on previous cardiovascular disease and cancer 
was collected from the self-administered questionnaires.   
 
Handling of blood samples  
Non-fasting blood samples were collected by venipuncture of an antecubital vein, with 
minimal stasis, into blood collection tubes containing ethylenediaminetetraacetic acid (K3-
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EDTA 40 µL, 0.37 mol/L per tube) (Becton Dickinson, Meylan Cedex, France). Cell counts 
were performed using a Coulter Counter (Coulter Electronics, Luton, UK). Platelet poor 
plasma (PPP) was prepared by centrifugation at 3000 x g for 10 minutes at room temperature. 
Plasma aliquots were transferred to 1 mL cryovials (Greiner Laboratechnik, Nürtringen, 
Germany) and stored at -80°C until analysis.  
 
Measurement of procoagulant phospholipid clotting time (PPLCT) in plasma 
PPL clotting time was measured in platelet free (PFP) EDTA plasma using a modified factor 
Xa-dependent clotting assay. In short, PPP samples were thawed and centrifuged at 13,500 x 
g for 2 minutes to generate PFP. Phospholipid-depleted plasma (PPLDP) used as a reagent in 
the assay was prepared from pooled citrated PFP (n = 18) centrifuged at 100,000 x g for 60 
minutes at 16°C (Beckman Optima LE-80K Ultracentrifuge, rotor SW40TI, Beckman 
Coulter, Indianapolis, Indiana, USA). PPLDP was aliquoted and stored at -80°C until use. 
Twenty-five μl of sample PFP was mixed with 25 μl of PPLDP, and incubated for 2 minutes 
at 37°C, before the reaction was initiated by the addition of 100 μl pre-warmed factor Xa 
reagent containing bovine Factor Xa (0.1 U/ml) in 15 mM calcium chloride, 100 mM sodium 
chloride and 20 mM HEPES buffer (pH 7.0). Clotting tests were carried out in duplicate on a 
StarT4 instrument from Diagnostica Stago (Asnières sur Seine Cedex, France) and measured 
in seconds of clotting time. The variation between runs were adjusted for by an internal 
standard. The technician carrying out the measurements was blinded to the identity and case-
control status of the samples. The PPL assay displayed low intra- and inter-series coefficients 





Measurements of thrombin generation in plasma  
Thrombin generation was assessed using a calibrated automated thrombinoscope, and was 
performed as described by Hemker et al [23] and manufacturer’s instructions 
(Thrombinoscope BV, Maastricht, the Netherlands). Thrombin generation was measured in a 
Fluoroscan Ascent Fluorometer (Thermolabsystems OY, Vantaa, Finland) equipped with a 
dispenser. Fluorescence intensity was detected at wavelengths of 355 nm (excitation filter) 
and 460 nm (emission filter). Briefly, 40 µl of plasma was mixed with 40 µl Hepes buffer (20 
mM Hepes and 140 mM NaCl) and pipetted into the wells of round bottom 96-well microtiter 
plates (Immulon, Lab Consult, Lillestrøm, Norway). Ten µl of TF solution (final 
concentration of 3 pM) (Innovin, Bade Behring) and 10 µl of a standardized phospholipid in 
solution (diluted 1:20) (UPTT, BioData Corporation, Horsham, Pennsylvania, USA.) was 
added as triggers. Both TF and UPTT were diluted to the stated concentrations in Hepes 
buffer. The plasma samples measured were a combination of pooled citrated PFP and PPLDP 
added in ratios of 100:0, 80:20, 60:40, 40:60, 20:80, 10:90, and 0:100, respectively. For each 
experiment, a fresh mixture of 2.5 mM fluorogenic substrate (Z-Gly-Gly-Arg-AMC from 
Bachem, Bubendorf, Switzerland), 0.1 M CaCl2, 20 mM Hepes (Sigma Aldrich, St Louis, 
USA) and 60 mg/ml BSA (A-7030, Sigma Aldrich) with pH 7.35 was prepared. Each dilution 
of PFP/PPLDP was assigned its own calibrator (Thrombinoscope BV, Maastricht, The 
Netherlands). The computer software calculated lag time (LG) (min), the time to peak (TTP) 
(min), the peak of thrombin generation (PEK) (nM) and the area under the thrombin 
generation curve (nM*min) and endogenous thrombin potential (ETP). Plasma samples were 






Statistical analysis  
Statistical analyses were performed using R (Version 4.0.4. for Windows; R Foundation). 
Unconditional logistic regression models were used to estimate odds ratios (ORs) for VTE 
with 95% confidence intervals (CIs) with plasma PPLCT used as a continuous variable, 
discretized to quartiles and dichotomized according to PPLCT  ≤ 25th percentile versus PPLCT  
> 95th percentile. The analyses were adjusted for age, sex and BMI. The PPLCT quartile cut 
offs were determined using the control group.  
 
As the follow-up time in the source cohort was long (more than 12 years for many 
persons), the results based on baseline PPLCT measurements could be influenced by regression 
dilution bias [24]. To investigate this, we performed analyses where we restricted the maximum 
time from blood sampling in Tromsø 4 to the VTE events, while keeping all controls in the 
analyses. The logistic regression analyses on time restrictions were set to require at least 10 
VTE events, and ORs were generated at every 0.1 year increase and plotted as a function of 
time from blood sampling to VTE. 
 
RESULTS 
The distribution of characteristics of the study population at baseline across quartiles of 
plasma PPLCT is presented in Table 1. The mean age and BMI were similar, while the 
percentage of men (42.9% in Q1 to 47.8% in Q4) and the proportion of individuals with self-
reported CVD (13.5% in Q1 to 18.8% in Q4) increased across quartiles. In contrast, the 
proportion of individuals with self-reported cancer decreased (7.1% in Q1 to 2.9% in Q4) 




Characteristics of patients at VTE diagnosis are shown in Table 2. The mean age at the time 
of VTE was 68 years, 47% were men, and 59% of the events were deep vein thrombosis. The 
majority of the VTE events were provoked (60.1%), and the leading provoking factors were 
active cancer (27.7%), surgery or trauma (21.3%), and immobilization (18.2%).  
 
The ORs of VTE across categories (quartiles and >95th percentile) and per one standard 
deviation (i.e. 14.5 s) increase in plasma PPLCT are shown in Table 3. There was a weak 
inverse association between plasma PPLCT and risk of VTE per one standard deviation 
increase of PPLCT (OR 0.93, 95% CI 0.80-1.07), and in subjects with PPLCT in the highest 
quartile (OR 0.89, 95% CI 0.60-1.30) compared to those in the lowest quartile, in analyses 
adjusted for age, sex, and BMI.  However, subjects with particularly prolonged PPLCT (>95
th 
percentile) had lower OR for VTE (OR 0.35, 95% CI 0.13-0.81) than those with PPLCT ≤25
th 
percentile in analyses adjusted for age, sex, and BMI.  Similar results were found for DVT 
and PE (Table 3), but the OR for PE (OR 0.14, 95% CI 0.01-0.69) was lower than for DVT 
(OR 0.50, 95% CI 0.17-1.25) in analyses comparing individuals with PPLCT >95
th percentile 
versus ≤25th percentile. The ORs for unprovoked and provoked VTE, DVT and PE, were 
similar to those found in the overall analyses (data not shown). 
 
To consider the possibility of underestimating ORs due to regression dilution bias, we 
estimated ORs for VTE among subjects with the highest (highest quartile) versus lowest 
(lowest quartile) plasma PPLCT as a function of time between blood sampling and the VTE 
events (Figure 1). The inverse association between high plasma PPLCT and VTE was stronger 
with shortened time between the blood sampling and the VTE events. The ORs for DVT and 
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PE as a function of time between blood sampling and events showed similar patterns as the 
ORs for overall VTE (data not shown).  
 
To study the effect of plasma procoagulant phospholipids on thrombin generation, mixtures of 
pooled PFP and PPLDP were analyzed using the CAT assay. As shown in Figure 2A, 
thrombin generation declined in a dose-dependent manner with declining percentage of PFP 
added (i.e. declining levels of PPL). A clear dose-response relationship was observed between 
plasma PPL levels and parameters of the CAT assay (i.e. lag-time and ETP) (Figures 2B and 
C). The PPLCT correlated strongly with both lag time (r= 0.99, p= <0.0001, Figure 2D) and 
ETP (r= -0.98, p= <0.0001, Figure 2E).  
 
DISCUSSION  
We investigated the association between plasma PPLCT and future risk of VTE in a population 
based nested case-control study. Prolonged PPLCT displayed a modest protective effect on 
VTE risk both when PPLCT were used as a continuous and as a categorized variable in the 
logistic regression models. However, subjects with extremely prolonged PPLCT (above the 
95th percentile) had lowered risk of VTE (OR 0.35, CI 95% 0.13-0.81) compared to those 
with PPLCT in the lowest quartile. Similar results were observed in subgroup analysis for PE 
and DVT. The results appeared to be influenced by regression dilution bias, as the ORs for 
VTE by plasma PPLCT decreased substantially with shortened time between blood collection 
and the VTE events. Our findings support the hypothesis of an inverse association between 




Our study is, to the best of our knowledge, the first to investigate the association between 
plasma PPLCT and future risk of VTE in the general population.  In a recent cross-sectional 
study including 100 patients referred to the Emergency Department under suspicion of VTE, 
plasma PPLCT, assessed by the STA Procoag PPL assay (Diagnostica Stago), did not 
discriminate between patients with (n=31) and without VTE [25]. The lack of discriminatory 
diagnostic power by the PPL assay may have been diluted by other conditions associated with 
shortened PPLCT among patients without VTE.  However, this does not exclude the potential 
association between plasma PPLCT and future risk of VTE. Further, plasma levels of 
modifiable biomarkers, such as PPLCT, are expected to change over time. Fluctuations in the 
exposure variable during follow-up will lead to the phenomenon called regression dilution 
bias [24], which usually results in an underestimation of the true association between 
exposure and outcome. Accordingly, we found that the risk estimates for VTE declined 
substantially with shortened time between measurement of plasma PPLCT and the VTE 
events. 
 
Circumstantial evidence support an association between plasma PPLCT and the risk of future 
VTE.  First, the PPLCT is inversely associated with annexin V-positive EVs [15, 26] and high 
plasma levels of EVs are associated with VTE risk in most [16-19], but not all studies [20, 
27]. Second, in a cross-sectional study including plasma samples from 100 healthy individuals 
and patients with obstructive sleep apnea, plasma PPLCT showed strong and inverse 
correlations to parameters of thrombin generation, such as ETP and peak thrombin 
concentration, using the CAT assay with the addition of minimal amounts of phospholipids 
and tissue factor (1 pM) to trigger thrombin generation [26]. Accordingly, we demonstrated a 
clear dose-response relationship between plasma PPLCT and parameters of the CAT assay. In 
addition, several studies have shown that parameters of the CAT assay, particularly lag-time 
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and ETP, are associated with incident [28-32] and recurrent [33-35] VTE. Third, carriers of 
rare (e.g. deficiencies of antithrombin, protein C and S) [36] and common (e.g. factor V 
Leiden and the prothrombin mutation G20210A) [37, 38] prothrombotic genotypes had 
significantly shorter plasma PPLCT than non-carriers, providing indirect evidence for lower 
risk of VTE with prolonged plasma PPLCT.    
 
Strengths of our study include recruitment of VTE patients from a population-based cohort 
with age- and sex-matched controls from the same source population where blood samples 
were collected prior to the VTE event. This allows assumptions on the direction of the 
observed association between plasma PPLCT and VTE. Further, the modified FXa-dependent 
PPL clotting assay is highly sensitive and displayed a low CV of ≤4%.  A limitation with our 
study is that plasma samples used were collected in 1994/95 and stored at -80°C until analysis 
>20 years later. The long storage time, as well as freezing and thawing, might possibly affect 
the plasma PPLCT.  However, it is unlikely that it would impact our end results, as the 
potential effects would be similar for both cases and controls. Moreover, the PPL levels were 
only measured in baseline samples, while potential changes during follow-up were not 
accounted for. This might lead to an underestimation of the true association between plasma 
levels of PPLCT and VTE risk due to regression dilution bias [24]. In our study, some plasma 
samples were excluded due to either missing samples or poor plasma quality. The plasma 
samples were missing completely at random, hence there was no selection bias.  
 
In conclusion, results from our nested case-control study indicate an inverse association 
between plasma PPLCT (measured by a modified FXa-dependent PPL clotting assay) and the 
risk of future VTE. Subjects with PPLCT above the 95
th percentile had particularly low risk of 
future VTE and the results were strongly influenced by regression dilution bias. Further 
17 
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TABLES AND FIGURES 
 
Table 1: Baseline characteristics of the study population (n=970) across quartiles of PPL 
clotting time. 
 Clotting time (seconds) 








Subjects, n 252 243 230 245 
Age, years 59 ± 14 61 ± 13 61 ± 14 61 ± 14 
Sex, % men (n) 42.9 (108) 47.7 (116) 46.5 (107) 47.8 (117) 
BMI, kg/m2 26.1 ± 4.5 26.6 ± 4.0 26.6 ± 4.4 26.5 ± 4.1 
CVD*, % (n) 13.5 (34) 16.0 (39) 15.2 (35) 18.8 (46) 
Cancer*,% (n)  7.1 (18)  6.2 (15)  5.2 (12)  2.9 (7) 
WBC, 109/L  7.2 ± 1.9  7.1 ± 3.3  6.8 ± 1.7  6.8 ± 1.9 
Platelet Count, 109/L 259 ± 57 247 ± 53 240 ± 47 230 ± 52 
Hematocrit, % 41.5 ± 3.3 41.7 ± 3.6 41.4 ± 3.0 41.5 ± 3.4 
CVD: cardiovascular disease (myocardial infarction, angina, stroke). WBC: white blood cell 
count.  
*Self-reported history of disease.  




Table 2: Characteristics of the VTE patients (n=296).  
  
Age at VTE, years 68 ± 14 
Sex, % men 47.0 (139) 
Deep vein thrombosis 58.8 (174) 
Pulmonary embolism 41.2 (122) 
Unprovoked VTE 39.9 (118) 
Provoked VTE 60.1 (178) 
 Active cancer 27.7 (82) 
 Surgery/ Trauma 21.3 (63) 
 Immobilization 18.2 (54) 
 Acute medical condition 15.9 (47) 
 Other factors 4.1 (12) 
Values are mean ± 1 standard deviation or percentage with absolute numbers in parenthesis.  
23 
 
Table 3. Odds ratios (OR) with 95% confidence intervals (CI) for venous thromboembolism 
(VTE), deep vein thrombosis and pulmonary embolism, per standard deviation (SD) increase 
and across increasing quartiles of PPL clotting time (seconds). 




Model 1  
(95% CI) 
Model 2  
OR (95% CI) 
Model 3  
OR (95% CI) 
Venous 
thromboembolism 
     
Per SD 296 674 0.94 (0.81-1.08) 0.94 (0.81-1.08) 0.93 (0.80-1.07) 
Q1 (26.5-54.3) 83 169 1.00 (ref)  1.00 (ref)  1.00 (ref)  
Q2 (54.3-63.5) 74 169 0.89 (0.61-1.30) 0.89 (0.61-1.30) 0.87 (0.59-1.27) 
Q3 (63.5-74.5) 63 167 0.77 (0.52-1.13) 0.77 (0.52-1.13) 0.75 (0.51-1.12) 
Q4 (74.5-148.5) 76 169 0.92 (0.63-1.34) 0.92 (0.63-1.34) 0.89 (0.60-1.30) 
      
≤ 25% (26.5-54.3) 83 169 1.00 (ref) 1.00 (ref) 1.00 (ref) 
>95% (89.9-148.5) 6 34 0.36 (0.13-0.83) 0.36 (0.13-0.83) 0.35 (0.13-0.81) 
Deep vein thrombosis      
Per 1 SD increase 174 674 0.98 (0.83-1.16) 0.98 (0.83-1.17) 0.97 (0.82-1.15) 
Q1 (26.5-54.3) 50 169 1.00 (ref)  1.00 (ref)  1.00 (ref)  
Q2 (54.3-63.5) 32 169 0.64 (0.39-1.04) 0.64 (0.39-1.05) 0.63 (0.38-1.03) 
Q3 (63.5-74.5) 47 167 0.95 (0.60-1.50) 0.96 (0.61-1.51) 0.95 (0.60-1.49) 
Q4 (74.5-148.5) 45 169 0.90 (0.57-1.42) 0.91 (0.57-1.43) 0.87 (0.55-1.38) 
      
≤ 25% (26.5-54.3) 50 169 1.00 (ref) 1.00 (ref) 1.00 (ref) 
>95% (89.9-148.5) 5 34 0.50 (0.16-1.24) 0.50 (0.16-1.25) 0.50 (0.16-1.25) 
Pulmonary embolism      
Per 1 SD increase 122 674 0.88 (0.72-1.07) 0.88 (0.71-1.06) 0.87 (0.71-1.06) 
Q1 (26.5-54.3) 33 169 1.00 (ref)  1.00 (ref)  1.00 (ref)  
Q2 (54.3-63.5) 42 169 1.27 (0.77-2.12) 1.26 (0.76-2.09) 1.22 (0.73-2.04) 
Q3 (63.5-74.5) 16 167 0.49 (0.25-0.91) 0.49 (0.25-0.90) 0.48 (0.25-0.89) 
Q4 (74.5-148.5) 31 169 0.94 (0.55-1.60) 0.92 (0.54-1.58) 0.89 (0.52-1.54) 
      
≤ 25% (26.5-54.3) 33 169 1.00 (ref) 1.00 (ref) 1.00 (ref) 
>95% (89.9-148.5) 1 34 0.15 (0.01-0.74) 0.15 (0.01-0.72) 0.14 (0.01-0.69) 
Model 1: Crude analysis 
Model 2: adjusted for age and sex 
Model 3: adjusted for age, sex and body mass index 







Figure 1. Estimated odds ratios (OR) for VTE for having PPLCT in quartile 4 compared to 
quartile 1.Each circle represents an analysis for a given maximum time between blood draw 
and VTE. At each time restriction, only VTE cases with a time below this maximum were 
included in the analysis, while all controls were included. The analysis are adjusted for age, 







Figure 2. Pooled platelet free plasma (PFP) was mixed in varying ratios (100%, 80%, 60%, 
40%, 20%, 10% and 0% PFP) with phospholipid depleted plasma (PPLDP) and run on the 
CAT assay. Thrombin generation curves are shown in 2A. A dose dependent relationship was 
observed for both lagtime (2B) and ETP (2C) and % PFP added to the reaction. PPL clotting 
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 Rosuvastatin treatment caused a 22% decrease in plasma PPL activity in participants 
with a previous history of VTE. 
 The effect was not explained by changes in total cholesterol nor changes in plasma 






Venous thromboembolism (VTE) is a frequent cardiovascular disease with severe 
complications, including recurrence and death. There is a great need for alternative prophylactic 
treatment options as anticoagulation is accompanied by increased bleeding risk. Statins are 
reported to reduce the risk of incident and recurrent VTE, but the mechanisms are elusive. 
Procoagulant phospholipids (PPL), and phosphatidylserine in particular, are crucial for efficient 
coagulation activation, but no study have investigate the effect of statin treatment on plasma 
PPL activity. We aimed to investigate the impact of rosuvastatin treatment on plasma PPL 
activity and levels of extracellular vesicles (EVs) in subjects with a history of VTE. Participants 
of the STAtins Reduce Thrombophilia (START) (NCT01613794) trial were randomized to 
either 20 mg/day of rosuvastatin treatment or no treatment for 28-days. Plasma sample were 
collected at baseline and study end. The PPL activity was measured in samples from 245 
participants using a FXa-dependent assay and plasma EV levels by a sensitive flow cytometer. 
Rosuvastatin treatment yielded an overall 22% (95% CI -38.2 to -5.8) reduction in PPL activity, 
and 37% (95% CI -62.9 to -11.2) reduction in PPL activity in participants with a history of 
pulmonary embolism. The effect of rosuvastatin on plasma PPL activity was not explained by 
changes in total cholesterol nor change in plasma levels of total- or platelet-derived EVs. 
Rosuvastatin treatment caused a substantial decrease in plasma PPL activity, suggesting that a 
PPL-dependent attenuation of coagulation activation may contribute to a reduced VTE risk 






Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a frequent cardiovascular disease with severe short- and long-term 
complications, including recurrence and death 1-3. At present, anticoagulation is the treatment 
of choice for primary and secondary prophylaxis of VTE 4. Although highly efficient, 
anticoagulation is accompanied by increased bleeding risk, where 1-4% annually experience 
major bleeding events, depending on type of anticoagulant, dose and duration of treatment 5-7. 
As VTE recurs in up to 30-40% of patients within 10 years of the initial event 8-11, there is a 
need for alternative prophylactic treatment options in patients with high bleeding risk. 
 
HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA) reductase inhibitors, known as statins, are a 
class of cholesterol-lowering drugs with cardioprotective effects independent of LDL 
cholesterol lowering, including protection against endothelial dysfunction, anti-inflammatory- 
and antithrombotic effects 12. Observational and randomized studies have reported a 14-54% 
reduction in the risk of a first VTE 13-17 and a 27-50% reduction in recurrent events 18-21 
following statin treatment. However, there is only limited knowledge on the pleiotropic effects 
of statins that may explain their beneficial effects on the risk of VTE. The STAtins Reduce 
Thrombophilia (START) trial was established to address this knowledge gap.  Previous results 
from the START trial have shown that rosuvastatin treatment modestly reduced (3-6%) the 
plasma level of several coagulation factors 22, in particular factor VIII, lowered the tissue factor 
(TF)-induced potential for thrombin generation in plasma by 10% 23, and increased the 
fibrinolytic potential in plasma 24. However, the beneficial effect of statins on VTE could not 
be explained by reduced platelet reactivity, measured by thromboxane-A2 mediated platelet 
aggregation 25.  
 
Negatively charged phospholipids, and phosphatidylserine (PS) in particular, are vital to 
coagulation. PS is located on the surface of activated platelets as well as on extracellular 
vesicles (EVs), and they facilitate the assembly of coagulation factors VII (FVII), FIX, FX and 
prothrombin (FII) 26 in blood. The presence of negatively charged phospholipids augment the 
activity of the extrinsic tenase complex, TF-FVIIa, by several orders of magnitude 27. The 
procoagulant phospholipid (PPL) activity of plasma samples can be measured using a factor Xa 




between PPL, measured by FXa-dependant clotting assays and plasma levels of PS-positive 
(PS+) extracellular vesicles (EVs) 28,29. However, the effect of statin treatment on plasma PPL 
activity has previously not been investigated. In the present study, we aimed to (i) investigate 
the impact of rosuvastatin treatment on plasma PPL activity in individuals with a history of 
VTE in a randomized controlled trial, and (ii) explore the effect of statin treatment on total- and 
platelet-derived EV counts using a sensitive flow cytometer.  
 
MATERIAL AND METHODS 
Trial design  
STAtins Reduce Thrombophilia, or the START trial (NCT01613794), is a multicenter, 
randomized, controlled, open label clinical trial aimed to investigate the impact of rosuvastatin 
treatment on the coagulation profile of individuals with a previous history of VTE. The study 
has been described in detail elsewhere 22. In brief, participants were recruited from three Dutch 
anticoagulation clinics (Leiden, Hoofddorp, and Rotterdam) which monitor anticoagulant 
treatment of VTE patients within a geographical area. Subjects with confirmed initial or 
recurrent symptomatic proximal DVT or PE allowed to stop oral anticoagulation treatment by 
their treating physician and aged 18 years or older, were invited to participate. Exclusion criteria 
were as following; individuals already using statins or other lipid lowering drugs, or if 
contraindications for 20 mg/day rosuvastatin use were present, based on information provided 
by the instruction leaflet of the drug manufacturer. Participants were randomly assigned to 
either 20 mg/day of rosuvastatin or no study medication for the 28-day study duration. 
Compliance to treatment was assessed by measurements of total cholesterol levels at baseline 
and at study end in all participants. The START trial was approved by the Medical Ethics 
Committee of the Leiden University Medical Center, Leiden, the Netherlands, and all study 
participants gave written informed consent prior to participation.  
 
Baseline measurements 
The study baseline was set as the last regular visit of the participant to the anticoagulation clinic. 
All participants were screened on acquired risk factors for VTE through a questionnaire, in 
addition to being tested on kidney and liver function. VTE patients stopped using vitamin K 




in Vacutainer tubes containing 3.2% sodium citrate (Becton Dickinson, Meylan Cedex, France) 
at baseline and at study end (i.e. 28 days later). Samples were centrifuged at 2,500 x g for 15 
min at 18°C and platelet poor plasma (PPP) was stored at -80°C until analysis. 
 
Measurement of procoagulant phospholipid (PPL) clotting activity in plasma  
A modified factor Xa-dependent PPL clotting assay (in-house) was used to measure plasma 
levels of PPL in citrated platelet free plasma (PFP) (n=247). Briefly, PPP samples were thawed 
and centrifuged 13,500 x g for 2 min to generate PFP. Phospholipid depleted plasma (PPL 
depleted plasma, PPLDP), was prepared from pooled citrated PFP (n = 18) centrifuged at 
100,000 x g for 60 min at 16°C (Beckman Optima LE-80K Ultracentrifuge, rotor SW40TI, 
Beckman Coulter, Indianapolis, Indiana, USA). PPLDP was aliquoted and stored at -80°C until 
further use. Twenty-five μl of test plasma was mixed with 25μl PPLDP, incubated for 2 min at 
37°C, before the reaction was initiated by the addition of 100μl of pre-warmed FXa reagent 
(0.1 U/ml bovine FXa in 15 mM calcium chloride, 100 mM sodium chloride and 20 mM HEPES 
buffer, pH 7.0). A commercially available standardized reagent containing 0.1% of rabbit brain 
cephalin in a buffered solution was used as calibrator (UPTT from BioData Corporation, 
Horsham, Pennsylvania, USA). Clotting tests were carried out in duplicate on a StarT4 
instrument from Diagnostica Stago. PPL levels were measured in seconds of clotting time, and 
converted to mU/ml, by the use of the UPTT calibrator. The PPL assay displayed low inter and 
intra CVs of ≤ 4% and variation between runs was adjusted for by an internal standard. 
 
Analysis of total- and platelet-derived microvesicles in plasma by flow cytometry  
Plasma samples were selected from 40 participants from the rosuvastatin treatment group and 
20 participants from the non-statin group. Participants with the largest decrease in plasma PPL 
activity were selected from the rosuvastatin treatment group as measurement of microvesicles 
by flow cytometry was expected to be less sensitive for changes than the plasma PPL activity. 
One sample from the no treatment group was later excluded due to technical failure. Plasma 
samples were thawed and centrifuged a second time for 2,500 x g for 15 min. Two hundred 
microliter of PFP was diluted 10x in pre-filtered (Amicon Ultra-15 filters, 10 kDa cutoff) 
Dulbecco's phosphate-buffered saline (DPBS) that is free of Ca2+/Mg2+ (Thermo Fisher 




Supernatants were carefully aspirated and the EV pellets were divided and stained for PS using 
FITC-labeled bovine lactadherin (Haematologic Technologies, Vermont, USA) and CD41 
APC-H7 clone HIP8 (Biolegend, San Diego, USA), or with FITC-labeled bovine lactadherin 
and matched isotype controls. All antibodies and isotype controls were filtered using 0.22 µm 
ultrafree-MC centrifugal filter (Merck, Millipore, Carrigtwohill, Ireland) before use. EV pellets 
were incubated with antibody or isotype control mixture for 20 min at 4°C in the dark. Samples 
were washed with 1 ml pre-filtered DPBS and centrifuged at 20,000 x g for 30 min at 4°C. 
Pellets were resuspended in 200 µl pre-filtered DPBS and samples were analyzed using 
CytoFLEX (Beckman Coulter, Indianapolis, USA) at the rate of 10 µl/min. Data analysis was 
performed using CytExpert 2.0 (Beckman Coulter, Indianapolis, USA). The EV gate was set 
using Rosetta calibration beads (Exometry, Amsterdam, The Netherlands). EVs were defined 
according to size and lactadherin-positive staining. The total number of EVs was calculated 
from the number of detected lactadherin-positive events in every sample, and further converted 




Statistical analysis were performed using R (Version 4.0.3 for Windows; R Foundation). 
Descriptive statistics were used to describe the baseline difference between the intervention and 
the control group. For the results tables, the treatment and non-treatment group, as well as 
subgroups, were compared using two-sample t-tests with equal variance assumed and standard 
multivariate linear regression models adjusting for age and sex. Pearson’s correlation 













Between December 2012 and December 2016 255 participants were randomized to either the 
rosuvastatin treatment group (n=131) or the no treatment group (n=124). A study flowchart is 
shown in Figure 1 with reasons for exclusion. Two participants did not start rosuvastatin 
treatment, and another six randomized participants did not complete the study, three in each 
study arm due to various reasons. The PPL assay measurements could not be performed in two 
participants due to technical failure, one in each study arm. The baseline characteristics of the 
study population are shown in Table 1. Participants allocated to no treatment were slightly older 
(mean age 59 years) compared to the statin-users (mean age 57 years), and were more often 
male (69% vs 54%). Other characteristics of the participants associated with VTE risk were 
equally distributed among the groups.  
 
Outcomes 
Table 2 and Figure 2 show absolute and changes in plasma PPL activity levels within and 
between the study arms. Plasma PPL activity levels decreased significantly from baseline to 
study end for rosuvastatin users (mean change, -0.48 mU/ml; 95% CI -0.81 to -0.15), while a 
minor increase was observed for non-users (mean change, 0.17 mU/ml; 95% CI -0.18 to 0.53) 
for overall VTE. Similar trends were observed in subgroup analyses of participants with a 
history of provoked and unprovoked VTE, as well as for DVT and PE. However, a pronounced 
change in plasma PPL activity was observed for the PE patients in the rosuvastatin group (mean 
difference, -0.94 mU/ml; 95% CI -1.52 to -0.36), and particularly for provoked PE (mean 
difference, -1.14 mU/ml; 95% CI -2.13 to -0.16) (Table 2 and Figure 2). The absolute and 
relative changes in PPL activity between the two study arms are shown in Table 3. Rosuvastatin 
treatment yielded a 22% (95% CI -38.2 to -5.8) reduction in PPL activity among all VTEs, and 
37% (95% CI -62.9 to -11.2) reduction in PPL activity in participants with a history of PE. The 
treatment effect of rosuvastatin on PPL activity for overall VTEs, DVTs and PEs are further 
illustrated in Figure 3. The treatment effect was also investigated in a linear model adjusted for 
age and sex, as these parameters were not balanced between groups at baseline 22. Adjustments 
for age and sex only marginally altered the mean differences between groups as well as the 





Total cholesterol levels were reduced from baseline to study end in the rosuvastatin treatment 
group by 35% (1.96 mmol/L) and by 3% (0.17 mmol/L) in the non-treatment group. In order to 
explore whether the reduction in PPL activity by statin treatment was explained by the statin-
dependent decrease in serum cholesterol, we plotted the absolute changes in total cholesterol 
against changes in PPL activity (Figure 4). A weak and Pearson’s correlation coefficient of -
0.10 (p-value 0.28) indicates that the reduction in PPL activity by statin treatment was 
independent of the cholesterol-lowering effect.  
 
To assess whether the observed effect of statin treatment on PPL activity could potentially be 
explained by alterations in EV count, EVs were isolated from plasma by ultracentrifugation, 
labeled with lactadherin (binds to membranes expressing PS) and CD41, a platelet specific 
marker, and counted using a sensitive flow cytometer. Plasma levels of lactadherin positive and 
platelet-derived EV, in number of EVs per µL, for the two study groups are shown as box-plots 
in Figure 5. EV counts are presented for the baseline sample, and compared to the end of study 
sample. The box-plots show no change in total EV count for the no treatment group (Figure 
5A), nor the statin treatment group (Figure 5B). Similar results were found for platelet-derived 
EVs (Figure 5C and D). The mean differences in lactadherin positive and CD41 positive EV 








In the present study, we investigated the effect of rosuvastatin treatment on plasma PPL activity, 
measured by a FXa-dependent PPL clotting assay, in patients with a history of VTE. Statin 
treatment caused a 22% reduction in PPL activity for all VTE patients and 37% reduction in 
PPL activity for PE patients compared to no treatment. The observed effect of rosuvastatin on 
PPL activity was not explained by changes in serum levels of total cholesterol or a parallel 
changed in plasma levels of total- and platelet-derived microvesicles by statin treatment. The 
results from our study support the beneficial effect of statin treatment on coagulation factors 
and thrombin generation potential in plasma. As the presence of negatively charged 
phospholipids augment the activity of the extrinsic tenase complex, TF-FVIIa, by several orders 
of magnitude 27, the combined effect of reduced PPL activity and modest decline in several 
coagulation factors may reduce coagulation activation and contribute to the explanation why 
rosuvastatin treatment lower the risk of VTE 16.  
 
Clinical studies have shown that statin treatment, either with simvastatin 30, atorvastatin 31,32, or 
cerivastatin 33 caused a beneficial effect on the coagulation system by a moderate lowering of 
specific coagulation factors and thrombin generation. In the START trial, rosuvastatin 
treatment showed favorable effects on the hemostatic system by reducing plasma levels of 
coagulation factors FVII, FVIII, and FXI by 4-6% 22, D-dimer by 3% 22, lowered the ex vivo 
thrombin generation potential by 10% 23, and increased the fibrinolytic potential assessed by 
shortening of the mean plasma clot lysis time and a decrease in both plasmin inhibitor levels 
and thrombin-activatable fibrinolysis inhibitor (TAFI) activity 24. The treatment effects of 
rosuvastatin on thrombin generation and plasma D-dimer levels were mainly driven by an 
increase among non-statin users 22,23. In contrast, we found a more profound beneficial effect 
of rosuvastatin treatment that was mainly driven by a significant decline in the PPL activity 
among rosuvastatin users accompanied by a minor increase in the PPL activity among the non-
users. The increase in hemostatic factors among non-statin users in our and previous studies 
from the START trial may be interpreted as a consequence of the rebound hypercoagulability 
often seen after discontinuation of anticoagulant treatment 34,35.  
 
Previous studies have demonstrated that plasma PPL activity is mainly due to the presence of 




increased EV-related plasma PPL activity in VTE patients compared to controls. Therefore, our 
findings of a profound decrease in PPL activity by statin treatment may contribute to the 
reduction of incident and recurrent VTE by statin treatment 13-21. Microvesicles (MVs) are 
larger EVs (100-1000 nm in diameter), which bud directly from the plasma membrane of 
activated cells, and express surface markers of their cell of origin 42,43. The largest proportion 
of MVs in circulating blood is derived from platelets 44,45 and the subsequent procoagulant 
activity in plasma is mediated by platelet-derived MVs (PDMVs) 36,44. A strong inverse 
correlation has also been reported between PPL clotting time and lactadherin positive EVs 
measured in PPP from healthy control subjects and patients with obstructive sleep apnoea 
(OSA), though the strength of the correlations was mainly driven by the OSA patients 29. We 
therefore hypothesized that the reduction we observed in plasma PPL activity following 
rosuvastatin treatment was caused by a parallel decline in plasma MV levels, and particularly 
platelet-derived MVs. In order to test our hypothesis, we isolated EVs from platelet free plasma 
and measured the total count (lactadherin-positive) and platelet-derived MVs (lactadherin- and 
CD41-positive) by flow cytometry. Although we found statin treatment to lower the PPL 
activity in the treatment group, we did not observe a reduction in total EV count, nor platelet 
derived EVs, for comparisons between – or within study groups.  
 
Our results show that rosuvastatin treatment did not affect plasma MV levels in patients with a 
history of VTE. Contradicting our findings, previous observational studies have shown that 
patients with arterial cardiovascular diseases or risk factors (hyperlipidemia in particular) had 
higher plasma MV levels than control individuals, and that statin treatment lowered plasma MV 
levels in most, but not all studies 46-51. Several factors may contribute to explain our findings. 
First, the effect of statin treatment on plasma MV levels may be limited to individuals with 
arterial cardiovascular diseases and risk factors, and not transferrable to VTE patients. Second, 
one might speculate that statin treatment could differentially influence EV formation from 
various intravascular cells and the subsequent process of externalization of PS to the outer 
leaflet of the cell membrane during EV formation 52. Accordingly, in a placebo-controlled 
randomized double-blinded crossover study, the treatment of 19 patients with peripheral arterial 
occlusive disease for 8 weeks with 80 mg atorvastatin daily showed a reduction in plasma MV 
levels expressing CD62P- and CD61-positive MVs without affecting plasma levels of 
lactadherin-positive EVs 49. Third, a well-recognized limitation of flow cytometry as a method 




vesicles above approximately 200 nm in diameter, and thereby exclude the larger population of 
EVs. Larger vesicles (> 200 nm in diameter) have been reported to only account for a minority 
of the EV population (< 5%) 53. This may imply that a possible decrease in plasma EVs after 
statin treatment could have been masked by the unchanged level of the larger EVs (>200 nm in 
diameter).  
 
Some aspects of our randomized controlled trial need attention. Neither the patients nor the 
physicians were blinded to treatment. However, it is unlikely that knowledge of the treatment 
would affect the laboratory outcomes. Furthermore, the technicians conducting the laboratory 
analyses were blinded to sample treatment. In addition, despite randomization, the distribution 
of age and sex was uneven between the study arms. We decided a priori to adjust analysis for 
age and sex as potential confounders, and adjustments did not influence the observed treatment 
effect. Even though results from subgroup analysis revealed the most pronounced decrease in 
plasma PPL activity in individuals with a history of PE, they should be interpreted with caution 
as the study was not originally powered to analyze differences in subgroups 22. Last, as 
participants were recruited from an outpatient setting, it limits the risk of confounding diseases 
at randomization, and for analysis, participants were compared with themselves. 
 
In conclusion, rosuvastatin treatment caused a substantial decrease in plasma PPL activity, 
suggesting that PPL-dependent attenuation of coagulation activation may contribute to a 
reduced VTE risk by statin treatment. Further studies are warranted to validate our findings and 
unravel underlying mechanisms.  
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FIGURES AND TABLES  
 
Table 1. Baseline characteristics of the study participants included in analysis.  




General   
Age (years) 57 (19 - 83) 59 (21 - 81) 
Male 67 (53.6) 83 (69.2) 
BMI (kg/m2) 27.4 (19.2 - 43.5) 27.8 (17.2 - 43.3) 
Baseline cholesterol (mmol/L) 5.59 (2.95 - 8.98) 5.59 (3.33 - 7.89) 
Aspirin use 5 (4) 5 (4.2) 
Venous thromboembolism characteristics   
Deep vein thrombosis 71 (56.8) 64 (53.3) 
Pulmonary embolism 54 (43.2) 56 (46.7) 
Unprovoked 56 (44.8) 63 (52.5) 
Provoked 69 (55.2) 57 (47.5) 
     Surgery/trauma/immobilization 32 (25.6) 31 (25.8) 
     Travel >4 h 22 (17.6) 14 (11.7) 
     Estrogen use (% in women) 24 (41.4) 14 (37.8) 
     Pregnancy/puerperium (% in women) 0 (0) 2 (5.4) 
     Malignancy 2 (1.6) 8 (6.7) 
Recurrent venous thromboembolism 10 (8) 8 (6.7) 
Cardiovascular risk factors   
Absent 37 (29.6) 25 (20.8) 
Present 88 (70.4) 95 (79.2) 
     Current smoking 18 (14.4) 17 (14.2) 
     Hypertension 24 (19.2) 21 (17.5) 
     Diabetes 3 (2.4) 0 (0) 
     Overweight (25 ≤ BMI < 30) 53 (42.4) 51 (42.5) 
     Obese (30 ≤ BMI)  29 (23.2) 35 (29.2) 






Table 2. Mean difference in measures of PPL activity (mU/ml) from baseline to study end within the treatment and no treatment group and 
between groups for all VTE and subgroups provoked and unprovoked VTE, DVT and PE.  















VTE          
All  3.30±2.47 2.82±2.08 -0.48 (-0.81,-0.15) 2.64±1.81 2.82±2.22 0.17 (-0.18,0.53) -0.66 (-1.14,-0.17) -0.63 (-1.12,-0.14) 
Provoked 3.32±2.56 2.88±2.24 -0.44 (-0.93,0.06) 2.62±1.65 2.78±2.31 0.15 (-0.44,0.75) -0.59 (-1.35,0.17) -0.54 (-1.31,0.23) 
Unprovoked 3.29±2.37 2.75±1.88 -0.54 (-0.97,-0.10) 2.66±1.95 2.85±2.14 0.19 (-0.24,0.62) -0.73 (-1.33,-0.12) -0.72 (-1.33,-0.10) 
DVT         
All 2.99±2.10 2.85±2.09 -0.13 (-0.51,0.24) 2.50±1.64 2.59±1.89 0.09 (-0.31,0.50) -0.23 (-0.77,0.32) -0.22 (-0.77,0.32) 
Provoked 2.74±1.97 2.85±2.24 0.11 (-0.31,0.52) 2.76±1.53 2.76±1.69 0.00 (-0.60,0.60) 0.11 (-0.58,0.80) 0.13 (-0.57,0.83) 
Unprovoked 3.29±2.24 2.86±1.92 -0.43 (-1.10,0.24) 2.29±1.72 2.45±2.05 0.16 (-0.41,0.73) -0.59 (-1.45,0.27) -0.60 (-1.47,0.27) 
PE          
All 3.72±2.85 2.78±2.09 -0.94 (-1.52,-0.36) 2.81±1.98 3.08±2.53 0.27 (-0.35,0.89) -1.21 (-2.05,-0.37) -1.13 (-2.01,-0.26) 
Provoked 4.07±3.05 2.92±2.29 -1.14 (-2.13,-0.16) 2.49±1.78 2.79±2.82 0.30 (-0.75,1.36) -1.45 (-2.86,-0.04) -1.34 (-2.85,0.18) 
Unprovoked 3.28±2.58 2.60±1.85 -0.68 (-1.21,-0.15) 3.16±2.16 3.39±2.18 0.23 (-0.45,0.92) -0.91 (-1.77,-0.05) -0.90 (-1.79,-0.00) 
Values are means ± 1 standard deviation (SD) or the mean difference between groups with 95% confidence intervals in parenthesis.  
* Adjusted for age and sex.  
PPL: procoagulant phospholipids, VTE: venous thromboembolism, DVT: deep vein thrombosis, PE: pulmonary embolism  
 
 
Table 3. Treatment effect of rosuvastatin on measures of PPL activity in percentage change 
and as a linear model for all VTE and subgroups provoked- and unprovoked VTE, DVT and 
PE.  








    
All  -0.66 (-1.14,-0.17) -22.0 (-38.2,-5.8) -0.63 (-1.12,-0.14) -21.0 (-37.5,-4.6) 
Provoked  -0.59 (-1.35,0.17) -19.7 (-45.0, 5.6) -0.22 (-0.77,0.32) -18.0 (-43.8, 7.7) 
Unprovoked  -0.73 (-1.33,-0.12) -24.7 (-45.1,-4.2) -0.72 (-1.33,-0.10) -24.3 (-45.1,-3.5) 
DVT     
All  -0.23 (-0.77,0.32) -8.2 (-28.0,11.6) -0.22 (-0.77,0.32) -8.1 (-27.9,11.8) 
Provoked  0.11 (-0.58,0.80) 3.9 (-21.2,29.0) 0.13 (-0.57,0.83) 4.6 (-20.8,30.0) 
Unprovoked  -0.59 (-1.45,0.27) -21.4 (-52.5, 9.7) -0.60 (-1.47,0.27) -21.7 (-53.3, 9.9) 
PE     
All  -1.21 (-2.05,-0.37) -37.0 (-62.9,-11.2) -1.13 (-2.01,-0.26) -34.8 (-61.7,-8.0) 
Provoked -1.45 (-2.86,-0.04) -43.9 (-86.8,-1.1) -1.34 (-2.85,0.18) -40.7 (-86.6, 5.3) 
Unprovoked -0.91 (-1.77,-0.05) -28.4 (-55.2,-1.6) -0.90 (-1.79,-0.00) -27.9 (-55.7,-0.1) 
Values are mean differences between groups with 95% confidence intervals in parenthesis or 
percentage change calculated using the mean difference and dividing it by the mean baseline 
levels of PPL for both groups.  
*Adjusted for age and sex 
PPL: procoagulant phospholipids, VTE: venous thromboembolism, DVT: deep vein 











Figure 1. Flow chart of the study participants with numbers at enrolment, randomization, 
follow-up and reasons for withdrawal.  





Figure 2. Forest plots of changes in plasma PPL activity (mU/ml) (after minus before) within 
the rosuvastatin treatment and the no treatment group and between groups for all VTEs, 
DVTs and PEs. Values are means with 95% confidence intervals.  
PPL: procoagulant phospholipids, VTE: venous thromboembolism, DVT: deep vein 





Figure 3. Forest plot of the treatment effects (change within the statin group minus the 
change in the no treatment group) as percentage change in PPL activity for all VTEs, DVTs, 
and PEs. Values are means with 95% confidence intervals. 
PPL: procoagulant phospholipids, VTE: venous thromboembolism, DVT: deep vein 





Figure 4. Change in individual total cholesterol levels from baseline to study end plotted 





Figure 5. The effect of rosuvastatin treatment on extracellular vesicle count, measured by 
flow cytometry. The changes in lactadherin positive EV count (A and B) and platelet-derived 
EV count (C and D) are shown for the two study groups, i.e. no treatment group (A and C) 
and the rosuvastatin treatment group (B and D). The larger circles represent the mean, and a 
line is drawn to connect the means between baseline and study end within the groups.  
PPL: procoagulant phospholipids, VTE: venous thromboembolism, DVT: deep vein 






Supplementary Table 1. Mean difference in lactadherin positive EV count (count/μl) from baseline to study end within the treatment and no 
treatment group and between groups for all VTE and subgroups provoked and unprovoked VTE, DVT and PE.  
 Treatment group (T) (n=40) No treatment group (NT) (n=19) t-test Linear model* 















VTE          
All  833±580 776±463 -57 (-274,159) 532±410 592±304  60 (-69,188) -117 (-440,206) -123 (-451,204) 
Provoked 768±492 795±454  27 (-234,289) 511±351 623±288  112 (-73,296) -85 (-441,272) -85 (-455,285) 
Unprovoked 899±662 757±483 -142 (-508,224) 569±526 539±347 -30 (-223,163) -112 (-736,511) -178 (-777,420) 
DVT         
All 812±758 717±472 -95 (-530,341) 331±235 482±229 151 (-34,335) -245 (-827,336) -339 (-952,274) 
Provoked 425±275 654±418  229 (-536,994) 374±279 538±267 164 (-139,467) 65 (-570,700)  142 (-518,801) 
Unprovoked 988±850 746±511 -242 (-833,349) 246±96 369±48 123 (-227,473) -365 (-1508,777) -519 (-1521,483) 
PE          
All 847±441 815±463 -32 (-278,213) 713±459 691±339 -22 (-218,174) -10 (-404,384) -12 (-418,393) 
Provoked 882±501 842±470 -40 (-341,261) 648±385 707±305  59 (-265,384) -100 (-598,399) -111 (-647,426) 
Unprovoked 789±338 770±476 -20 (-538,499) 812±603 667±435 -145 (-433,144) 125 (-646,896)   61 (-765,888) 
Values are means ± 1 standard deviation or the mean difference between groups with 95% confidence intervals in parenthesis.  
* Adjusted for age and sex 




Supplementary Table 2. Mean difference in platelet-derived extracellular vesicle count (count/μl) from baseline to study end within the 
treatment and no treatment group and between groups for all VTE and subgroups provoked and unprovoked VTE, DVT and PE. 
 Treatment group (T) (n=40) No treatment group (NT) (n=19) t-test Linear model* 















VTE          
All  419±347 407±312 -12 (-150,126) 245±253 281±199   37 ( -50,123) -49 (-256,158) -53 (-262,157) 
Provoked 386±315 408±306  22 (-146,190) 231±205 311±183   80 ( -46,205) -58 (-288,173) -60 (-299,179) 
Unprovoked 452±382 406±327 -46 (-281,189) 267±337 231±230 -37 (-151,77)   -9 (-408,390) -48 (-443,347) 
DVT         
All 411±424 381±296  -30 (-287,227) 121±86 212±168   91 (-32,214) -121 (-466,224) -179 (-542,183) 
Provoked 206±176 340±247  134 (-314,582) 150±91 267±185   117 (-88,322)    17 (-368,402)    54 (-350,457) 
Unprovoked 504±476 399±325 -105 (-458,248) 62±27 101±13   39 (-40,118) -144 (-826,538) -230 (-851,391) 
PE          
All 424±295 424±328    0 (-171,171) 356±304 344±212 -12 (-148,124)   12 (-262,286)    7 (-275,289) 
Provoked 446±332 431±328 -15 (-216,185) 312±262 355±187  42 (-179,264)  -58 (-390,275) -74 (-428,280) 
Unprovoked 387±233 413±348  26 (-351,403) 421±391 328±276 -94 (-318,130) 120 (-442,681)   78 (-537,693) 
Values are means ± 1 standard deviation or the mean difference between groups with 95% confidence intervals in parenthesis.  
* Adjusted for age and sex 
PPL: procoagulant phospholipids, VTE: venous thromboembolism, DVT: deep vein thrombosis, PE: pulmonary embolism 
 
 
 
 
  
 
 
 
 
